

# Appendix H: Meta-analysis and Network meta-analysis Results

## H.1 Patient information

- What information do people with cataracts and their carers find useful, and what format (for example written or verbal) do they prefer it to be provided in?
- What information on cataract surgery do people and their carers find useful when deciding whether surgery is appropriate for them, and before, during and after any operation(s) they elect to undergo? What format (for example written or verbal) do they prefer it to be provided in?

There were no meta-analyses conducted for these questions.

## **H.2 Indicators for referral**

- What are the indicators for referral for cataract surgery?
- What are the optimal clinical thresholds in terms of severity and impairment for referral for cataract surgery?

There were no meta-analyses conducted for these questions.


### H.3 Pre-operative assessment and biometry

- What is the effectiveness of different techniques for undertaking biometry?
- What are the most appropriate formulae to optimise intraocular lens biometry calculation?
- What is the effectiveness of strategies used to select intraocular lens constants in order to optimise biometry calculation?
- What other factors should be considered such as, who should undertake biometry and when should preoperative biometry be assessed?
- What is the effectiveness of risk stratification techniques to reduce surgical complications?
- What are the risk factors associated with increased surgical complications in cataract surgery?


#### H.3.1 Biometry techniques - Forest plots of outcomes

##### H.3.1.1 Ultrasound (immersion and contact) and optical biometry to measure axial length

###### Mean absolute prediction errors



### Cumulative proportion of eyes within various ranges of absolute prediction errors




### H.3.1.2 Keratometry (manual and automated) and topography to measure corneal curvature

#### Mean absolute prediction errors

Study or Subgroup	Keratometry			Topography			Wei
	Mean	SD	Total	Mean	SD	Total	
Antcliff 1995	0.8	0.65	23	0.55	0.62	23	100.
<b>Total (95% CI)</b>			<b>23</b>			<b>23</b>	<b>100.</b>
Heterogeneity: Not applicable							
Test for overall effect: Z = 1.33 (P = 0.18)							


### Cumulative proportion of eyes within various ranges of absolute prediction errors




### H.3.1.3 Observational studies in people undergoing phacoemulsification cataract surgery with a history of corneal refractive surgery

Studies including mixed populations of individuals with a history of different types of refractive surgery (laser-assisted in situ keratomileusis, photorefractive keratectomy and radial keratotomy) for various indications (myopia, hyperopia)

#### Mean prediction errors




#### Mean absolute prediction errors




## Studies including individuals with a history of laser-assisted in situ keratomileusis and photorefractive keratectomy for myopia


### Mean prediction errors: keratometry (SRK-T formula) vs topography (SRK-T formula)




### Mean prediction errors: keratometry (Haigis-L formula) vs topography (SRK-T formula)



**Cumulative proportion of eyes within various ranges of absolute prediction errors: keratometry (SRK-T formula) vs topography (SRK-T formula)**



**Cumulative proportion of eyes within various ranges of absolute prediction errors: keratometry (Haigis-L formula) vs topography (SRK-T formula)**





### H.3.2 Intraocular lens formulas: Network meta-analyses results: Virgin eyes without a history of corneal refractive surgery

#### H.3.2.1 Model fit statistics for all outcomes

**Table 1: Model fit statistics used to select fixed or random effect models for all comparisons and outcomes**


Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
<b>VIRGIN EYES WITHOUT A HISTORY OF CORNEAL REFRACTIVE SURGERY</b>								
<b>Axial length less than 22.00mm</b>								
7 (Carifi, Cooke, Day, Doshi, Moschos, Ozcura, Srivannaboon)	Mean absolute error	FE	43.024	87.582	137.8	37	-	RE
		RE	-44.558		36.72		0.267 (0.174, 0.424)	
5 (Aristodemou, Day, Eom, Kane, Srivannaboon)	Within 0.25D	FE	157.592	-1.143	22.47	28	-	FE
		RE	158.735		21.67		0.124 (0.004, 0.439)	
11 (Aristodemou, Carifi, Cooke, Day, Doshi, Eom, Kane, Moschos, Ozcura, Percival, Srivannaboon)	Within 0.5D	FE	344.21	28.658	97.82	52	-	RE
		RE	315.552		52.32		0.589 (0.345, 0.920)	
11 (Aristodemou, Carifi, Cooke, Day, Doshi, Eom, Kane, Moschos, Ozcura, Percival, Srivannaboon)	Within 1.0D	FE	295.164	18.295	83.66	52	-	RE
		RE	276.869		50.87		0.653 (0.367, 1.035)	
3 (Carifi, Kane, Ozcura)	Within 2.0D	FE	43.015	-1.091	9.174	12	-	FE
		RE	44.106		9.731		0.593 (0.024, 1.834)	
<b>Axial length 22.00 to 24.50mm</b>								
2 (Ozcura, Srivannaboon)	Mean absolute error	FE	-20.877	-0.027	6.015	6	-	FE
		RE	-20.85		6.028		1004 (0.051, 1.948)	

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
3 (Aristodemou, Kane, Srivannaboon)	Within 0.25D	FE	126.75 2	-1.491	12.98	14	-	FE
		RE	128.24 3		12.62		0.069 (0.005, 0.360)	
4 (Aristodemou, Kane, Ozcura, Srivannaboon)	Within 0.5D	FE	138.89	-2.357	12.8	16	-	FE
		RE	141.24 7		13.65		0.046 (0.002, 0.242)	
4 (Aristodemou, Kane, Ozcura, Srivannaboon)	Within 1.0D	FE	119.79 9	-1.358	13.68	16	-	FE
		RE	121.15 7		13.7		0.090 (0.003, 0.465)	
2 (Kane, Ozcura)	Within 2.0D	FE	43.439	-1.011	7.367	8	-	FE
		RE	44.45		7.782		0.745 (0.044, 1.918)	
<b>Axial length 24.50 to 26.00mm</b>								
1 (Srivannaboon)	Mean absolute error	FE	-6.133	0.009	3.991	4	-	FE
		RE	-6.142		3.986		0.964 (0.040, 1.949)	
3 (Aristodemou, Kane, Srivannaboon)	Within 0.25D	FE	99.785	-1.785	11.55	14	-	FE
		RE	101.57		12.01		0.132 (0.006, 0.726)	
4 (Aristodemou, Kane, Percival, Srivannaboon)	Within 0.5D	FE	113.31 9	-2.338	15	17	-	FE
		RE	115.65 7		15.63		0.129 (0.004, 0.755)	
6 (Aristodemou, El-Nafees, Kane, Mitra, Percival, Srivannaboon)	Within 1.0D	FE	113.40 2	-1.7	20.9	21	-	FE
		RE	115.10 2		20.49		0.227 (0.012, 1.052)	
1 (Kane)	Within 2.0D	FE	26.195	-0.029	6.666	6	-	FE

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
		RE	26.224		6.711		1.010 (0.059, 1.948)	
<b>Axial length greater than 26.00mm</b>								
2 (Bang, Cooke)	Mean absolute error	FE	-19.062	1.227	16.31	13	-	FE
		RE	-20.289		13.25		0.294 (0.021, 1.623)	
2 (Aristodemou, Kane)	Within 0.25D	FE	73.422	-2.148	10.05	12	-	FE
		RE	75.57		10.93		0.260 (0.008, 1.540)	
5 (Aristodemou, Bang, Cooke, Kane, Percival)	Within 0.5D	FE	160.51	-1.369	24.45	28	-	FE
		RE	161.879		24.31		0.122 (0.007, 0.457)	
8 (Aristodemou, Bang, Cooke, El-Nafees, Kane, Mitra, Percival, Petermeier)	Within 1.0D	FE	196.074	19.255	64.1	35	-	RE
		RE	176.819		35.1		0.974 (0.506, 1.724)	
2 (Bang, Kane)	Within 2.0D	FE	44.466	1.002	13.49	10	-	FE
		RE	43.464		10.79		1.033 (0.095, 1.933)	

H.3.2.2 Full dataset: Axial length subgroup – less than 22.00mm

MEAN ABSOLUTE ERROR – random effects model



**Figure 1: AL <22.0mm: Mean absolute error - random effects model – evidence network**

**Table 2: AL <22.0mm: Mean absolute error - random effects model – input data**

	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	Holladay2-LT	LadasSuperFormula	Olsen_standalone	T2
Cooke & (2016)	0.40 (0.51)	0.39 (0.48)	0.41 (0.51)	0.48 (0.49)		0.44 (0.47)	0.43 (0.47)		0.40 (0.48)	0.46 (0.57)	0.39 (0.49)
Doshi et al. (2017)	0.54 (0.46)		1.36 (0.75)	0.59 (0.36)							
Ozcura et al. (2016)	0.70 (0.64)			0.76 (0.65)							
Carifi et al. (2015)	1.34 (1.04)		1.03 (0.87)	0.95 (0.78)	0.82 (0.77)						
Srivannaboon et al. (2013)			0.44 (0.40)	0.42 (0.33)	0.44 (0.31)			0.45 (0.30)			
Day et al. (2012)	0.52 (0.42)		0.44 (0.35)	0.46 (0.39)							
Day et al. (2012)	0.50 (0.37)		0.37 (0.28)	0.50 (0.37)							
Day et al. (2012)	0.79 (0.56)		0.86 (0.58)	0.74 (0.58)							
Day et al. (2012)	0.85 (0.56)		0.77 (0.51)	0.83 (0.61)							
Moschos et al. (2014)	0.97 (0.38)		0.43 (0.22)	0.72 (0.51)							

**Table 3: AL <22.0mm: Mean absolute error - random effects model – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	Holladay2-LT	LadasSuperFo rmula	Olsen_standal one	T2
SRKT		-0.01 (-0.22, 0.20)	-0.03 (-0.30, 0.24)	-0.05 (-0.14, 0.04)	-0.52 (-1.00, - 0.04)	0.04 (-0.17, 0.25)	0.03 (-0.19, 0.24)	-	0.00 (-0.21, 0.21)	0.06 (-0.18, 0.29)	-0.01 (-0.22, 0.21)
BarrettUniversall	-0.07 (-0.57, 0.44)		0.02 (-0.20, 0.23)	0.09 (-0.12, 0.30)	-	0.05 (-0.15, 0.26)	0.04 (-0.17, 0.24)	-	0.01 (-0.20, 0.22)	0.07 (-0.16, 0.29)	0.00 (-0.21, 0.21)
Haigis	-0.04 (-0.25, 0.18)	0.03 (-0.48, 0.54)		-0.03 (-0.22, 0.15)	-0.05 (-0.27, 0.17)	0.04 (-0.18, 0.25)	0.02 (-0.19, 0.23)	0.01 (-0.24, 0.26)	-0.01 (-0.22, 0.21)	0.05 (-0.18, 0.28)	-0.01 (-0.23, 0.20)
HofferQ	-0.06 (-0.27, 0.14)	0.01 (-0.49, 0.51)	-0.02 (-0.23, 0.18)		-0.02 (-0.22, 0.18)	-0.04 (-0.25, 0.17)	-0.06 (-0.26, 0.15)	0.03 (-0.20, 0.26)	-0.08 (-0.29, 0.13)	-0.03 (-0.25, 0.20)	-0.09 (-0.30, 0.12)
Holladay2	-0.16 (-0.58, 0.27)	-0.09 (-0.72, 0.54)	-0.12 (-0.53, 0.28)	-0.09 (-0.50, 0.30)		-	-	0.01 (-0.21, 0.23)	-	-	-
Holladay2_NoPreSurgRef	-0.02 (-0.51, 0.48)	0.05 (-0.54, 0.65)	0.02 (-0.48, 0.52)	0.04 (-0.46, 0.54)	0.14 (-0.49, 0.77)		-0.02 (-0.22, 0.19)	-	-0.04 (-0.25, 0.16)	0.02 (-0.21, 0.24)	-0.05 (-0.26, 0.16)
Holladay2_PreSurgRef	-0.04 (-0.54, 0.47)	0.03 (-0.57, 0.64)	0.00 (-0.51, 0.50)	0.02 (-0.48, 0.53)	0.12 (-0.50, 0.75)	-0.02 (-0.62, 0.57)		-	-0.03 (-0.23, 0.18)	0.03 (-0.19, 0.26)	-0.03 (-0.24, 0.18)
Holladay2-LT	-0.07 (-0.61, 0.47)	0.00 (-0.72, 0.72)	-0.03 (-0.56, 0.49)	-0.01 (-0.53, 0.52)	0.08 (-0.46, 0.65)	-0.05 (-0.76, 0.66)	-0.03 (-0.75, 0.68)		-	-	-
LadasSuperFormula	-0.06 (-0.56, 0.45)	0.01 (-0.60, 0.61)	-0.02 (-0.53, 0.48)	0.00 (-0.50, 0.51)	0.10 (-0.53, 0.72)	-0.04 (-0.63, 0.54)	-0.02 (-0.62, 0.58)	0.01 (-0.70, 0.72)		0.06 (-0.17, 0.28)	-0.01 (-0.22, 0.20)

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	Holladay2-LT	LadasSuperFo rmula	Olsen_standal one	T2
Olsen_standalone	0.00 (-0.52, 0.50)	0.07 (-0.54, 0.67)	0.04 (-0.49, 0.54)	0.06 (-0.46, 0.56)	0.16 (-0.48, 0.79)	0.02 (-0.59, 0.62)	0.04 (-0.57, 0.64)	0.07 (-0.65, 0.78)	0.06 (-0.55, 0.67)		-0.06 (-0.29, 0.17)
T2	-0.07 (-0.57, 0.43)	0.00 (-0.60, 0.60)	-0.03 (-0.54, 0.47)	-0.01 (-0.51, 0.49)	0.09 (-0.54, 0.71)	-0.05 (-0.65, 0.55)	-0.03 (-0.63, 0.56)	0.00 (-0.71, 0.71)	-0.01 (-0.61, 0.59)	-0.07 (-0.67, 0.53)	





Figure 2: AL <22.0mm: Mean absolute error - random effects model – relative effect of all options versus common comparator

**Table 4: AL <22.0mm: Mean absolute error - random effects model – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
SRKT	0.005	7 (2, 11)
BarrettUniversalll	0.122	5 (1, 11)
Haigis	0.012	6 (2, 10)
HofferQ	0.017	6 (2, 10)
Holladay2	0.214	3 (1, 11)
Holladay2_NoPreSurgRef	0.078	7 (1, 11)
Holladay2_PreSurgRef	0.090	6 (1, 11)
Holladay2-LT	0.155	5 (1, 11)
LadasSuperFormula	0.112	6 (1, 11)
Olsen_standalone	0.073	7 (1, 11)
T2	0.122	5 (1, 11)





**Figure 3: AL <22.0mm: Mean absolute error - random effects model – rank probability histograms**


**Table 5: AL <22.0mm: Mean absolute error - random effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
36.72 (compared to 37 datapoints)	-78.017	-111.476	33.459	-44.558	0.267 (95%CI: 0.174, 0.424)

**Table 6: AL <22.0mm: Mean absolute error - random effects model – notes**

- |   |
|---|
| <ul style="list-style-type: none"> <li>• Continuous (normal; identity link); random effects</li> <li>• Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul> |
|---|

**PROPORTION WITHIN 0.25 DIOPTRIS – fixed effects model**



**Figure 4: AL <22.0mm: Within 0.25D - fixed effects model – evidence network**

**Table 7: AL <22.0mm: Within 0.25D - fixed effects model – input data**

	SRKT	BarrettUniversa II	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Kane,J. et al. (2016)	51/156	48/156	57/156	44/156	49/156		52/156
Eom et al. (2014)			28/75	22/75			
Srivannaboon et al. (2013)			5/15	6/15	5/15	5/15	
Day et al. (2012)	11/32		12/32	10/32			
Day et al. (2012)	32/100		35/100	39/100			
Day et al. (2012)	2/19		3/19	3/19			
Day et al. (2012)	3/12		2/12	4/12			
Aristodemou et al. (2011)	50/151			44/151			
Aristodemou et al. (2011)	145/457			168/457			

**Table 8: AL <22.0mm: Within 0.25D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
SRKT		0.92 (0.57, 1.47)	1.16 (0.83, 1.61)	1.09 (0.90, 1.33)	0.94 (0.59, 1.52)	-	1.03 (0.64, 1.65)
BarrettUniversall	1.01 (0.67, 1.53)		1.30 (0.81, 2.07)	0.88 (0.54, 1.44)	1.03 (0.64, 1.66)	-	1.13 (0.70, 1.81)
Haigis	1.23	1.21		0.86	0.81	1.00	0.87

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
	(0.92, 1.64)	(0.79, 1.85)		(0.64, 1.15)	(0.52, 1.27)	(0.22, 4.56)	(0.55, 1.38)
HofferQ	1.09 (0.90, 1.32)	1.07 (0.71, 1.62)	0.88 (0.67, 1.16)		1.12 (0.70, 1.77)	0.75 (0.17, 3.33)	1.27 (0.79, 2.06)
Holladay2	1.04 (0.70, 1.55)	1.03 (0.64, 1.65)	0.85 (0.56, 1.27)	0.96 (0.64, 1.41)		1.00 (0.22, 4.56)	1.09 (0.68, 1.75)
Holladay2-LT	0.99 (0.26, 3.53)	0.98 (0.24, 3.57)	0.81 (0.21, 2.82)	0.92 (0.24, 3.20)	0.96 (0.25, 3.38)		-
T2	1.14 (0.76, 1.71)	1.13 (0.70, 1.83)	0.93 (0.61, 1.42)	1.05 (0.70, 1.57)	1.10 (0.69, 1.76)	1.15 (0.31, 4.64)	




Figure 5: AL <22.0mm: Within 0.25D - fixed effects model – relative effect of all options versus common comparator

**Table 9: AL <22.0mm: Within 0.25D - fixed effects model – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
SRKT	0.007	5 (2, 7)
BarrettUniversalll	0.066	5 (1, 7)
Haigis	0.286	2 (1, 6)
HofferQ	0.044	4 (1, 7)
Holladay2	0.074	5 (1, 7)
Holladay2-LT	0.327	5 (1, 7)
T2	0.196	3 (1, 7)




Figure 6: AL <22.0mm: Within 0.25D - fixed effects model – rank probability histograms

**Table 10: AL <22.0mm: Within 0.25D - fixed effects model – model fit statistics**


Residual deviance	Dbar	Dhat	pD	DIC	
22.47 (compared to 28 datapoints)	142.482	127.373	15.109	157.592	

**Table 11: AL <22.0mm: Within 0.25D - fixed effects model – notes**

<ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); fixed effects</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
---



**PROPORTION WITHIN 0.5 DIOPTRES – random effects model**



**Figure 7: AL <22.0mm: Within 0.50D - random effects model – evidence network**

**Table 12: AL <22.0mm: Within 0.50D - random effects model - input data**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	Holladay2-LT	LadasSuperFormula	Olsen_standalone	T2
Cooke & (2016)	28/41		32/41	28/41	26/41		30/41	27/41		33/41	25/41	30/41
Doshi et al. (2017)	22/40			7/40	17/40							
Kane,J. et al. (2016)	93/156		97/156	98/156	87/156	96/156						94/156
Ozcura et al. (2016)	14/32				15/32							
Carifi et al. (2015)	6/28			12/28	11/28	12/28						
Eom et al. (2014)				50/75	47/75							
Srivannaboon et al. (2013)				6/15	9/15	7/15			7/15			
Day et al. (2012)	20/32			24/32	18/32							
Day et al. (2012)	54/100			68/100	60/100							
Day et al. (2012)	6/19			4/19	9/19							
Day et al. (2012)	4/12			4/12	4/12							
Aristodemou et al. (2011)	91/151				85/151							
Aristodemou et al. (2011)	276/457				293/457							
Percival et al. (2002)	25/54	36/54			35/54							
Moschos et al. (2014)	13/69			50/69	41/69							

**Table 13: AL <22.0mm: Within 0.50D - random effects model - relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	Holladay2-LT	LadasSuperFormula	Olsen_standalone	T2

	SRKT	AvgHofferQSR KT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	Holladay2-LT	LadasSuperFo rmula	Olsen_standal one	T2
SRKT		2.32 (1.06, 5.05)	1.19 (0.79, 1.80)	1.38 (0.68, 2.80)	1.25 (0.92, 1.71)	1.47 (0.62, 3.45)	1.27 (0.49, 3.29)	0.90 (0.36, 2.25)	-	1.92 (0.69, 5.28)	0.73 (0.29, 1.80)	1.07 (0.71, 1.61)
AvgHofferQSRKT	1.82 (0.51, 6.65)		-	-	0.92 (0.42, 2.04)	-	-	-	-	-	-	-
BarrettUniversall	1.65 (0.70, 3.92)	0.91 (0.20, 4.12)		0.94 (0.62, 1.42)	0.71 (0.47, 1.07)	0.97 (0.62, 1.54)	0.77 (0.28, 2.11)	0.54 (0.20, 1.45)	-	1.16 (0.40, 3.38)	0.44 (0.17, 1.16)	0.89 (0.59, 1.35)
Haigis	1.38 (0.84, 2.21)	0.76 (0.20, 2.80)	0.84 (0.34, 1.96)		0.90 (0.65, 1.26)	0.98 (0.65, 1.47)	1.27 (0.49, 3.29)	0.90 (0.36, 2.25)	1.31 (0.31, 5.58)	1.92 (0.69, 5.28)	0.73 (0.29, 1.80)	0.96 (0.63, 1.44)
HofferQ	1.30 (0.86, 1.96)	0.71 (0.20, 2.53)	0.79 (0.34, 1.85)	0.94 (0.61, 1.50)		1.18 (0.79, 1.76)	1.57 (0.62, 4.02)	1.11 (0.45, 2.75)	0.58 (0.14, 2.48)	2.38 (0.88, 6.47)	0.90 (0.37, 2.20)	1.26 (0.84, 1.90)
Holladay2	1.45 (0.66, 3.17)	0.80 (0.18, 3.42)	0.88 (0.31, 2.43)	1.05 (0.49, 2.31)	1.11 (0.52, 2.41)		-	-	1.00 (0.24, 4.20)	-	-	0.95 (0.60, 1.49)
Holladay2_NoPreSurgRef	1.53 (0.43, 5.53)	0.84 (0.14, 4.98)	0.93 (0.23, 3.75)	1.11 (0.32, 4.08)	1.17 (0.34, 4.21)	1.06 (0.26, 4.40)		0.71 (0.27, 1.82)	-	1.51 (0.54, 4.26)	0.57 (0.23, 1.46)	1.00 (0.38, 2.66)
Holladay2_PreSurgRef	1.07 (0.31, 3.67)	0.59 (0.10, 3.36)	0.65 (0.17, 2.50)	0.78 (0.23, 2.69)	0.83 (0.24, 2.81)	0.74 (0.18, 2.95)	0.70 (0.15, 3.30)		-	2.14 (0.78, 5.85)	0.81 (0.33, 1.99)	1.41 (0.55, 3.64)
Holladay2-LT	1.23 (0.24, 6.19)	0.67 (0.09, 5.14)	0.75 (0.13, 4.28)	0.90 (0.18, 4.45)	0.95 (0.19, 4.60)	0.85 (0.16, 4.39)	0.80 (0.11, 5.95)	1.14 (0.16, 8.35)		-	-	-
LadasSuperFormula	2.36 (0.64, 8.96)	1.30 (0.21, 7.91)	1.44 (0.35, 6.04)	1.73 (0.47, 6.49)	1.82 (0.49, 6.79)	1.64 (0.39, 7.07)	1.55 (0.31, 7.85)	2.21 (0.46, 10.94)	1.94 (0.26, 14.95)		0.38 (0.14, 1.02)	0.66 (0.23, 1.86)

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	Holladay2-LT	LadasSuperFormula	Olsen_standalone	T2
Olsen_standalone	0.86 (0.25, 2.98)	0.47 (0.08, 2.72)	0.52 (0.14, 2.01)	0.62 (0.18, 2.17)	0.66 (0.19, 2.25)	0.59 (0.15, 2.41)	0.56 (0.12, 2.64)	0.80 (0.18, 3.69)	0.70 (0.10, 5.04)	0.36 (0.07, 1.73)		1.75 (0.69, 4.44)
T2	1.42 (0.60, 3.35)	0.78 (0.17, 3.48)	0.86 (0.31, 2.36)	1.03 (0.44, 2.47)	1.09 (0.47, 2.56)	0.98 (0.35, 2.72)	0.93 (0.23, 3.64)	1.32 (0.35, 4.97)	1.15 (0.20, 6.75)	0.60 (0.14, 2.43)	1.65 (0.43, 6.43)	





Figure 8: AL <22.0mm: Within 0.50D - random effects model – relative effect of all options versus common comparator

**Table 14: AL <22.0mm: Within 0.50D - random effects model – rankings for each comparator**

	Probability best	Median rank (95%CI)
SRKT	0.000	10 (5, 12)
AvgHofferQSRKT	0.217	4 (1, 12)
BarrettUniversalll	0.074	4 (1, 11)
Haigis	0.006	6 (2, 10)
HofferQ	0.002	7 (3, 11)
Holladay2	0.034	6 (1, 11)
Holladay2_NoPreSurgRef	0.113	5 (1, 12)
Holladay2_PreSurgRef	0.032	9 (1, 12)
Holladay2-LT	0.122	8 (1, 12)
LadasSuperFormula	0.357	2 (1, 11)
Olsen_standalone	0.014	11 (2, 12)
T2	0.031	6 (1, 12)



**Figure 9: AL <22.0mm: Within 0.50D - random effects model – rank probability histograms**

**Table 15: AL <22.0mm: Within 0.50D - random effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
52.32 (compared to 52 datapoints)	272.542	229.532	43.01	315.552	0.589 (95%CI: 0.345, 0.920)

**Table 16: AL <22.0mm: Within 0.50D - random effects model – notes**

- |  |
|--|
| <ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); random effects</li> <li>• Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul> |
|--|

PROPORTION WITHIN 1.0 DIOPTRE – random effects model




Figure 10: AL <22.0mm: Within 1.0D - random effects model – evidence network



**Table 17: AL <22.0mm: Within 1.0D - random effects model - input data**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	Holladay2-LT	LadasSuperFormula	Olsen_standalone	T2
Cooke & (2016)	39/41		38/41	39/41	36/41		36/41	38/41		38/41	39/41	39/41
Doshi et al. (2017)	33/40			14/40	36/40							
Kane,J. et al. (2016)	144/156		144/156	142/156	142/156	143/156						145/156
Ozcura et al. (2016)	24/32				26/32							
Carifi et al. (2015)	12/28			13/28	17/28	18/28						
Eom et al. (2014)				66/75	66/75							
Srivannaboon et al. (2013)				11/15	13/15	13/15			13/15			
Day et al. (2012)	28/32			31/32	28/32							
Day et al. (2012)	89/100			93/100	92/100							
Day et al. (2012)	14/19			12/19	14/19							
Day et al. (2012)	6/12			7/12	6/12							
Aristodemou et al. (2011)	130/151				131/151							
Aristodemou et al. (2011)	399/457				408/457							
Percival et al. (2002)	43/54	45/54			48/54							
Moschos et al. (2014)	47/69			64/69	59/69							

**Table 18: AL <22.0mm: Within 1.0D - random effects model - relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	Holladay2-LT	LadasSuperFormula	Olsen_standalone	T2

	SRKT	AvgHofferQSR KT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	Holladay2-LT	LadasSuperFo rmula	Olsen_standal one	T2
SRKT		1.28 (0.48, 3.39)	0.93 (0.44, 1.99)	1.10 (0.49, 2.48)	1.29 (1.02, 1.65)	1.39 (0.55, 3.53)	0.37 (0.07, 2.02)	0.65 (0.10, 4.11)	-	0.65 (0.10, 4.11)	1.00 (0.13, 7.46)	1.08 (0.50, 2.37)
AvgHofferQSRKT	1.05 (0.23, 4.61)		-	-	1.60 (0.53, 4.86)	-	-	-	-	-	-	-
BarrettUniversall	1.27 (0.43, 3.83)	1.21 (0.20, 7.73)		0.93 (0.44, 1.95)	0.77 (0.38, 1.57)	0.92 (0.40, 2.08)	0.57 (0.13, 2.55)	1.00 (0.19, 5.27)	-	1.00 (0.19, 5.27)	1.54 (0.24, 9.73)	1.17 (0.54, 2.52)
Haigis	1.07 (0.62, 1.88)	1.02 (0.22, 4.95)	0.84 (0.28, 2.50)		1.18 (0.63, 2.20)	1.44 (0.79, 2.63)	0.37 (0.07, 2.02)	0.65 (0.10, 4.11)	2.36 (0.36, 15.45)	0.65 (0.10, 4.11)	1.00 (0.13, 7.46)	1.25 (0.58, 2.68)
HofferQ	1.32 (0.81, 2.11)	1.26 (0.28, 5.75)	1.04 (0.34, 3.00)	1.23 (0.71, 2.10)		1.10 (0.60, 2.03)	1.00 (0.27, 3.75)	1.76 (0.39, 7.90)	1.00 (0.12, 8.21)	1.76 (0.39, 7.90)	2.71 (0.49, 14.84)	1.49 (0.71, 3.13)
Holladay2	1.56 (0.63, 4.02)	1.48 (0.27, 8.68)	1.23 (0.35, 4.38)	1.45 (0.59, 3.70)	1.18 (0.48, 3.04)		-	-	1.00 (0.12, 8.21)	-	-	1.20 (0.52, 2.76)
Holladay2_NoPreSurgRef	0.63 (0.13, 3.23)	0.60 (0.07, 5.29)	0.50 (0.09, 2.81)	0.59 (0.12, 2.94)	0.48 (0.10, 2.41)	0.41 (0.07, 2.40)		1.76 (0.39, 7.90)	-	1.76 (0.39, 7.90)	2.71 (0.49, 14.84)	2.71 (0.49, 14.84)
Holladay2_PreSurgRef	1.20 (0.22, 8.15)	1.16 (0.12, 13.02)	0.95 (0.15, 7.30)	1.12 (0.20, 7.69)	0.91 (0.16, 6.23)	0.77 (0.12, 6.00)	1.90 (0.25, 16.72)		-	1.00 (0.19, 5.27)	1.54 (0.24, 9.73)	1.54 (0.24, 9.73)
Holladay2-LT	2.00 (0.26, 22.38)	1.94 (0.16, 32.60)	1.58 (0.17, 21.34)	1.87 (0.25, 21.28)	1.52 (0.20, 17.15)	1.29 (0.16, 14.88)	3.20 (0.24, 55.29)	1.70 (0.10, 30.39)		-	-	-
LadasSuperFormula	1.18 (0.21, 7.80)	1.14 (0.12, 12.03)	0.94 (0.14, 6.75)	1.11 (0.20, 7.26)	0.90 (0.16, 5.99)	0.76 (0.11, 5.82)	1.87 (0.24, 16.44)	0.99 (0.10, 9.58)	0.59 (0.03, 8.93)		1.54 (0.24, 9.73)	1.54 (0.24, 9.73)

	SRKT	AvgHofferQSRKT	BarrettUniversalll	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	Holladay2-LT	LadasSuperFormula	Olsen_standalone	T2
Olsen_standalone	2.00 (0.31, 20.29)	1.96 (0.17, 27.07)	1.58 (0.21, 16.97)	1.86 (0.28, 18.71)	1.51 (0.24, 15.13)	1.29 (0.17, 14.30)	3.21 (0.35, 38.30)	1.66 (0.15, 22.15)	1.01 (0.05, 19.87)	1.69 (0.16, 21.88)		1.00 (0.13, 7.46)
T2	1.57 (0.53, 4.94)	1.50 (0.24, 9.77)	1.23 (0.34, 4.73)	1.46 (0.48, 4.64)	1.19 (0.40, 3.73)	1.01 (0.28, 3.68)	2.46 (0.43, 14.60)	1.31 (0.17, 8.54)	0.79 (0.06, 7.53)	1.32 (0.17, 8.98)	0.78 (0.07, 6.03)	





Figure 11: AL <22.0mm: Within 1.0D - random effects model – relative effect of all options versus common comparator

**Table 19: AL <22.0mm: Within 1.0D - random effects model – rankings for each comparator**

	Probability best	Median rank (95%CI)
SRKT	0.001	8 (4, 12)
AvgHofferQSRKT	0.058	8 (1, 12)
BarrettUniversalll	0.032	6 (1, 12)
Haigis	0.002	8 (3, 11)
HofferQ	0.006	6 (2, 10)
Holladay2	0.056	5 (1, 11)
Holladay2_NoPreSurgRef	0.012	11 (2, 12)
Holladay2_PreSurgRef	0.095	7 (1, 12)
Holladay2-LT	0.298	3 (1, 12)
LadasSuperFormula	0.093	7 (1, 12)
Olsen_standalone	0.273	3 (1, 12)
T2	0.075	5 (1, 11)



**Figure 12: AL <22.0mm: Within 1.0D - random effects model – rank probability histograms**


**Table 20: AL <22.0mm: Within 1.0D - random effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
50.87 (compared to 52 datapoints)	236.411	195.954	40.458	276.869	0.653 (95%CI: 0.367, 1.035)

**Table 21: AL <22.0mm: Within 1.0D - random effects model – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations

**PROPORTION WITHIN 2.0 DIOPTRES – fixed effects model**



**Figure 13: AL <22.0mm: Within 2.0D - fixed effects model – evidence network**

**Table 22: AL <22.0mm: Within 2.0D - fixed effects model – input data**

	SRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	155/156	156/156	156/156	156/156	156/156	155/156

	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	T2
Ozcura et al. (2016)	31/32			31/32		
Carifi et al. (2015)	22/28		24/28	25/28	26/28	

**Table 23: AL <22.0mm: Within 2.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	T2
SRKT		3.02 (0.12, 74.69)	1.83 (0.51, 6.48)	2.05 (0.61, 6.86)	3.42 (0.76, 15.35)	1.00 (0.06, 16.13)
BarrettUniversall	4.65 (0.25, 2033.00)		1.00 (0.02, 50.71)	1.00 (0.02, 50.71)	1.00 (0.02, 50.71)	0.33 (0.01, 8.19)
Haigis	1.77 (0.51, 7.04)	0.38 (0.00, 8.10)		1.33 (0.30, 5.81)	1.90 (0.38, 9.54)	0.33 (0.01, 8.19)
HofferQ	2.14 (0.63, 8.20)	0.46 (0.00, 9.67)	1.21 (0.28, 5.31)		1.44 (0.27, 7.74)	0.33 (0.01, 8.19)
Holladay2	3.61 (0.85, 21.95)	0.77 (0.00, 20.64)	2.03 (0.40, 13.61)	1.67 (0.32, 11.15)		0.33 (0.01, 8.19)
T2	0.91 (0.10, 12.74)	0.20 (0.00, 6.00)	0.51 (0.05, 7.38)	0.42 (0.04, 6.24)	0.25 (0.02, 4.14)	






Figure 14: AL <22.0mm: Within 2.0D - fixed effects model – relative effect of all options versus common comparator

Table 24: AL <22.0mm: Within 2.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.003	5 (3, 6)
BarrettUniversalll	0.492	2 (1, 6)
Haigis	0.052	4 (1, 6)
HofferQ	0.089	3 (1, 6)
Holladay2	0.309	2 (1, 5)
T2	0.055	5 (1, 6)




Figure 15: AL <22.0mm: Within 2.0D - fixed effects model – rank probability histograms

Table 25: AL <22.0mm: Within 2.0D - fixed effects model – model fit statistics


Residual deviance	Dbar	Dhat	pD	DIC
9.174 (compared to 12 datapoints)	35.541	28.066	7.474	43.015

**Table 26: AL <22.0mm: Within 2.0D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

**H.3.2.3 Full dataset: Axial length subgroup – 22.00 to 24.50mm**

**MEAN ABSOLUTE ERROR – fixed effects model**



**Figure 16: AL 22.0-24.5mm: Mean absolute error - fixed effects model – evidence network**

**Table 27: AL 22.0-24.5mm: Mean absolute error - fixed effects model – input data**

	SRKT	Haigis	HofferQ	Holladay2	Holladay2-LT
Ozcura et al. (2016)	0.51 (0.42)		0.55 (0.44)		
Srivannaboon et al. (2013)		0.40 (0.33)	0.39 (0.33)	0.41 (0.31)	0.42 (0.30)

**Table 28: AL 22.0-24.5mm: Mean absolute error - fixed effects model – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	SRKT	Haigis	HofferQ	Holladay2	Holladay2-LT
SRKT		-	0.04 (-0.02, 0.10)	-	-
Haigis	0.05 (-0.05, 0.15)		-0.01 (-0.09, 0.07)	0.01 (-0.07, 0.09)	0.02 (-0.06, 0.10)
HofferQ	0.04 (-0.02, 0.10)	-0.01 (-0.09, 0.07)		0.02 (-0.06, 0.10)	0.03 (-0.05, 0.11)
Holladay2	0.06 (-0.04, 0.16)	0.01 (-0.07, 0.09)	0.02 (-0.06, 0.10)		0.01 (-0.07, 0.09)
Holladay2-LT	0.07 (-0.03, 0.17)	0.02 (-0.06, 0.10)	0.03 (-0.05, 0.11)	0.01 (-0.07, 0.09)	




Figure 17: AL 22.0-24.5mm: Mean absolute error - fixed effects model – relative effect of all options versus common comparator

Table 29: AL 22.0-24.5mm: Mean absolute error - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.739	1 (1, 4)
Haigis	0.123	3 (1, 5)
HofferQ	0.037	3 (1, 5)
Holladay2	0.068	4 (1, 5)
Holladay2-LT	0.032	4 (1, 5)




Figure 18: AL 22.0-24.5mm: Mean absolute error - fixed effects model – rank probability histograms


Table 30: AL 22.0-24.5mm: Mean absolute error - fixed effects model – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC
6.015 (compared to 6 datapoints)	-26.891	-32.905	6.014	-20.877

**Table 31: AL 22.0-24.5mm: Mean absolute error - fixed effects model – notes**

<ul style="list-style-type: none"><li>• Continuous (normal; identity link); fixed effects</li><li>• 50000 burn-ins; 10000 recorded iterations</li></ul>
---

**PROPORTION WITHIN 0.25 DIOPTRES – fixed effects model**



**Figure 19: AL 22.0-24.5mm: Within 0.25D - fixed effects model – evidence network**

**Table 32: AL 22.0-24.5mm: Within 0.25D - fixed effects model – input data**

	SRKT	BarrettUniversa II	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Kane,J. et al. (2016)	1018/2638	1126/2638	1029/2638	1029/2638	1000/2638		1029/2638
Srivannaboon et al. (2013)			52/124	50/124	45/124	46/124	
Aristodemou et al. (2011)	599/1508			609/1508			
Aristodemou et al. (2011)	1985/4699			1900/4699			

**Table 33: AL 22.0-24.5mm: Within 0.25D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
SRKT		1.19 (1.06, 1.32)	1.02 (0.91, 1.14)	0.97 (0.91, 1.03)	0.97 (0.87, 1.09)	-	1.02 (0.91, 1.14)
BarrettUniversall	1.16 (1.05, 1.28)		0.86 (0.77, 0.96)	0.86 (0.77, 0.96)	0.82 (0.73, 0.92)	-	0.86 (0.77, 0.96)
Haigis	1.00 (0.90, 1.10)	0.86 (0.77, 0.96)		1.00 (0.89, 1.11)	0.95 (0.85, 1.05)	0.82 (0.49, 1.36)	1.00 (0.90, 1.12)
HofferQ	0.97 (0.91, 1.03)	0.84 (0.76, 0.93)	0.97 (0.88, 1.08)		0.95 (0.85, 1.06)	0.87 (0.52, 1.46)	1.00 (0.90, 1.12)
Holladay2	0.94 (0.85, 1.04)	0.82 (0.73, 0.91)	0.95 (0.85, 1.06)	0.97 (0.88, 1.07)		1.04 (0.62, 1.74)	1.05 (0.94, 1.17)



	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Holladay2-LT	0.87 (0.57, 1.33)	0.76 (0.49, 1.15)	0.88 (0.57, 1.33)	0.90 (0.59, 1.36)	0.93 (0.60, 1.41)		-
T2	0.99 (0.90, 1.10)	0.86 (0.77, 0.96)	1.00 (0.89, 1.11)	1.02 (0.93, 1.13)	1.05 (0.94, 1.18)	1.14 (0.75, 1.76)	




Figure 20: AL 22.0-24.5mm: Within 0.25D - fixed effects model – relative effect of all options versus common comparator

Table 34: AL 22.0-24.5mm: Within 0.25D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.001	3 (2, 6)
BarrettUniversall	0.895	1 (1, 2)
Haigis	0.003	4 (2, 7)
HofferQ	0.000	5 (2, 7)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2	0.000	6 (3, 7)
Holladay2-LT	0.098	7 (1, 7)
T2	0.003	4 (2, 7)




Figure 21: AL 22.0-24.5mm: Within 0.25D - fixed effects model – rank probability histograms

**Table 35: AL 22.0-24.5mm: Within 0.25D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC
12.98 (compared to 14 datapoints)	116.779	106.805	9.974	126.752

**Table 36: AL 22.0-24.5mm: Within 0.25D - fixed effects model – notes**

<ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); fixed effects</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
---

PROPORTION WITHIN 0.5 DIOPTRES – fixed effects model




Figure 22: AL 22.0-24.5mm: Within 0.5D - fixed effects model – evidence network

**Table 37: AL 22.0-24.5mm: Within 0.5D - fixed effects model – input data**

	SRKT	BarrettUniversa II	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Kane,J. et al. (2016)	1868/2638	1881/2638	1820/2638	1796/2638	1796/2638		1833/2638
Ozcura et al. (2016)	245/422			221/422			
Srivannaboon et al. (2013)			82/124	84/124	87/124	89/124	
Aristodemou et al. (2011)	1062/1508			1033/1508			
Aristodemou et al. (2011)	3353/4699			3266/4699			

**Table 38: AL 22.0-24.5mm: Within 0.5D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
SRKT		1.02 (0.91, 1.15)	0.92 (0.82, 1.03)	0.90 (0.84, 0.96)	0.88 (0.78, 0.99)	-	0.94 (0.83, 1.06)
BarrettUniversall	1.04 (0.93, 1.15)		0.90 (0.80, 1.01)	0.86 (0.76, 0.97)	0.86 (0.76, 0.97)	-	0.92 (0.81, 1.03)
Haigis	0.92 (0.83, 1.03)	0.89 (0.79, 1.00)		0.96 (0.86, 1.08)	0.97 (0.86, 1.09)	1.30 (0.76, 2.23)	1.02 (0.91, 1.15)
HofferQ	0.90 (0.84, 0.96)	0.87 (0.78, 0.96)	0.97 (0.88, 1.08)		1.01 (0.90, 1.13)	1.21 (0.70, 2.08)	1.07 (0.95, 1.20)
Holladay2	0.89 (0.81, 0.99)	0.86 (0.77, 0.97)	0.97 (0.86, 1.09)	1.00 (0.90, 1.11)		1.08 (0.62, 1.87)	1.07 (0.95, 1.20)
Holladay2-LT	1.09	1.05	1.18	1.21	1.22		-

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
	(0.70, 1.73)	(0.67, 1.68)	(0.75, 1.87)	(0.78, 1.92)	(0.78, 1.93)		
T2	0.95 (0.85, 1.06)	0.92 (0.81, 1.03)	1.03 (0.92, 1.16)	1.06 (0.95, 1.17)	1.06 (0.95, 1.19)	0.87 (0.55, 1.37)	




Figure 23: AL 22.0-24.5mm: Within 0.5D - fixed effects model – relative effect of all options versus common comparator

Table 39: AL 22.0-24.5mm: Within 0.5D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.094	3 (1, 5)
BarrettUniversall	0.318	2 (1, 4)
Haigis	0.004	5 (2, 7)
HofferQ	0.000	6 (4, 7)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2	0.000	6 (3, 7)
Holladay2-LT	0.569	1 (1, 7)
T2	0.016	4 (2, 7)






Figure 24: AL 22.0-24.5mm: Within 0.5D - fixed effects model – rank probability histograms


**Table 40: AL 22.0-24.5mm: Within 0.5D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC
12.8 (compared to 16 datapoints)	127.886	116.882	11.004	138.89

**Table 41: AL 22.0-24.5mm: Within 0.5D - fixed effects model – notes**

<ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); fixed effects</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
---

**PROPORTION WITHIN 1.0 DIOPTRE – fixed effects model**



**Figure 25: AL 22.0-24.5mm: Within 1.0D - fixed effects model – evidence network**

**Table 42: AL 22.0-24.5mm: Within 1.0D - fixed effects model – input data**

	SRKT	BarrettUniversaII	Haigis	HofferQ	Holladay2	Holladay2-LT	T2

	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Kane,J. et al. (2016)	2477/2638	2485/2638	2453/2638	2451/2638	2480/2638		2467/2638
Ozcura et al. (2016)	374/422			374/422			
Srivannaboon et al. (2013)			114/124	118/124	118/124	118/124	
Aristodemou et al. (2011)	1398/1508			1400/1508			
Aristodemou et al. (2011)	4430/4699			4432/4699			

**Table 43: AL 22.0-24.5mm: Within 1.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
SRKT		1.06 (0.84, 1.33)	0.86 (0.69, 1.07)	0.96 (0.86, 1.08)	1.02 (0.81, 1.28)	-	0.94 (0.75, 1.17)
BarrettUniversall	1.12 (0.91, 1.38)		0.82 (0.65, 1.02)	0.81 (0.65, 1.01)	0.97 (0.77, 1.22)	-	0.89 (0.71, 1.11)
Haigis	0.90 (0.75, 1.10)	0.81 (0.65, 1.00)		1.01 (0.82, 1.24)	1.20 (0.97, 1.49)	1.73 (0.61, 4.90)	1.09 (0.88, 1.35)
HofferQ	0.96 (0.86, 1.08)	0.86 (0.70, 1.05)	1.07 (0.88, 1.29)		1.19 (0.96, 1.48)	1.00 (0.31, 3.19)	1.10 (0.89, 1.36)
Holladay2	1.09 (0.89, 1.33)	0.97 (0.77, 1.22)	1.21 (0.97, 1.49)	1.13 (0.92, 1.38)		1.00 (0.31, 3.19)	0.92 (0.74, 1.15)

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Holladay2-LT	1.25 (0.51, 3.57)	1.12 (0.45, 3.25)	1.39 (0.57, 3.99)	1.30 (0.54, 3.70)	1.15 (0.47, 3.29)		-
T2	1.00 (0.82, 1.22)	0.89 (0.71, 1.11)	1.10 (0.89, 1.37)	1.03 (0.85, 1.27)	0.92 (0.73, 1.14)	0.79 (0.28, 1.97)	




Figure 26: AL 22.0-24.5mm: Within 1.0D - fixed effects model – relative effect of all options versus common comparator

Table 44: AL 22.0-24.5mm: Within 1.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.017	4 (2, 7)
BarrettUniversall	0.245	2 (1, 6)
Haigis	0.001	6 (3, 7)
HofferQ	0.003	5 (2, 7)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2	0.141	3 (1, 6)
Holladay2-LT	0.562	1 (1, 7)
T2	0.029	4 (1, 7)




Figure 27: AL 22.0-24.5mm: Within 1.0D - fixed effects model – rank probability histograms

**Table 45: AL 22.0-24.5mm: Within 1.0D - fixed effects model – model fit statistics**


Residual deviance	Dbar	Dhat	pD	DIC
13.68 (compared to 16 datapoints)	108.82	97.841	10.979	119.799

**Table 46: AL 22.0-24.5mm: Within 1.0D - fixed effects model – notes**

<ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); fixed effects</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
---



**PROPORTION WITHIN 2.0 DIOPTRES – fixed effects model**



**Figure 28: AL 22.0-24.5mm: Within 2.0D - fixed effects model – evidence network**

**Table 47: AL 22.0-24.5mm: Within 2.0D - fixed effects model – input data**

	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	2633/2638	2635/2638	2627/2638	2627/2638	2630/2638	2630/2638

	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	T2
Ozcura et al. (2016)	420/422			415/422		

**Table 48: AL 22.0-24.5mm: Within 2.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	T2
SRKT		1.67 (0.40, 6.99)	0.45 (0.16, 1.31)	0.39 (0.16, 0.93)	0.62 (0.20, 1.91)	0.62 (0.20, 1.91)
BarrettUniversall	1.57 (0.41, 7.93)		0.27 (0.08, 0.98)	0.27 (0.08, 0.98)	0.37 (0.10, 1.41)	0.37 (0.10, 1.41)
Haigis	0.39 (0.14, 1.05)	0.25 (0.05, 0.83)		1.00 (0.43, 2.31)	1.38 (0.55, 3.43)	1.38 (0.55, 3.43)
HofferQ	0.37 (0.14, 0.87)	0.24 (0.05, 0.77)	0.95 (0.41, 2.14)		1.38 (0.55, 3.43)	1.38 (0.55, 3.43)
Holladay2	0.54 (0.18, 1.59)	0.35 (0.07, 1.23)	1.39 (0.56, 3.66)	1.46 (0.61, 3.71)		1.00 (0.37, 2.67)
T2	0.55 (0.18, 1.59)	0.35 (0.07, 1.25)	1.39 (0.56, 3.70)	1.46 (0.61, 3.75)	1.00 (0.36, 2.75)	




Figure 29: AL 22.0-24.5mm: Within 2.0D - fixed effects model – relative effect of all options versus common comparator

Table 49: AL 22.0-24.5mm: Within 2.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.242	2 (1, 4)
BarrettUniversall	0.714	1 (1, 3)
Haigis	0.002	5 (3, 6)
HofferQ	0.001	5 (3, 6)
Holladay2	0.020	4 (2, 6)
T2	0.022	4 (2, 6)




Figure 30: AL 22.0-24.5mm: Within 2.0D - fixed effects model – rank probability histograms

Table 50: AL 22.0-24.5mm: Within 2.0D - fixed effects model – model fit statistics


Residual deviance	Dbar	Dhat	pD	DIC
7.367 (compared to 8 datapoints)	36.6	29.761	6.839	43.439

**Table 51: AL 22.0-24.5mm: Within 2.0D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

**H.3.2.4 Full dataset: Axial length subgroup – 24.50 to 26.00mm**

**MEAN ABSOLUTE ERROR – fixed effects model**




**Figure 31: AL 24.5-26.0mm: Mean absolute error - fixed effects model – evidence network**

**Table 52: AL 24.5-26.0mm: Mean absolute error - fixed effects model – input data**

	Haigis	HofferQ	Holladay2	Holladay2-LT
Srivannaboon et al. (2013)	0.39 (0.32)	0.45 (0.35)	0.38 (0.34)	0.39 (0.33)

**Table 53: AL 24.5-26.0mm: Mean absolute error - fixed effects model – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	Haigis	HofferQ	Holladay2	Holladay2-LT
Haigis		0.06 (-0.13, 0.25)	-0.01 (-0.20, 0.18)	0.00 (-0.18, 0.18)
HofferQ	0.06 (-0.13, 0.25)		-0.07 (-0.27, 0.13)	-0.06 (-0.25, 0.13)
Holladay2	-0.01 (-0.20, 0.18)	-0.07 (-0.27, 0.13)		0.01 (-0.18, 0.20)
Holladay2-LT	0.00 (-0.18, 0.18)	-0.06 (-0.25, 0.13)	0.01 (-0.18, 0.20)	



**Figure 32: AL 24.5-26.0mm: Mean absolute error - fixed effects model – relative effect of all options versus common comparator**

**Table 54: AL 24.5-26.0mm: Mean absolute error - fixed effects model – rankings for each comparator**

	Probability best	Median rank (95%CI)
Haigis	0.280	2 (1, 4)
HofferQ	0.085	4 (1, 4)
Holladay2	0.349	2 (1, 4)
Holladay2-LT	0.286	2 (1, 4)




Figure 33: AL 24.5-26.0mm: Mean absolute error - fixed effects model – rank probability histograms

Table 55: AL 24.5-26.0mm: Mean absolute error - fixed effects model – model fit statistics


Residual deviance	Dbar	Dhat	pD	DIC
3.991 (compared to 4 datapoints)	-10.123	-14.114	3.991	-6.133



**Table 56: AL 24.5-26.0mm: Mean absolute error - fixed effects model – notes**

<ul style="list-style-type: none"><li>• Continuous (normal; identity link); fixed effects</li><li>• 50000 burn-ins; 10000 recorded iterations</li></ul>
---

**PROPORTION WITHIN 0.25 DIOPTRES – fixed effects model**



**Figure 34: AL 24.5-26.0mm: Within 0.25D - fixed effects model – evidence network**

**Table 57: AL 24.5-26.0mm: Within 0.25D - fixed effects model – input data**

	SRKT	BarrettUniversa II	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Kane,J. et al. (2016)	144/372	172/372	143/372	130/372	154/372		147/372
Srivannaboon et al. (2013)			12/24	10/24	14/24	12/24	
Aristodemou et al. (2011)	105/234			104/234			
Aristodemou et al. (2011)	272/712			275/712			

**Table 58: AL 24.5-26.0mm: Within 0.25D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
SRKT		1.36 (1.02, 1.82)	0.99 (0.74, 1.33)	0.96 (0.82, 1.13)	1.12 (0.83, 1.50)	-	1.03 (0.77, 1.39)
BarrettUniversall	1.45 (1.12, 1.89)		0.73 (0.54, 0.97)	0.62 (0.47, 0.84)	0.82 (0.61, 1.10)	-	0.76 (0.57, 1.02)
Haigis	1.06 (0.81, 1.38)	0.73 (0.54, 0.97)		0.85 (0.64, 1.13)	1.15 (0.86, 1.52)	1.00 (0.32, 3.10)	1.05 (0.78, 1.40)
HofferQ	0.96 (0.82, 1.12)	0.66 (0.51, 0.86)	0.91 (0.70, 1.18)		1.35 (1.01, 1.80)	1.40 (0.45, 4.38)	1.22 (0.90, 1.64)
Holladay2	1.21 (0.93, 1.57)	0.83 (0.63, 1.11)	1.15 (0.86, 1.52)	1.27 (0.98, 1.64)		0.71 (0.23, 2.23)	0.92 (0.69, 1.24)

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Holladay2-LT	1.07 (0.41, 2.76)	0.74 (0.28, 1.94)	1.01 (0.39, 2.61)	1.12 (0.43, 2.89)	0.88 (0.34, 2.30)		-
T2	1.10 (0.85, 1.44)	0.76 (0.57, 1.01)	1.05 (0.78, 1.40)	1.15 (0.88, 1.51)	0.91 (0.68, 1.22)	1.04 (0.39, 2.73)	




Figure 35: AL 24.5-26.0mm: Within 0.25D - fixed effects model – relative effect of all options versus common comparator

Table 59: AL 24.5-26.0mm: Within 0.25D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.001	5 (3, 7)
BarrettUniversall	0.658	1 (1, 3)
Haigis	0.005	4 (2, 7)
HofferQ	0.000	6 (3, 7)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2	0.065	3 (1, 6)
Holladay2-LT	0.256	4 (1, 7)
T2	0.015	4 (2, 7)




Figure 36: AL 24.5-26.0mm: Within 0.25D - fixed effects model – rank probability histograms

**Table 60: AL 24.5-26.0mm: Within 0.25D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
11.55 (compared to 14 datapoints)	89.771	79.757	10.014	99.785	

**Table 61: AL 24.5-26.0mm: Within 0.25D - fixed effects model – notes**

<ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); fixed effects</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
---

**PROPORTION WITHIN 0.5 DIOPTRES – fixed effects model**




Figure 37: AL 24.5-26.0mm: Within 0.5D - fixed effects model – evidence network

Table 62: AL 24.5-26.0mm: Within 0.5D - fixed effects model – input data

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2-LT	T2

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Kane,J. et al. (2016)	248/372		285/372	255/372	256/372	250/372		265/372
Srivannaboon et al. (2013)				19/24	14/24	17/24	14/24	
Aristodemou et al. (2011)	170/234				173/234			
Aristodemou et al. (2011)	481/712				473/712			
Percival et al. (2002)	20/26	21/26			20/26			

**Table 63: AL 24.5-26.0mm: Within 0.5D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
SRKT		1.26 (0.33, 4.79)	1.64 (1.19, 2.26)	1.09 (0.80, 1.48)	1.01 (0.86, 1.19)	1.02 (0.75, 1.39)	-	1.24 (0.91, 1.69)
AvgHofferQSRKT	1.30 (0.41, 4.73)		-	-	0.79 (0.21, 3.02)	-	-	-
BarrettUniversall	1.59 (1.19, 2.15)	1.21 (0.33, 4.02)		0.67 (0.48, 0.92)	0.67 (0.49, 0.93)	0.63 (0.45, 0.86)	-	0.76 (0.54, 1.05)
Haigis	1.08 (0.82, 1.43)	0.83 (0.22, 2.75)	0.68 (0.49, 0.94)		0.95 (0.71, 1.29)	0.92 (0.68, 1.24)	0.37 (0.10, 1.32)	1.14 (0.83, 1.55)
HofferQ	1.00 (0.85, 1.17)	0.77 (0.21, 2.45)	0.63 (0.47, 0.84)	0.92 (0.70, 1.22)		0.97 (0.72, 1.30)	1.00 (0.32, 3.15)	1.12 (0.82, 1.54)



	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Holladay2	1.00 (0.76, 1.31)	0.76 (0.21, 2.53)	0.63 (0.46, 0.86)	0.92 (0.68, 1.24)	1.00 (0.76, 1.31)		0.58 (0.17, 1.91)	1.21 (0.88, 1.65)
Holladay2-LT	0.63 (0.24, 1.72)	0.48 (0.10, 2.21)	0.40 (0.15, 1.10)	0.58 (0.22, 1.58)	0.63 (0.24, 1.70)	0.63 (0.24, 1.71)		-
T2	1.20 (0.91, 1.60)	0.92 (0.25, 3.07)	0.76 (0.54, 1.05)	1.11 (0.81, 1.52)	1.20 (0.90, 1.60)	1.20 (0.88, 1.63)	1.90 (0.69, 5.16)	




Figure 38: AL 24.5-26.0mm: Within 0.5D - fixed effects model – relative effect of all options versus common comparator

Table 64: AL 24.5-26.0mm: Within 0.5D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.000	6 (3, 8)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
AvgHofferQSRKT	0.373	2 (1, 8)
BarrettUniversalll	0.574	1 (1, 3)
Haigis	0.003	4 (2, 7)
HofferQ	0.000	6 (3, 8)
Holladay2	0.001	6 (2, 8)
Holladay2-LT	0.025	8 (2, 8)
T2	0.025	3 (2, 7)




Figure 39: AL 24.5-26.0mm: Within 0.5D - fixed effects model – rank probability histograms


**Table 65: AL 24.5-26.0mm: Within 0.5D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC
15 (compared to 17 datapoints)	101.303	89.288	12.015	113.319

**Table 66: AL 24.5-26.0mm: Within 0.5D - fixed effects model – notes**

<ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); fixed effects</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
---

**PROPORTION WITHIN 1.0 DIOPTRE – fixed effects model**



**Figure 40: AL 24.5-26.0mm: Within 1.0D - fixed effects model – evidence network**

**Table 67: AL 24.5-26.0mm: Within 1.0D - fixed effects model – input data**

	SRKT	AvgHofferQSRKT	BarrettUniversalII	Haigis	HofferQ	Holladay2	Holladay2-LT	T2

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
Kane,J. et al. (2016)	351/372		364/372	349/372	350/372	348/372		353/372
Srivannaboon et al. (2013)				24/24	22/24	20/24	20/24	
Aristodemou et al. (2011)	215/234				224/234			
Aristodemou et al. (2011)	673/712				672/712			
Percival et al. (2002)	26/26	26/26			26/26			
Mitra et al. (2014)	17/43				19/43			
El-Nafees et al. (2010)	44/53			44/53				

**Table 68: AL 24.5-26.0mm: Within 1.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
SRKT		1.00 (0.02, 52.29)	2.72 (1.19, 6.23)	0.93 (0.55, 1.57)	1.12 (0.82, 1.52)	0.87 (0.47, 1.59)	-	1.11 (0.59, 2.10)
AvgHofferQSRKT	1.58 (0.03, 769.90)		-	-	1.00 (0.02, 52.29)	-	-	-
BarrettUniversall	3.03 (1.46, 7.12)	1.96 (0.00, 130.80)		0.33 (0.15, 0.76)	0.35 (0.15, 0.80)	0.32 (0.14, 0.72)	-	0.41 (0.18, 0.94)
Haigis	1.07 (0.67, 1.73)	0.67 (0.00, 42.56)	0.35 (0.15, 0.75)		0.95 (0.53, 1.71)	0.81 (0.46, 1.42)	0.09 (0.00, 1.83)	1.22 (0.66, 2.29)

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2-LT	T2
HofferQ	1.11 (0.82, 1.51)	0.71 (0.00, 43.61)	0.37 (0.16, 0.76)	1.04 (0.64, 1.71)		0.85 (0.48, 1.49)	0.45 (0.07, 2.76)	1.17 (0.62, 2.20)
Holladay2	0.88 (0.53, 1.46)	0.55 (0.00, 34.21)	0.29 (0.12, 0.61)	0.82 (0.48, 1.42)	0.79 (0.48, 1.32)		1.00 (0.22, 4.56)	1.28 (0.69, 2.38)
Holladay2-LT	0.51 (0.14, 2.12)	0.32 (0.00, 24.96)	0.17 (0.04, 0.77)	0.48 (0.13, 1.94)	0.46 (0.13, 1.87)	0.59 (0.16, 2.35)		-
T2	1.21 (0.70, 2.18)	0.77 (0.00, 48.51)	0.40 (0.16, 0.90)	1.14 (0.63, 2.14)	1.09 (0.63, 1.99)	1.39 (0.76, 2.60)	2.37 (0.55, 9.43)	




Figure 41: AL 24.5-26.0mm: Within 1.0D - fixed effects model – relative effect of all options versus common comparator

**Table 69: AL 24.5-26.0mm: Within 1.0D - fixed effects model – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
SRKT	0.000	5 (3, 8)
AvgHofferQSRKT	0.386	2 (1, 8)
BarrettUniversalll	0.598	1 (1, 2)
Haigis	0.001	5 (2, 7)
HofferQ	0.001	4 (2, 7)
Holladay2	0.000	6 (3, 8)
Holladay2-LT	0.007	8 (2, 8)
T2	0.007	3 (2, 7)






Figure 42: AL 24.5-26.0mm: Within 1.0D - fixed effects model – rank probability histograms


**Table 70: AL 24.5-26.0mm: Within 1.0D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
20.9 (compared to 21 datapoints)	99.813	86.224	13.589	113.402	

**Table 71: AL 24.5-26.0mm: Within 1.0D - fixed effects model – notes**

<ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); fixed effects</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
---

**PROPORTION WITHIN 2.0 DIOPTRES – fixed effects model**



**Figure 43: AL 24.5-26.0mm: Within 2.0D - fixed effects model – evidence network**

**Table 72: AL 24.5-26.0mm: Within 2.0D - fixed effects model – input data**

	SRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	371/372	372/372	370/372	370/372	371/372	371/372

**Table 73: AL 24.5-26.0mm: Within 2.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	T2
SRKT		3.01 (0.12, 74.08)	0.50 (0.05, 5.52)	0.50 (0.05, 5.52)	1.00 (0.06, 16.05)	1.00 (0.06, 16.05)
BarrettUniversall	5.33 (0.18, 2510.00)		0.20 (0.01, 4.16)	0.20 (0.01, 4.16)	0.33 (0.01, 8.19)	0.33 (0.01, 8.19)
Haigis	0.56 (0.04, 4.75)	0.11 (0.00, 2.01)		1.00 (0.14, 7.14)	2.01 (0.18, 22.21)	2.01 (0.18, 22.21)
HofferQ	0.56 (0.04, 4.76)	0.11 (0.00, 1.99)	1.01 (0.14, 7.20)		2.01 (0.18, 22.21)	2.01 (0.18, 22.21)
Holladay2	1.04 (0.07, 15.34)	0.19 (0.00, 5.79)	1.83 (0.22, 24.22)	1.83 (0.22, 25.09)		1.00 (0.06, 16.05)
T2	1.03 (0.07, 15.35)	0.20 (0.00, 5.62)	1.83 (0.21, 24.40)	1.82 (0.21, 24.37)	1.00 (0.07, 14.99)	




Figure 44: AL 24.5-26.0mm: Within 2.0D - fixed effects model – relative effect of all options versus common comparator

Table 74: AL 24.5-26.0mm: Within 2.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.097	3 (1, 6)
BarrettUniversallI	0.651	1 (1, 5)
Haigis	0.021	5 (2, 6)
HofferQ	0.021	5 (2, 6)
Holladay2	0.104	3 (1, 6)
T2	0.106	3 (1, 6)




Figure 45: AL 24.5-26.0mm: Within 2.0D - fixed effects model – rank probability histograms

Table 75: AL 24.5-26.0mm: Within 2.0D - fixed effects model – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC
6.666 (compared to 6 datapoints)	20.791	15.387	5.404	26.195

**Table 76: AL 24.5-26.0mm: Within 2.0D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations






**Table 77: AL >26.0mm: Mean absolute error - fixed effects model – input data**

	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	Holladay2_NoPre SurgRef	Holladay2_PreS urgRef	LadasSuperFor mula	Olsen_standalo ne	T2
Cooke & (2016)	0.40 (0.45)	0.30 (0.38)	0.28 (0.37)	0.43 (0.45)		0.39 (0.41)	0.41 (0.43)	0.35 (0.40)	0.29 (0.35)	0.32 (0.40)
Bang et al. (2011)	0.62 (0.77)		0.52 (0.63)	1.02 (0.88)	0.81 (0.81)					

**Table 78: AL >26.0mm: Mean absolute error - fixed effects model – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	LadasSuperFo rmula	Olsen_standal one	T2
SRKT		-0.10 (-0.25, 0.06)	-0.11 (-0.25, 0.02)	0.11 (-0.04, 0.26)	0.19 (-0.11, 0.49)	-0.01 (-0.17, 0.15)	0.01 (-0.16, 0.17)	-0.05 (-0.21, 0.11)	-0.11 (-0.26, 0.04)	-0.08 (-0.24, 0.08)
BarrettUniversall	-0.07 (-0.22, 0.08)		-0.02 (-0.16, 0.12)	0.13 (-0.03, 0.28)	-	0.09 (-0.06, 0.24)	0.10 (-0.05, 0.26)	0.05 (-0.10, 0.19)	-0.01 (-0.15, 0.12)	0.02 (-0.13, 0.16)
Haigis	-0.11 (-0.25, 0.02)	-0.04 (-0.18, 0.09)		0.23 (0.09, 0.36)	0.29 (0.01, 0.57)	0.11 (-0.04, 0.26)	0.13 (-0.02, 0.28)	0.07 (-0.08, 0.21)	0.01 (-0.13, 0.15)	0.04 (-0.11, 0.18)
HofferQ	0.11 (-0.04, 0.26)	0.18 (0.03, 0.33)	0.22 (0.09, 0.36)		-0.21 (-0.53, 0.11)	-0.04 (-0.20, 0.12)	-0.02 (-0.19, 0.14)	-0.08 (-0.24, 0.08)	-0.14 (-0.29, 0.01)	-0.11 (-0.27, 0.05)
Holladay2	0.12 (-0.15, 0.38)	0.19 (-0.09, 0.46)	0.23 (-0.02, 0.48)	0.01 (-0.26, 0.27)		-	-	-	-	-
Holladay2_NoPreSurgRef	0.02 (-0.14, 0.17)	0.09 (-0.06, 0.24)	0.13 (-0.01, 0.27)	-0.09 (-0.25, 0.06)	-0.10 (-0.38, 0.18)		0.02 (-0.14, 0.17)	-0.04 (-0.19, 0.11)	-0.10 (-0.24, 0.04)	-0.07 (-0.22, 0.08)
Holladay2_PreSurgRef	0.03	0.10	0.15	-0.08	-0.08	0.02		-0.06	-0.12	-0.09


	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	LadasSuperFo rmula	Olsen_standal one	T2
	(-0.13, 0.19)	(-0.05, 0.26)	(0.00, 0.29)	(-0.24, 0.08)	(-0.36, 0.20)	(-0.14, 0.17)		(-0.22, 0.10)	(-0.26, 0.03)	(-0.24, 0.07)
LadasSuperFormula	-0.02 (-0.18, 0.13)	0.05 (-0.10, 0.19)	0.09 (-0.05, 0.23)	-0.14 (-0.29, 0.02)	-0.14 (-0.42, 0.14)	-0.04 (-0.19, 0.11)	-0.06 (-0.21, 0.10)		-0.06 (-0.20, 0.08)	-0.03 (-0.18, 0.12)
Olsen_standalone	-0.08 (-0.23, 0.06)	-0.01 (-0.15, 0.13)	0.03 (-0.10, 0.16)	-0.19 (-0.34, - 0.05)	-0.20 (-0.47, 0.07)	-0.10 (-0.24, 0.04)	-0.12 (-0.26, 0.03)	-0.06 (-0.20, 0.09)		0.03 (-0.11, 0.17)
T2	-0.05 (-0.21, 0.10)	0.02 (-0.13, 0.16)	0.06 (-0.08, 0.20)	-0.17 (-0.32, - 0.01)	-0.17 (-0.45, 0.11)	-0.07 (-0.22, 0.08)	-0.09 (-0.25, 0.07)	-0.03 (-0.18, 0.12)	0.03 (-0.11, 0.17)	



**Figure 47: AL >26.0mm: Mean absolute error - fixed effects model – relative effect of all options versus common comparator**

**Table 79: AL >26.0mm: Mean absolute error - fixed effects model – rankings for each comparator**

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
SRKT	0.012	6 (2, 9)
BarrettUniversalll	0.153	3 (1, 8)
Haigis	0.450	2 (1, 5)
HofferQ	0.000	9 (6, 10)
Holladay2	0.025	9 (1, 10)
Holladay2_NoPreSurgRef	0.008	7 (2, 10)
Holladay2_PreSurgRef	0.004	7 (3, 10)
LadasSuperFormula	0.038	5 (1, 9)
Olsen_standalone	0.204	3 (1, 7)
T2	0.105	4 (1, 8)



**Figure 48: AL >26.0mm: Mean absolute error - fixed effects model – rank probability histograms**


**Table 80: AL >26.0mm: Mean absolute error - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC
16.31 (compared to 13 datapoints)	-30.087	-41.112	11.025	-19.062

**Table 81: AL >26.0mm: Mean absolute error - fixed effects model – notes**

<ul style="list-style-type: none"> <li>• Continuous (normal; identity link); fixed effects</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
--

**PROPORTION WITHIN 0.25 DIOPTRES – fixed effects model**



**Figure 49: AL >26.0mm: Within 0.25D - fixed effects model – evidence network**

**Table 82: AL >26.0mm: Within 0.25D - fixed effects model – input data**

	SRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	30/77	26/77	28/77	26/77	25/77	24/77

	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	T2
Aristodemou et al. (2011)	21/47			18/47		
Aristodemou et al. (2011)	111/271			96/271		
Aristodemou et al. (2011)	5/17			2/17		

**Table 83: AL >26.0mm: Within 0.25D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	T2
SRKT		0.80 (0.41, 1.54)	0.90 (0.47, 1.72)	0.77 (0.58, 1.02)	0.75 (0.39, 1.46)	0.71 (0.36, 1.38)
BarrettUniversall	0.78 (0.43, 1.41)		1.12 (0.58, 2.17)	1.00 (0.51, 1.95)	0.94 (0.48, 1.85)	0.89 (0.45, 1.74)
Haigis	0.88 (0.48, 1.57)	1.12 (0.58, 2.21)		0.89 (0.46, 1.73)	0.84 (0.43, 1.64)	0.79 (0.41, 1.55)
HofferQ	0.77 (0.58, 1.02)	0.98 (0.55, 1.80)	0.88 (0.49, 1.61)		0.94 (0.48, 1.85)	0.89 (0.45, 1.74)
Holladay2	0.74 (0.40, 1.32)	0.94 (0.48, 1.84)	0.84 (0.43, 1.63)	0.96 (0.52, 1.71)		0.94 (0.48, 1.86)
T2	0.69 (0.38, 1.25)	0.88 (0.45, 1.74)	0.79 (0.40, 1.55)	0.90 (0.49, 1.63)	0.94 (0.48, 1.85)	




Figure 50: AL >26.0mm: Within 0.25D - fixed effects model – relative effect of all options versus common comparator

Table 84: AL >26.0mm: Within 0.25D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.490	2 (1, 4)
BarrettUniversall	0.119	4 (1, 6)
Haigis	0.247	3 (1, 6)
HofferQ	0.011	4 (2, 6)
Holladay2	0.079	4 (1, 6)
T2	0.053	5 (1, 6)






Figure 51: AL >26.0mm: Within 0.25D - fixed effects model – rank probability histograms


Table 85: AL >26.0mm: Within 0.25D - fixed effects model – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC
10.05 (compared to 12 datapoints)	64.405	55.388	9.017	73.422

**Table 86: AL >26.0mm: Within 0.25D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

**PROPORTION WITHIN 0.5 DIOPTRES – fixed effects model**



**Figure 52: AL >26.0mm: Within 0.5D - fixed effects model – evidence network**

**Table 87: AL >26.0mm: Within 0.5D - fixed effects model – input data**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	LadasSuperFormula	Olsen_standalone	T2
Cooke & (2016)	41/54		41/54	44/54	34/54		37/54	37/54	41/54	45/54	44/54
Kane,J. et al. (2016)	48/77		48/77	44/77	41/77	44/77					49/77
Bang et al. (2011)	27/53			30/53	18/53	22/53					
Aristodemou et al. (2011)	37/47				33/47						
Aristodemou et al. (2011)	197/271				167/271						
Aristodemou et al. (2011)	10/17				3/17						
Percival et al. (2002)	16/20	15/20			12/20						

**Table 88: AL >26.0mm: Within 0.5D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	LadasSuperFormula	Olsen_standalone	T2
SRKT		0.75 (0.17, 3.33)	1.00 (0.59, 1.69)	1.05 (0.68, 1.62)	0.57 (0.44, 0.73)	0.75 (0.46, 1.23)	0.69 (0.30, 1.61)	0.69 (0.30, 1.61)	1.00 (0.41, 2.42)	1.59 (0.61, 4.10)	1.16 (0.68, 1.98)
AvgHofferQSRKT	0.98 (0.29, 3.72)		-	-	0.50 (0.13, 1.93)	-	-	-	-	-	-
BarrettUniversall	0.97	0.98		0.96	0.63	0.81	0.69	0.69	1.00	1.59	1.16

	SRKT	AvgHofferQSR KT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	LadasSuperFo rmula	Olsen_standal one	T2
	(0.61, 1.54)	(0.25, 3.65)		(0.57, 1.63)	(0.38, 1.04)	(0.42, 1.54)	(0.30, 1.61)	(0.30, 1.61)	(0.41, 2.42)	(0.61, 4.10)	(0.68, 1.98)
Haigis	1.03 (0.69, 1.53)	1.05 (0.26, 3.74)	1.07 (0.64, 1.74)		0.56 (0.36, 0.86)	0.78 (0.48, 1.27)	0.49 (0.20, 1.21)	0.49 (0.20, 1.21)	0.72 (0.28, 1.81)	1.14 (0.42, 3.06)	1.21 (0.70, 2.07)
HofferQ	0.56 (0.43, 0.72)	0.57 (0.15, 1.95)	0.58 (0.37, 0.91)	0.54 (0.37, 0.80)		1.25 (0.76, 2.05)	1.28 (0.58, 2.84)	1.28 (0.58, 2.84)	1.86 (0.81, 4.27)	2.94 (1.19, 7.26)	1.85 (1.10, 3.10)
Holladay2	0.75 (0.49, 1.17)	0.76 (0.19, 2.79)	0.77 (0.45, 1.32)	0.73 (0.45, 1.17)	1.34 (0.87, 2.08)		-	-	-	-	1.31 (0.69, 2.51)
Holladay2_NoPreSurgRef	0.63 (0.33, 1.27)	0.65 (0.15, 2.62)	0.65 (0.32, 1.37)	0.61 (0.30, 1.27)	1.13 (0.58, 2.26)	0.84 (0.40, 1.82)		1.00 (0.44, 2.25)	1.45 (0.62, 3.38)	2.30 (0.92, 5.75)	2.02 (0.83, 4.95)
Holladay2_PreSurgRef	0.63 (0.33, 1.28)	0.64 (0.15, 2.63)	0.65 (0.32, 1.38)	0.61 (0.31, 1.27)	1.13 (0.58, 2.26)	0.84 (0.40, 1.82)	1.00 (0.44, 2.29)		1.45 (0.62, 3.38)	2.30 (0.92, 5.75)	2.02 (0.83, 4.95)
LadasSuperFormula	0.93 (0.46, 1.97)	0.95 (0.21, 3.93)	0.96 (0.45, 2.12)	0.90 (0.44, 1.95)	1.65 (0.82, 3.48)	1.23 (0.57, 2.80)	1.46 (0.62, 3.52)	1.46 (0.63, 3.50)		1.59 (0.61, 4.10)	1.40 (0.55, 3.53)
Olsen_standalone	1.50 (0.69, 3.52)	1.53 (0.32, 6.72)	1.54 (0.68, 3.79)	1.45 (0.65, 3.49)	2.66 (1.23, 6.27)	1.99 (0.86, 4.99)	2.37 (0.94, 6.21)	2.36 (0.95, 6.21)	1.62 (0.62, 4.35)		0.88 (0.33, 2.37)
T2	1.13 (0.71, 1.81)	1.14 (0.28, 4.25)	1.16 (0.68, 1.99)	1.09 (0.66, 1.81)	2.01 (1.26, 3.22)	1.50 (0.87, 2.58)	1.78 (0.85, 3.66)	1.78 (0.84, 3.65)	1.22 (0.55, 2.58)	0.75 (0.31, 1.72)	





Figure 53: AL >26.0mm: Within 0.5D - fixed effects model – relative effect of all options versus common comparator

Table 89: AL >26.0mm: Within 0.5D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.017	5 (2, 8)
AvgHofferQSRKT	0.231	5 (1, 11)
BarrettUniversalll	0.029	5 (1, 9)
Haigis	0.035	4 (1, 8)
HofferQ	0.000	10 (8, 11)
Holladay2	0.002	8 (3, 11)
Holladay2_NoPreSurgRef	0.005	9 (3, 11)
Holladay2_PreSurgRef	0.004	9 (3, 11)
LadasSuperFormula	0.069	6 (1, 11)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Olsen_standalone	0.508	1 (1, 8)
T2	0.100	3 (1, 8)



**Figure 54: AL >26.0mm: Within 0.5D - fixed effects model – rank probability histograms**

**Table 90: AL >26.0mm: Within 0.5D - fixed effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC
24.45 (compared to 28 datapoints)	143.413	126.316	17.097	160.51

**Table 91: AL >26.0mm: Within 0.5D - fixed effects model – notes**

<ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); fixed effects</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
---



PROPORTION WITHIN 1.0 DIOPTRE – random effects model




Figure 55: AL >26.0mm: Within 1.0D - random effects model – evidence network

**Table 92: AL >26.0mm: Within 1.0D - random effects model – input data**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	LadasSuperFormula	Olsen_standalone	T2
Cooke & (2016)	53/54		53/54	53/54	52/54		53/54	53/54	52/54	53/54	53/54
Kane,J. et al. (2016)	71/77		71/77	68/77	64/77	68/77					67/77
Bang et al. (2011)	35/53			39/53	32/53	33/53					
Aristodemou et al. (2011)	44/47				43/47						
Aristodemou et al. (2011)	253/271				239/271						
Aristodemou et al. (2011)	14/17				12/17						
Petermeier et al. (2009)	50/50			32/50	50/50						
Percival et al. (2002)	19/20	17/20			17/20						
Mitra et al. (2014)	17/43				19/43						
El-Nafees et al. (2010)	44/53			44/53							

**Table 93: AL >26.0mm: Within 1.0D - random effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	AvgHofferQSRKT	BarrettUniversall	Haigis	HofferQ	Holladay2	Holladay2_NoPreSurgRef	Holladay2_PreSurgRef	LadasSuperFormula	Olsen_standalone	T2
SRKT		0.30 (0.03, 3.15)	1.00 (0.34, 2.96)	0.71 (0.28, 1.78)	0.65 (0.45, 0.92)	0.77 (0.40, 1.46)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)	0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	0.61 (0.22, 1.65)
AvgHofferQSRKT	0.46		-	-	1.00	-	-	-	-	-	-

	SRKT	AvgHofferQSR KT	BarrettUnivers all	Haigis	HofferQ	Holladay2	Holladay2_No PreSurgRef	Holladay2_Pre SurgRef	LadasSuperFo rmula	Olsen_standal one	T2
	(0.04, 5.92)				(0.18, 5.67)						
BarrettUniversall	1.05 (0.19, 6.08)	2.28 (0.12, 47.00)		0.68 (0.25, 1.86)	0.43 (0.17, 1.10)	0.64 (0.22, 1.89)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)	0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	0.61 (0.22, 1.65)
Haigis	0.48 (0.16, 1.36)	1.04 (0.07, 15.16)	0.46 (0.07, 2.53)		1.07 (0.30, 3.81)	0.74 (0.39, 1.38)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)	0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	0.90 (0.36, 2.23)
HofferQ	0.65 (0.27, 1.49)	1.40 (0.11, 17.29)	0.62 (0.11, 3.36)	1.35 (0.46, 4.25)		1.25 (0.69, 2.27)	2.04 (0.18, 23.17)	2.04 (0.18, 23.17)	1.00 (0.14, 7.37)	2.04 (0.18, 23.17)	1.43 (0.62, 3.30)
Holladay2	0.63 (0.15, 2.59)	1.35 (0.08, 23.34)	0.59 (0.08, 4.24)	1.31 (0.30, 6.02)	0.97 (0.23, 4.04)		-	-	-	-	0.89 (0.34, 2.32)
Holladay2_NoPreSurgRef	1.07 (0.07, 41.13)	2.48 (0.06, 174.90)	1.03 (0.05, 46.32)	2.24 (0.14, 88.12)	1.64 (0.11, 63.46)	1.75 (0.09, 77.21)		1.00 (0.06, 16.41)	0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)
Holladay2_PreSurgRef	1.08 (0.07, 46.67)	2.46 (0.06, 215.20)	1.03 (0.05, 49.49)	2.22 (0.14, 104.20)	1.66 (0.11, 72.32)	1.73 (0.09, 89.57)	1.01 (0.01, 77.45)		0.49 (0.04, 5.58)	1.00 (0.06, 16.41)	1.00 (0.06, 16.41)
LadasSuperFormula	0.42 (0.03, 5.61)	0.91 (0.03, 32.60)	0.40 (0.03, 6.94)	0.87 (0.07, 12.61)	0.64 (0.06, 9.08)	0.68 (0.04, 11.28)	0.38 (0.01, 10.65)	0.38 (0.01, 11.08)		2.04 (0.18, 23.17)	2.04 (0.18, 23.17)
Olsen_standalone	1.10 (0.07, 45.60)	2.43 (0.06, 207.10)	1.05 (0.05, 49.59)	2.28 (0.14, 97.44)	1.71 (0.10, 69.48)	1.79 (0.09, 83.45)	1.01 (0.02, 70.36)	0.98 (0.01, 70.90)	2.64 (0.09, 158.90)		1.00 (0.06, 16.41)
T2	0.68 (0.13, 3.61)	1.48 (0.08, 30.72)	0.64 (0.09, 4.94)	1.41 (0.28, 8.25)	1.05 (0.21, 5.74)	1.10 (0.17, 7.52)	0.63 (0.01, 12.17)	0.63 (0.01, 12.54)	1.62 (0.10, 23.86)	0.62 (0.01, 12.23)	





Figure 56: AL >26.0mm: Within 1.0D - random effects model – relative effect of all options versus common comparator

Table 94: AL >26.0mm: Within 1.0D - random effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.045	4 (1, 8)
AvgHofferQSRKT	0.066	8 (1, 11)
BarrettUniversalll	0.102	4 (1, 10)
Haigis	0.002	8 (3, 11)
HofferQ	0.004	7 (3, 10)
Holladay2	0.022	7 (2, 11)
Holladay2_NoPreSurgRef	0.227	4 (1, 11)
Holladay2_PreSurgRef	0.229	4 (1, 11)
LadasSuperFormula	0.042	9 (1, 11)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Olsen_standalone	0.226	4 (1, 11)
T2	0.035	6 (1, 11)



**Figure 57: AL >26.0mm: Within 1.0D - random effects model – rank probability histograms**


**Table 95: AL >26.0mm: Within 1.0D - random effects model – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
35.1 (compared to 35 datapoints)	147.479	118.139	29.34	176.819	0.974 (95%CI: 0.506, 1.724)

**Table 96: AL >26.0mm: Within 1.0D - random effects model – notes**

<ul style="list-style-type: none"> <li>• Dichotomous synchronic (binomial; logit link); random effects</li> <li>• Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul>
--

**PROPORTION WITHIN 2.0 DIOPTRES – fixed effects model**



**Figure 58: AL >26.0mm: Within 2.0D - fixed effects model – evidence network**

**Table 97: AL >26.0mm: Within 2.0D - fixed effects model – input data**

	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	T2
Kane,J. et al. (2016)	75/77	77/77	76/77	76/77	75/77	77/77



	SRKT	BarrettUniversal II	Haigis	HofferQ	Holladay2	T2
Bang et al. (2011)	51/53		52/53	42/53	50/53	

**Table 98: AL >26.0mm: Within 2.0D - fixed effects model – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT	BarrettUnivers all	Haigis	HofferQ	Holladay2	T2
SRKT		5.13 (0.24, 108.68)	2.03 (0.37, 11.30)	0.31 (0.10, 0.97)	0.79 (0.21, 3.03)	5.13 (0.24, 108.68)
BarrettUniversall	5.53 (0.33, 2725.00)		0.33 (0.01, 8.20)	0.33 (0.01, 8.20)	0.19 (0.01, 4.13)	1.00 (0.02, 51.04)
Haigis	1.93 (0.39, 12.36)	0.36 (0.00, 7.38)		0.15 (0.03, 0.68)	0.39 (0.07, 2.05)	3.04 (0.12, 75.77)
HofferQ	0.31 (0.09, 0.90)	0.06 (0.00, 0.76)	0.16 (0.03, 0.58)		2.61 (0.89, 7.67)	3.04 (0.12, 75.77)
Holladay2	0.79 (0.20, 3.02)	0.14 (0.00, 2.21)	0.41 (0.07, 1.85)	2.55 (0.92, 8.15)		5.13 (0.24, 108.68)
T2	5.32 (0.34, 2364.00)	0.98 (0.00, 635.90)	2.75 (0.13, 1348.00)	17.49 (1.34, 7933.00)	6.84 (0.44, 3162.00)	




Figure 59: AL >26.0mm: Within 2.0D - fixed effects model – relative effect of all options versus common comparator

Table 99: AL >26.0mm: Within 2.0D - fixed effects model – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT	0.014	4 (2, 5)
BarrettUniversalll	0.445	2 (1, 5)
Haigis	0.096	3 (1, 5)
HofferQ	0.000	6 (5, 6)
Holladay2	0.005	5 (2, 6)
T2	0.440	2 (1, 5)




Figure 60: AL >26.0mm: Within 2.0D - fixed effects model – rank probability histograms

Table 100: AL >26.0mm: Within 2.0D - fixed effects model – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC
13.49 (compared to 10 datapoints)	38.132	31.797	6.335	44.466

**Table 101: AL >26.0mm: Within 2.0D - fixed effects model – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

### H.3.3 Intraocular lens formulas: Network meta-analyses results: Eyes with a history of myopic LASIK/LASEK/PRK

#### H.3.3.1 Model fit statistics for all outcomes

**Table 102: Model fit statistics used to select fixed or random effect models for all comparisons and outcomes**

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
<b>FULL DATASET: HISTORICAL AND NO HISTORICAL DATA METHODS</b>								
2 (Fam, Savini)	Mean absolute error	FE	9.833		38.54	27	-	RE
		RE	0.2		27.1		0.81 (0.24, 1.89)	
5 (Fam, Huang, Kim, Savini, Xu)	Prediction error	FE	62.1	46.7	79.7	31	-	RE
		RE	15.3		31		1.42 (0.72, 1.97)	
5 (Fam, Huang, Kim, Saiki, Xu)	Within 0.5D	FE	144.0	0.7	29.8	26	-	RE
		RE	143.3		27.4		0.96 (0.07, 1.93)	
5 (Fam, Huang, Kim, Saiki, Xu)	Within 1.0D	FE	151.7	5.8	34.7	26	-	RE
		RE	145.9		27.0		1.21 (0.29, 1.95)	
1 ( <i>Kim – pairwise comparison</i> )	Within 1.5D	FE	-	-	-	-	-	FE
1 (Fam)	Within 2.0D	FE	29.4	-	6.4	6	-	FE
1 ( <i>Kim – pairwise comparison</i> )		FE	-	-	-	-	-	FE
<b>NO HISTORICAL DATA METHODS ONLY</b>								
4 (Huang, Kim, Saiki, Xu)	Within 0.5D	FE	78.7	1.1	17.5	14	-	RE
		RE	77.6		14.9		0.94 (0.07, 1.93)	
4 (Huang, Kim, Saiki, Xu)	Within 1.0D	FE	86.0	6.1	22.4	14	-	RE
		RE	79.9		14.5		1.20 (0.30, 1.95)	
<b>HISTORICAL DATA METHODS ONLY</b>								
2 (Fam, Savini)	Mean absolute error	FE	9.8	9.7	32.5	21	-	RE
		RE	0.13		21.0		0.82 (0.24, 1.89)	
2 (Fam, Saiki) – NB: network connector (SRKT DK) uses historical data in Fam but no historical data in Saiki	Within 0.5D	FE	60.0	-	11.4	11	-	FE

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
2 (Fam, Saiki) – NB: network connector (SRKT DK) uses historical data in Fam but no historical data in Saiki	Within 1.0D	FE	60.5	-	11.3	11	-	FE
1 (Fam)	Within 2.0D	FE	29.4	-	6.4	6	-	FE

H.3.3.2 Full dataset: historical and no historical methods

MEAN ABSOLUTE ERROR – random effects model




Figure 61: Myopic corneal refractive surgery: Mean absolute error – evidence network

**Table 103: Myopic corneal refractive surgery: Mean absolute error – input data**

	Clinical history	Camellin-Calossi	HofferQ DK	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
Savini et al. (2010)	1.62 (1.25)	1.41 (0.76)			0.93 (0.48)		1.33 (1.03)	1.00 (0.57)	1.79 (1.13)	0.62 (0.52)	0.56 (0.45)	0.53 (0.46)	1.60 (0.98)	1.87 (1.44)	2.04 (1.48)	2.18 (1.52)	1.08 (0.86)	0.76 (0.49)	3.64 (1.45)	1.94 (1.01)
Fam & (2008)			0.75 (0.52)	0.75 (0.62)		1.32 (0.73)		0.76 (0.60)						0.93 (0.83)		0.80 (0.63)				

**Table 104: Myopic corneal refractive surgery: Mean absolute error – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	Clinical history	Camellin-Calossi	HofferQ DK	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
Clinical history		-0.21 (-0.75, 0.33)	-	-	-0.69 (-1.19, 0.19)	-	-0.29 (-0.89, 0.31)	-0.62 (-1.13, 0.11)	0.17 (-0.45, 0.79)	-1.00 (-1.50, 0.50)	-1.06 (-1.55, 0.57)	-1.09 (-1.58, 0.60)	-0.02 (-0.61, 0.57)	0.25 (-0.46, 0.96)	0.42 (-0.30, 1.14)	0.56 (-0.17, 1.29)	-0.54 (-1.10, 0.02)	-0.86 (-1.36, 0.36)	2.02 (1.31, 2.73)	0.32 (-0.28, 0.92)
Camellin-Calossi	-0.20 (-5.27, 4.82)		-	-	-0.48 (-0.81, 0.15)	-	-0.08 (-0.55, 0.39)	-0.41 (-0.76, 0.06)	0.38 (-0.12, 0.88)	-0.79 (-1.13, 0.45)	-0.85 (-1.18, 0.52)	-0.88 (-1.21, 0.55)	0.19 (-0.27, 0.65)	0.46 (-0.14, 1.06)	0.63 (0.01, 1.25)	0.77 (0.14, 1.40)	-0.33 (-0.76, 0.10)	-0.65 (-0.98, 0.32)	2.23 (1.62, 2.84)	0.53 (0.06, 1.00)
HofferQ DK	-0.06 (-5.75, 6.04)	0.14 (-5.72, 6.24)		0.00 (-0.26, 0.26)	-	0.57 (0.28, 0.86)	-	0.01 (-0.25, 0.27)	-	-	-	-	-	0.18 (-0.14, 0.50)	-	0.05 (-0.21, 0.31)	-	-	-	-
Holladay2 DK	-0.07 (-5.66, 5.96)	0.13 (-5.52, 6.08)	0.00 (-5.08, 5.04)		-	0.57 (0.26, 0.88)	-	0.01 (-0.27, 0.29)	-	-	-	-	-	0.18 (-0.15, 0.51)	-	0.05 (-0.23, 0.33)	-	-	-	-
Shammas-PL	-0.69 (-5.55, 4.17)	-0.48 (-5.36, 4.40)	-0.62 (-6.50, 5.20)	-0.62 (-6.57, 5.33)		-	0.40 (-0.02, 0.82)	0.07 (-0.21, 0.35)	0.86 (0.41, 1.31)	-0.31 (-0.57, -0.05)	-0.37 (-0.61, -0.13)	-0.40 (-0.65, -0.15)	0.67 (0.27, 1.07)	0.94 (0.38, 1.50)	1.11 (0.53, 1.69)	1.25 (0.66, 1.84)	0.15 (-0.21, 0.51)	-0.17 (-0.42, 0.08)	2.71 (2.14, 3.28)	1.01 (0.60, 1.42)



	Clinical history	Camellin-Calossi	HofferQ DK	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Sa vini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
	4.63)	4.81)	5.44)	5.45)			0.82)	0.35)	1.31)	0.05)	0.13)	0.15)	1.07)	1.50)	1.69)	1.84)	0.51)	0.08)	3.28)	1.42)
SRKT Clinical history	0.49 (-5.24, 6.52)	0.69 (-5.09, 6.67)	0.56 (-4.64, 5.56)	0.57 (-4.59, 5.72)	1.18 (-4.75, 7.02)		-	-0.56 (-0.86, 0.26)	-	-	-	-	-	-0.39 (-0.75, 0.03)	-	-0.52 (-0.83, 0.21)	-	-	-	-
SRKT Diehl	-0.28 (-5.11, 4.98)	-0.08 (-5.10, 5.04)	-0.22 (-6.08, 5.43)	-0.21 (-6.11, 5.52)	0.41 (-4.81, 5.39)	-0.79 (-6.63, 4.93)		-0.33 (-0.77, 0.11)	0.46 (-0.11, 1.03)	-0.71 (-1.14, 0.28)	-0.77 (-1.19, 0.35)	-0.80 (-1.22, 0.38)	0.27 (-0.26, 0.80)	0.54 (-0.12, 1.20)	0.71 (0.04, 1.38)	0.85 (0.17, 1.53)	-0.25 (-0.75, 0.25)	-0.57 (-0.99, 0.15)	2.31 (1.65, 2.97)	0.61 (0.08, 1.14)
SRKT DK	-0.34 (-4.78, 4.35)	-0.13 (-4.75, 4.46)	-0.27 (-4.96, 4.26)	-0.26 (-4.94, 4.28)	0.35 (-4.45, 4.87)	-0.84 (-5.45, 4.87)	-0.06 (-4.72, 4.51)		0.79 (0.32, 1.26)	-0.38 (-0.67, 0.09)	-0.44 (-0.71, 0.17)	-0.47 (-0.74, 0.20)	0.60 (0.18, 1.02)	0.48 (-0.20, 1.16)	1.04 (0.45, 1.63)	0.58 (-0.54, 1.69)	0.08 (-0.30, 0.46)	-0.24 (-0.52, 0.04)	2.64 (2.06, 3.22)	0.94 (0.51, 1.37)
SRKT DK Awwad	0.16 (-4.64, 5.51)	0.37 (-4.53, 5.70)	0.23 (-5.66, 6.36)	0.23 (-5.65, 6.23)	0.85 (-4.26, 6.06)	-0.34 (-6.03, 5.68)	0.45 (-4.63, 5.68)	0.50 (-4.03, 5.37)		-1.17 (-1.63, 0.71)	-1.23 (-1.68, 0.78)	-1.26 (-1.71, 0.81)	-0.19 (-0.74, 0.36)	0.08 (-0.60, 0.76)	0.25 (-0.44, 0.94)	0.39 (-0.31, 1.09)	-0.71 (-1.24, 0.18)	-1.03 (-1.49, 0.57)	1.85 (1.17, 2.53)	0.15 (-0.41, 0.71)
SRKT DK Savini	-1.01 (-5.76, 4.24)	-0.79 (-5.77, 4.31)	-0.93 (-6.95, 4.98)	-0.93 (-6.75, 4.98)	-0.31 (-5.57, 4.78)	-1.51 (-7.46, 4.35)	-0.72 (-5.93, 4.37)	-0.66 (-5.29, 4.06)	-1.17 (-6.33, 3.91)		-0.06 (-0.31, 0.19)	-0.09 (-0.35, 0.17)	0.98 (0.57, 1.39)	1.25 (0.68, 1.82)	1.42 (0.84, 2.00)	1.56 (0.96, 2.16)	0.46 (0.09, 0.83)	0.14 (-0.12, 0.40)	3.02 (2.45, 3.59)	1.32 (0.90, 1.74)
SRKT DK Seitz/Speicher	-1.07 (-6.07, 4.11)	-0.86 (-5.94, 4.32)	-0.99 (-6.94, 4.78)	-0.99 (-6.95, 4.83)	-0.37 (-6.95, 4.71)	-1.56 (-7.36, 4.29)	-0.78 (-5.86, 4.31)	-0.72 (-5.41, 3.94)	-1.22 (-6.50, 3.77)	-0.06 (-5.23, 5.07)		-0.03 (-0.27, 0.21)	1.04 (0.64, 1.44)	1.31 (0.75, 1.87)	1.48 (0.91, 2.05)	1.62 (1.03, 2.21)	0.52 (0.16, 0.88)	0.20 (-0.05, 0.45)	3.08 (2.52, 3.64)	1.38 (0.97, 1.79)
SRKT DK Seitz/Speicher/Savini	-1.09 (-5.98, 4.07)	-0.88 (-5.81, 4.25)	-1.01 (-6.86, 4.76)	-1.02 (-6.86, 4.77)	-0.40 (-5.64, 4.62)	-1.58 (-7.32, 4.29)	-0.81 (-5.89, 4.32)	-0.74 (-5.33, 3.95)	-1.25 (-6.41, 3.64)	-0.08 (-5.09, 5.02)	-0.02 (-4.99, 5.09)		1.07 (0.67, 1.47)	1.34 (0.78, 1.90)	1.51 (0.94, 2.08)	1.65 (1.06, 2.24)	0.55 (0.19, 0.91)	0.23 (-0.02, 0.48)	3.11 (2.55, 3.67)	1.41 (1.00, 1.82)
SRKT DK Shammas	-0.02 (-4.87, 5.06)	0.18 (-4.81, 5.29)	0.05 (-5.84, 5.89)	0.05 (-5.80, 5.73)	0.66 (-4.41, 5.53)	-0.52 (-6.31, 5.21)	0.26 (-4.80, 5.28)	0.32 (-4.19, 4.86)	-0.18 (-5.41, 4.62)	0.97 (-4.14, 5.94)	1.05 (-4.10, 6.06)	1.07 (-4.03, 6.04)		0.27 (-0.38, 0.92)	0.44 (-0.22, 1.10)	0.58 (-0.09, 1.25)	-0.52 (-1.00, 0.04)	-0.84 (-1.25, 0.43)	2.04 (1.39, 2.69)	0.34 (-0.18, 0.86)
SRKT Feiz-Mannis	0.15 (-4.37, 5.01)	0.37 (-4.18, 5.07)	0.23 (-4.41, 4.92)	0.25 (-4.42, 4.84)	0.86 (-3.89, 5.49)	-0.33 (-4.88, 4.30)	0.46 (-4.12, 5.00)	0.50 (-3.03, 4.17)	0.00 (-4.84, 4.52)	1.16 (-3.53, 5.86)	1.23 (-3.40, 5.81)	1.26 (-3.32, 5.86)	0.19 (-4.39, 4.81)		0.17 (-0.59, 0.93)	-0.05 (-0.38, 0.27)	-0.79 (-1.41, 0.17)	-1.11 (-1.67, 0.55)	1.77 (1.01, 2.53)	0.07 (-0.58, 0.72)
SRKT Feiz-Mannis nomogram	0.42 (-4.33, 5.70)	0.63 (-4.36, 5.80)	0.49 (-5.33, 6.26)	0.49 (-5.33, 6.27)	1.11 (-4.03, 6.21)	-0.09 (-5.86, 5.73)	0.71 (-4.41, 5.78)	0.76 (-3.74, 5.37)	0.26 (-4.95, 5.27)	1.42 (-3.73, 6.61)	1.49 (-3.51, 6.52)	1.51 (-3.51, 6.53)	0.44 (-4.67, 5.70)	0.25 (-4.34, 4.97)		0.14 (-0.65, 0.93)	-0.96 (-1.59, 0.33)	-1.28 (-1.86, 0.70)	1.60 (0.83, 2.37)	-0.10 (-0.76, 0.56)
SRKT Ladas-Stark	0.22 (-4.17, 5.10)	0.42 (-4.00, 5.17)	0.28 (-4.35, 4.96)	0.28 (-4.22, 4.92)	0.91 (-3.77, 5.64)	-0.29 (-4.81, 4.42)	0.50 (-4.14, 5.12)	0.56 (-3.01, 4.22)	0.05 (-4.68, 4.62)	1.22 (-3.35, 6.03)	1.28 (-3.20, 5.94)	1.30 (-3.29, 5.90)	0.23 (-4.35, 4.91)	0.05 (-3.43, 3.61)	-0.20 (-4.80, 4.46)		-1.10 (-1.75, 0.45)	-1.42 (-2.01, 0.83)	1.46 (0.68, 2.24)	-0.24 (-0.92, 0.44)
SRKT Latkany	-0.54 (-5.45, 4.37)	-0.33 (-5.39, 4.73)	-0.48 (-6.28, 5.32)	-0.47 (-6.36, 5.42)	0.15 (-5.04, 5.74)	-1.05 (-6.79, 4.69)	-0.26 (-5.31, 4.79)	-0.20 (-4.78, 4.38)	-0.71 (-5.95, 4.54)	0.46 (-4.64, 5.74)	0.52 (-4.45, 5.41)	0.55 (-4.36, 5.41)	-0.52 (-5.56, 4.52)	-0.70 (-5.33, 4.93)	-0.96 (-6.06, 5.14)	-0.76 (-5.48, 4.48)		-0.32 (-0.69, 0.05)	2.56 (1.94, 3.18)	0.86 (0.37, 1.35)

Meta-analysis and network meta-analysis results

	Clinical history	Carnellin-Calossi	HofferQ DK	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Sa vini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Lalkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
	4.70)	4.96)	5.38)	5.33)	5.26)	4.90)	4.84)	4.50)	4.30)	5.58)	5.72)	5.59)	4.62)	3.98)	4.03)	3.98)		0.05)	3.18)	1.35)
SRKT Masket	-0.85 (-5.63, 4.47)	-0.64 (-5.63, 4.64)	-0.79 (-6.55, 5.18)	-0.78 (-6.73, 5.25)	-0.17 (-5.32, 5.06)	-1.35 (-7.20, 4.68)	-0.57 (-5.48, 4.63)	-0.51 (-4.99, 4.31)	-1.01 (-6.22, 4.22)	0.15 (-4.70, 5.27)	0.21 (-4.79, 5.33)	0.25 (-4.75, 5.35)	-0.83 (-5.79, 4.36)	-1.02 (-5.63, 3.79)	-1.27 (-6.28, 3.94)	-1.06 (-5.65, 3.67)	-0.32 (-5.36, 4.90)		2.88 (2.31, 3.45)	1.18 (0.76, 1.60)
SRKT SK Ferrara	2.01 (-2.79, 7.30)	2.21 (-2.73, 7.42)	2.08 (-3.74, 7.90)	2.09 (-3.64, 7.93)	2.71 (-2.43, 7.68)	1.51 (-4.14, 7.46)	2.30 (-2.82, 7.50)	2.35 (-2.19, 7.18)	1.86 (-3.29, 6.81)	3.01 (-1.95, 8.27)	3.07 (-1.90, 8.20)	3.10 (-1.84, 8.09)	2.03 (-2.83, 7.19)	1.85 (-2.62, 6.53)	1.59 (-3.48, 6.71)	1.80 (-2.85, 6.53)	2.55 (-2.38, 7.80)	2.86 (-2.16, 7.84)		-1.70 (-2.35, -1.05)
SRKT SK Rosa	0.32 (-4.47, 5.49)	0.53 (-4.42, 5.75)	0.40 (-5.53, 6.31)	0.40 (-5.49, 6.19)	1.01 (-4.04, 6.02)	-0.17 (-5.93, 5.83)	0.61 (-4.44, 5.66)	0.67 (-3.90, 5.44)	0.16 (-5.09, 5.32)	1.32 (-3.66, 6.33)	1.39 (-3.69, 6.51)	1.41 (-3.58, 6.56)	0.34 (-4.64, 5.47)	0.16 (-4.43, 4.86)	-0.09 (-5.13, 5.03)	0.11 (-4.50, 4.68)	0.86 (-4.16, 5.96)	1.18 (-4.00, 6.21)	-1.69 (-6.78, 3.31)	





Figure 62: Myopic corneal refractive surgery: Mean absolute error – relative effect of all options versus common comparator

**Table 105: Myopic corneal refractive surgery: Mean absolute error – rankings for each comparator**

	Probability best	Median rank (95%CI)
Clinical history	0.019	12 (2, 19)
Camellin-Calossi	0.024	10 (2, 19)
HofferQ DK	0.035	11 (1, 20)
Holladay2 DK	0.035	11 (1, 20)
Shammas-PL	0.067	6 (1, 18)
SRKT Clinical history	0.017	16 (2, 20)
SRKT Diehl	0.030	9 (1, 19)
SRKT DK	0.011	9 (2, 17)
SRKT DK Awwad	0.014	13 (2, 20)
SRKT DK Savini	0.157	4 (1, 18)
SRKT DK Seitz/Speicher	0.186	4 (1, 17)
SRKT DK Seitz/Speicher/Savini	0.200	4 (1, 17)
SRKT DK Shammas	0.018	12 (2, 19)
SRKT Feiz-Mannis	0.004	13 (4, 19)
SRKT Feiz-Mannis nomogram	0.010	15 (3, 20)
SRKT Ladas-Stark	0.004	14 (4, 19)
SRKT Latkany	0.051	7 (1, 19)
SRKT Masket	0.106	5 (1, 18)
SRKT SK Ferrara	0.002	20 (7, 20)
SRKT SK Rosa	0.012	15 (2, 20)



**Figure 63: Myopic corneal refractive surgery: Mean absolute error – rank probability histograms**


**Table 106: Myopic corneal refractive surgery: Mean absolute error – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
23.18 (compared to 23 datapoints)	-23.582	-46.65	23.068	-0.513	1.053 (95%CI: 0.250, 7.282)

**Table 107: Myopic corneal refractive surgery: Mean absolute error – notes**

- |  |
|--|
| <ul style="list-style-type: none"> <li>• Continuous (normal; identity link); random effects</li> <li>• Prior distribution for between-study heterogeneity: uniform (Min=0; Max=10)</li> <li>• 50000 burn-ins; 10000 recorded iterations</li> </ul> |
|--|

**PREDICTION ERROR – random effects model**



**Figure 64: Myopic corneal refractive surgery: prediction error – evidence network**

**Table 108: Myopic corneal refractive surgery: prediction error – input data**

	Clinical history	Camellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Sa	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP
Xu et al. (2014)					1.58 (1.20)	-2.30 (1.25)													1.64 (0.93)						-1.79 (1.11)
Huang et al. (2013)			0.14 (0.83)					0.24 (0.82)																	
Kim et al. (2013)			0.03 (1.06)																1.68 (1.34)						
Savini et al. (2010)	1.08 (1.75)	1.37 (0.83)						0.50 (0.94)	0.83 (1.48)	-0.8 (0.75)	1.73 (1.23)	0.21 (0.79)	0.05 (0.73)	0.09 (0.70)	1.60 (0.98)	1.37 (1.94)	2.00 (1.53)		1.83 (1.95)	0.80 (1.13)	-0.27 (0.88)	3.64 (1.45)	1.90 (1.10)		
Fam & (2008)				0.19 (0.90)			-0.04 (0.98)		1.15 (0.99)		-0.19 (0.95)									-0.01 (1.02)					



**Table 109: Myopic corneal refractive surgery: prediction error – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	Clinical history	Camellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Sa	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT K	SRKT Ladas-Stark	SRKT Laitkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP
Clinical history		0.29 (-0.43, 1.01)	-	-	-	-	-	-0.58 (-1.32, 0.16)	-	-0.25 (-1.10, 0.60)	-1.96 (-2.67, 1.25)	0.65 (-0.14, 1.44)	-0.87 (-1.58, 0.16)	-1.03 (-1.73, 0.33)	-0.99 (-1.69, 0.29)	0.52 (-0.22, 1.26)	0.29 (-0.68, 1.26)	0.92 (0.06, 1.78)	-	0.75 (-0.22, 1.72)	-0.28 (-1.05, 0.49)	-1.35 (-2.08, 0.62)	2.56 (1.72, 3.40)	0.82 (0.05, 1.59)	-
Camellin-Calossi	0.30 (-2.67, 3.28)		-	-	-	-	-	-0.87 (-1.33, 0.41)	-	-0.54 (-1.17, 0.09)	-2.25 (-2.66, 1.84)	0.36 (-0.19, 0.91)	-1.16 (-1.58, 0.74)	-1.32 (-1.73, 0.91)	-1.28 (-1.68, 0.88)	0.23 (-0.25, 0.71)	0.00 (-0.78, 1.27)	0.63 (-0.01, 1.27)	-	0.46 (-0.32, 1.24)	-0.57 (-1.09, 0.05)	-1.64 (-2.09, 1.19)	2.27 (1.65, 2.89)	0.53 (0.02, 1.04)	-
Haigis-L	-0.66 (-4.85, 3.58)	-0.94 (-5.14, 3.22)		-	-	-	-	0.10 (-0.24, 0.44)	-	-	-	-	-	-	-	-	-	-	1.65 (1.16, 2.14)	-	-	-	-	-	-
HofferQ DK	0.06 (-3.35, 3.57)	-0.24 (-3.64, 3.25)	0.71 (-3.80, 5.18)		-	-	-0.23 (-0.66, 0.20)	-	0.96 (0.53, 1.39)	-	-0.38 (-0.80, 0.04)	-	-	-	-	-	-0.70 (-1.17, 0.23)	-	-	-0.20 (-0.64, 0.24)	-	-	-	-	-
HofferQ K	0.95 (-5.07, 6.96)	0.65 (-5.28, 6.55)	1.59 (-2.61, 5.80)	0.87 (-5.31, 7.03)		-3.88 (-4.44, 3.32)	-	-	-	-	-	-	-	-	-	-	-	-	0.06 (-0.43, 0.55)	-	-	-	-	-	-3.37 (-3.90, 2.84)
HofferQ TNP	-2.93 (-8.90, 3.01)	-3.24 (-9.18, 2.68)	-2.29 (-6.49, 1.92)	-3.01 (-9.14, 3.14)	-3.88 (-6.82, 0.93)		-	-	-	-	-	-	-	-	-	-	-	-	3.94 (3.44, 4.44)	-	-	-	-	-	0.51 (-0.03, 1.05)
Holladay2 DK	-0.16 (-3.60, 3.33)	-0.45 (-3.84, 3.05)	0.50 (-4.03, 5.02)	-0.21 (-3.15, 2.76)	-1.12 (-7.27, 5.15)	2.79 (-3.37, 8.96)		-	1.19 (0.74, 1.64)	-	-0.15 (-0.59, 0.29)	-	-	-	-	-	-0.47 (-0.96, 0.02)	-	-	0.03 (-0.43, 0.49)	-	-	-	-	-
Shammas-PL	-0.56 (-3.54, 2.49)	-0.86 (-3.82, 2.11)	0.08 (-2.88, 3.02)	-0.63 (-4.01, 2.77)	-1.51 (-6.65, 3.68)	2.36 (-2.79, 7.54)	-0.41 (-3.83, 3.01)		-	0.33 (-0.32, 0.98)	-1.38 (-1.83, 0.93)	1.23 (0.66, 1.80)	-0.29 (-0.74, 0.16)	-0.45 (-0.89, 0.01)	-0.41 (-0.84, 0.02)	1.10 (0.60, 1.60)	0.87 (0.07, 1.67)	1.50 (0.83, 2.17)	-	1.33 (0.53, 2.13)	0.30 (-0.24, 0.84)	-0.77 (-1.25, 1.25)	3.14 (2.50, 3.78)	1.40 (0.86, 1.94)	-

Meta-analysis and network meta-analysis results

	Clinical history	Camellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT K	SRKT Ladas-Stark	SRKT Lalkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP
																					0.29)				
SRKT Clinical history	1.03 (-2.38, 4.57)	0.74 (-2.63, 4.18)	1.68 (-2.86, 6.23)	0.97 (-1.94, 3.88)	0.10 (-6.02, 6.33)	3.96 (-2.18, 10.18)	1.19 (-1.77, 4.13)	1.60 (-1.81, 5.02)			-1.34 (-1.78, 0.90)						-1.66 (-2.15, 1.17)			-1.16 (-1.62, 0.70)					
SRKT Diehl	-0.24 (-3.26, 2.79)	-0.54 (-3.53, 2.45)	0.41 (-3.77, 4.64)	-0.32 (-3.78, 3.12)	-1.18 (-7.09, 4.82)	2.67 (-3.21, 8.67)	-0.10 (-3.56, 3.30)	0.33 (-2.69, 3.26)	-1.27 (-4.76, 2.10)		-1.71 (-2.32, 1.10)	0.90 (0.19, 1.61)	-0.62 (-1.24, 0.00)	-0.78 (-1.39, 0.17)	-0.74 (-1.35, 0.13)	0.77 (0.11, 1.43)	0.54 (-0.36, 1.44)	1.17 (0.38, 1.96)		1.00 (0.09, 1.91)	-0.03 (-0.72, 0.66)	-1.10 (-1.74, 0.46)	2.81 (2.04, 3.58)	1.07 (0.39, 1.75)	
SRKT DK	-1.13 (-3.84, 1.61)	-1.43 (-4.14, 1.31)	-0.47 (-4.53, 3.52)	-1.19 (-3.91, 1.49)	-2.06 (-7.87, 3.85)	1.80 (-4.00, 7.71)	-0.98 (-3.69, 1.67)	-0.56 (-3.28, 2.12)	-2.16 (-4.87, 0.52)	-0.89 (-3.61, 1.84)		2.61 (2.08, 3.14)	1.09 (0.69, 1.49)	0.93 (0.54, 1.32)	0.97 (0.59, 1.35)	2.48 (2.02, 2.94)	0.95 (-1.57, 3.46)	2.88 (2.25, 3.51)		1.42 (-1.05, 3.90)	1.68 (1.18, 2.18)	0.61 (0.18, 1.04)	4.52 (3.92, 5.12)	2.78 (2.29, 3.27)	
SRKT DK Awwad	0.66 (-2.35, 3.71)	0.36 (-2.63, 3.36)	1.30 (-2.90, 5.50)	0.59 (-2.87, 4.04)	-0.29 (-6.28, 5.70)	3.56 (-2.36, 9.53)	0.81 (-2.63, 4.22)	1.24 (-1.76, 4.18)	-0.39 (-3.85, 3.08)	0.90 (-2.12, 3.90)	1.79 (-0.93, 4.50)		-1.52 (-2.06, 0.98)	-1.68 (-2.21, 1.15)	-1.64 (-2.16, 1.12)	-0.13 (-0.71, 0.45)	-0.36 (-1.21, 0.49)	0.27 (-0.46, 1.00)		0.10 (-0.75, 0.95)	-0.93 (-1.55, 0.31)	-2.00 (-2.56, 1.44)	1.91 (1.21, 2.61)	0.17 (-0.44, 0.78)	
SRKT DK Savini	-0.85 (-3.87, 2.19)	-1.16 (-4.14, 1.79)	-0.21 (-4.46, 3.98)	-0.93 (-4.39, 2.47)	-1.81 (-7.78, 4.14)	2.06 (-3.86, 8.10)	-0.70 (-4.20, 2.68)	-0.29 (-3.28, 2.65)	-1.89 (-5.35, 1.49)	-0.62 (-3.63, 2.39)	0.26 (-2.46, 2.94)	-1.51 (-4.48, 1.49)		-0.16 (-0.56, 0.24)	-0.12 (-0.51, 0.27)	1.39 (0.92, 1.86)	1.16 (0.38, 1.94)	1.79 (1.15, 2.43)		1.62 (0.84, 2.40)	0.59 (0.08, 1.10)	-0.48 (-0.92, 0.04)	3.43 (2.82, 4.04)	1.69 (1.19, 2.19)	
SRKT DK Seitz/Speicher	-1.02 (-4.00, 1.97)	-1.32 (-4.31, 1.64)	-0.38 (-4.59, 3.81)	-1.08 (-4.56, 2.28)	-1.97 (-7.93, 4.00)	1.92 (-4.05, 7.89)	-0.87 (-4.36, 2.51)	-0.46 (-3.43, 2.47)	-2.05 (-5.51, 1.27)	-0.77 (-3.76, 2.20)	0.11 (-2.63, 2.76)	-1.68 (-4.67, 1.28)	-0.15 (-3.08, 2.80)		0.04 (-0.33, 0.41)	1.55 (1.10, 2.00)	1.32 (0.55, 2.09)	1.95 (1.32, 2.58)		1.78 (1.01, 2.55)	0.75 (0.25, 1.25)	-0.32 (-0.74, 0.10)	3.59 (2.99, 4.19)	1.85 (1.36, 2.34)	
SRKT DK Seitz/Speicher/Savini	-0.99 (-3.98, 2.02)	-1.28 (-4.26, 1.70)	-0.35 (-4.53, 3.84)	-1.04 (-4.57, 2.36)	-1.93 (-7.83, 4.04)	1.95 (-3.99, 7.96)	-0.83 (-4.28, 2.53)	-0.42 (-3.38, 2.54)	-2.01 (-5.47, 1.39)	-0.74 (-3.73, 2.24)	0.14 (-2.60, 2.84)	-1.64 (-4.67, 1.32)	-0.12 (-3.08, 2.85)		0.04 (-2.91, 3.02)	1.51 (1.06, 1.96)	1.28 (0.52, 2.04)	1.91 (1.29, 2.53)		1.74 (0.97, 2.51)	0.71 (0.22, 1.20)	-0.36 (-0.78, 0.06)	3.55 (2.95, 4.15)	1.81 (1.33, 2.29)	
SRKT DK Shammas	0.53 (-2.44, 3.54)	0.22 (-2.71, 3.18)	1.16 (-3.01, 5.37)	0.46 (-3.04, 3.81)	-0.44 (-6.39, 5.58)	3.43 (-2.46, 9.42)	0.68 (-2.79, 4.08)	1.08 (-1.87, 4.05)	-0.51 (-3.98, 2.89)	0.77 (-2.20, 3.73)	1.66 (-1.05, 4.37)	-0.13 (-3.13, 2.83)	1.39 (-1.54, 4.33)	1.55 (-1.39, 4.50)	1.50 (-1.48, 4.51)		-0.23 (-1.04, 0.58)	0.40 (-0.27, 1.07)		0.23 (-0.58, 1.04)	-0.80 (-1.35, 0.25)	-1.87 (-2.36, 1.38)	2.04 (1.39, 2.69)	0.30 (-0.25, 0.85)	

	Clinical history	Camellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Sa vidl	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT K	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP
SRKT Feiz-Mannis	-0.20 (-2.89, 2.58)	-0.49 (-3.20, 2.25)	0.47 (-3.62, 4.48)	-0.25 (-2.97, 2.42)	-1.14 (-6.93, 4.77)	2.74 (-3.06, 8.65)	-0.04 (-2.75, 2.65)	0.37 (-2.36, 3.10)	-1.22 (-3.96, 1.45)	0.06 (-2.68, 2.82)	0.93 (-1.16, 3.05)	-0.85 (-3.58, 1.90)	0.67 (-2.04, 3.43)	0.83 (-1.87, 3.60)	0.80 (-1.92, 3.51)	-0.71 (-3.42, 2.02)	0.63 (-0.29, 1.55)	-	0.49 (0.05, 0.94)	-0.57 (-1.40, 0.26)	-1.64 (-2.43, -0.85)	2.27 (1.37, 3.17)	0.53 (-0.30, 1.36)	-	
SRKT Feiz-Mannis nomogram	0.93 (-2.11, 3.98)	0.64 (-2.37, 3.63)	1.59 (-2.66, 5.82)	0.87 (-2.58, 4.27)	-0.01 (-6.01, 5.96)	3.86 (-2.11, 9.87)	1.10 (-2.45, 4.49)	1.51 (-1.52, 4.49)	-0.09 (-3.57, 3.35)	1.18 (-1.84, 4.22)	2.08 (-0.65, 4.80)	0.28 (-2.77, 3.28)	1.80 (-1.19, 4.81)	1.96 (-1.01, 4.94)	1.92 (-1.04, 4.90)	0.42 (-2.58, 3.41)	1.13 (-1.66, 3.87)	-	-0.17 (-1.09, 0.75)	-1.20 (-1.90, -0.50)	-2.27 (-2.92, -1.62)	1.64 (0.86, 2.42)	-0.10 (-0.80, 0.60)	-	
SRKT K	1.00 (-4.17, 6.16)	0.71 (-4.40, 5.83)	1.65 (-1.29, 4.59)	0.93 (-4.43, 6.35)	0.06 (-2.87, 3.01)	3.94 (0.95, 6.94)	1.13 (-4.30, 6.54)	1.59 (-2.59, 5.75)	-0.03 (-5.41, 5.42)	1.25 (-3.89, 6.40)	2.14 (-2.89, 7.10)	0.33 (-4.73, 5.52)	1.87 (-3.27, 7.06)	2.03 (-3.12, 7.17)	1.99 (-3.15, 7.08)	0.49 (-4.72, 5.65)	1.19 (-5.15, 5.21)	0.08 (-5.15, 5.21)	-	-	-	-	-	-	-3.43 (-3.90, -2.96)
SRKT Ladas-Stark	0.28 (-2.47, 3.08)	-0.02 (-2.72, 2.76)	0.92 (-3.09, 4.96)	0.23 (-2.51, 2.94)	-0.67 (-6.47, 5.18)	3.20 (-2.56, 9.13)	0.44 (-2.28, 3.14)	0.86 (-1.86, 3.58)	-0.76 (-3.46, 1.94)	0.53 (-2.23, 3.29)	1.42 (-0.70, 3.51)	-0.37 (-3.15, 2.38)	1.13 (-1.57, 3.90)	1.30 (-1.39, 4.07)	1.27 (-1.41, 4.04)	-0.23 (-2.95, 2.51)	0.47 (-1.67, 2.61)	-0.66 (-3.39, 2.15)	-0.71 (-5.72, 4.26)	-	-1.03 (-1.86, -0.20)	-2.10 (-2.89, -1.31)	1.81 (0.91, 2.71)	0.07 (-0.76, 0.90)	-
SRKT Latkany	-0.26 (-3.27, 2.69)	-0.57 (-3.51, 2.40)	0.38 (-3.88, 4.57)	-0.34 (-3.72, 3.05)	-1.21 (-7.16, 4.82)	2.66 (-3.28, 8.69)	-0.12 (-3.55, 3.25)	0.31 (-2.66, 3.28)	-1.31 (-4.72, 2.07)	-0.03 (-3.01, 2.96)	0.87 (-1.85, 3.54)	-0.93 (-3.91, 2.05)	0.59 (-2.39, 3.57)	0.75 (-2.17, 3.72)	0.73 (-2.23, 3.67)	-0.78 (-3.74, 2.16)	-0.08 (-2.83, 2.63)	-1.21 (-4.19, 1.74)	-1.27 (-6.37, 3.91)	-0.54 (-3.31, 2.14)	-	-1.07 (-1.60, -0.54)	2.84 (2.16, 3.52)	1.10 (0.52, 1.68)	-
SRKT Masket	-1.35 (-4.33, 1.66)	-1.64 (-4.59, 1.27)	-0.71 (-4.88, 3.49)	-1.41 (-4.87, 2.01)	-2.29 (-8.23, 3.68)	1.58 (-4.37, 7.59)	-1.20 (-4.63, 2.14)	-0.77 (-3.79, 2.12)	-2.37 (-5.82, 1.02)	-1.09 (-4.05, 1.86)	-0.22 (-2.94, 2.47)	-2.00 (-5.03, 0.98)	-0.48 (-3.47, 2.48)	-0.33 (-3.26, 2.65)	-0.36 (-3.32, 2.58)	-1.87 (-4.84, 1.08)	-1.16 (-3.88, 1.53)	-2.28 (-5.29, 0.65)	-2.35 (-7.42, 2.75)	-1.63 (-4.38, 1.06)	-1.08 (-4.01, 1.84)	-	3.91 (3.28, 4.54)	2.17 (1.65, 2.69)	-
SRKT SK Ferrara	2.56 (-0.48, 5.57)	2.27 (-0.74, 5.29)	3.20 (-1.05, 7.41)	2.49 (-0.99, 5.92)	1.61 (-4.35, 7.61)	5.49 (-0.50, 11.47)	2.71 (-0.78, 6.13)	3.13 (0.08, 6.12)	1.52 (-2.02, 5.01)	2.80 (-0.20, 5.87)	3.69 (0.92, 6.42)	1.91 (-1.14, 4.93)	3.43 (0.46, 6.42)	3.59 (0.57, 6.62)	3.55 (0.50, 6.52)	2.04 (-0.95, 5.04)	2.76 (-0.02, 5.46)	1.62 (-1.39, 4.65)	1.56 (-3.64, 6.71)	2.28 (-0.56, 5.04)	2.83 (-0.17, 5.80)	3.91 (0.93, 6.89)	-1.74 (-2.41, -1.07)	-	
SRKT SK Rosa	0.82 (-2.17, 3.82)	0.53 (-2.43, 3.48)	1.46 (-2.68, 5.67)	0.77 (-2.71, 4.16)	-0.12 (-5.99, 5.79)	3.76 (-2.19, 9.77)	0.98 (-2.51, 4.39)	1.39 (-1.59, 4.35)	-0.22 (-3.65, 3.22)	1.07 (-1.92, 4.08)	1.96 (-0.78, 4.65)	0.16 (-2.83, 3.20)	1.68 (-1.28, 4.66)	1.84 (-1.12, 4.87)	1.82 (-1.14, 4.78)	0.30 (-2.66, 3.27)	1.02 (-1.72, 3.75)	-0.11 (-3.07, 2.91)	-0.17 (-5.26, 4.97)	0.54 (-2.22, 3.29)	1.09 (-1.89, 4.09)	2.18 (-0.78, 5.13)	-1.74 (-4.71, 1.27)	-	

Meta-analysis and network meta-analysis results

	Clinical history	Carnellin-Calossi	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Shammas-PL	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Sa vidl	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT K	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa	SRKT TNP
SRKT TNP	-2.43 (-8.33, 3.58)	-2.73 (-8.57, 3.24)	-1.78 (-5.94, 2.38)	-2.51 (-8.63, 3.68)	-3.37 (-6.34, 0.37)	0.49 (-2.50, 3.50)	-2.30 (-8.45, 3.81)	-1.87 (-6.94, 3.31)	-3.45 (-9.62, 2.67)	-2.20 (-8.18, 3.74)	-1.28 (-7.14, 4.48)	-3.10 (-9.01, 2.83)	-1.56 (-7.54, 4.42)	-1.40 (-7.32, 4.50)	-1.43 (-7.37, 4.45)	-2.94 (-8.88, 2.98)	-2.25 (-8.09, 3.59)	-3.36 (-9.26, 2.55)	-3.44 (-6.38, 0.45)	-2.71 (-8.52, 3.09)	-2.15 (-8.04, 3.79)	-1.09 (-6.95, 4.84)	-4.98 (-10.99, 1.03)	-3.25 (-9.16, 2.62)	





Figure 65: Myopic corneal refractive surgery: prediction error – relative effect of all options versus common comparator

**Table 110: Myopic corneal refractive surgery: prediction error – rankings for each comparator**

	Probability best	Median rank (95%CI)
Clinical history	0.009	14 (3, 24)
Camellin-Calossi	0.004	16 (4, 24)
Haigis-L	0.014	9 (2, 23)
HofferQ DK	0.013	14 (2, 24)
HofferQ K	0.001	20 (3, 25)
HofferQ TNP	0.423	2 (1, 22)
Holladay2 DK	0.018	13 (2, 24)
Shammas-PL	0.007	10 (3, 21)
SRKT Clinical history	0.002	20 (5, 25)
SRKT Diehl	0.013	12 (2, 23)
SRKT DK	0.039	7 (1, 17)
SRKT DK Awwad	0.002	18 (5, 25)
SRKT DK Savini	0.038	8 (1, 21)
SRKT DK Seitz/Speicher	0.048	7 (1, 20)
SRKT DK Seitz/Speicher/Savini	0.046	7 (1, 20)
SRKT DK Shammas	0.002	17 (5, 24)
SRKT Feiz-Mannis	0.003	13 (4, 22)
SRKT Feiz-Mannis nomogram	0.001	20 (6, 25)
SRKT K	0.000	20 (4, 25)
SRKT Ladas-Stark	0.001	16 (5, 23)
SRKT Latkany	0.012	12 (2, 23)
SRKT Masket	0.084	6 (1, 19)
SRKT SK Ferrara	0.000	24 (15, 25)
SRKT SK Rosa	0.001	19 (6, 25)
SRKT TNP	0.218	2 (1, 22)



**Figure 66: Myopic corneal refractive surgery: prediction error – rank probability histograms**

**Table 111: Myopic corneal refractive surgery: prediction error – model fit statistics**


Residual deviance	Dbar	Dhat	pD	DIC	tau
31 (compared to 31 datapoints)	-15.563	-46.424	30.86	15.297	1.416 (95%CI: 0.720, 1.966)

**Table 112: Myopic corneal refractive surgery: prediction error – notes**

- Continuous (normal; identity link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)



**PROPORTION WITHIN 0.5 DIOPTRES – random effects model**



**Figure 67: Myopic corneal refractive surgery: within 0.5D – evidence network**

**Table 113: Myopic corneal refractive surgery: within 0.5D – input data**

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
Xu et al. (2014)								6/37	3/37									4/37		3/37
Huang et al. (2013)						21/46							21/46							
Kim et al. (2013)						30/47												5/47		
Saiki et al. (2013)		3/28	9/19	4/12	1/12	6/25					4/12	5/12	7/28	13/28	12/25	5/28				5/28
Fam & (2008)	5/37						13/37			17/37						19/37	15/37		17/37	

**Table 114: Myopic corneal refractive surgery: within 0.5D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
SRKT Clinical history	-	-	-	-	-	-	3.47 (1.09, 11.05)	-	-	5.44 (1.73, 17.06)	-	-	-	-	-	6.76 (2.16, 21.16)	4.36 (1.38, 13.76)	-	5.44 (1.73, 17.06)	-
BESSt	3.88 (0.08, 180.60)	-	7.50 (1.68, 33.56)	4.17 (0.76, 22.71)	0.76 (0.07, 8.12)	2.63 (0.58, 11.90)	-	-	-	-	4.17 (0.76, 22.71)	5.95 (1.13, 31.26)	2.78 (0.64, 12.10)	7.22 (1.76, 29.56)	7.69 (1.84, 32.20)	1.81 (0.39, 8.44)	-	-	-	1.81 (0.39, 8.44)
Camellin-Calossi	32.89 (0.76, 1490.00)	8.63 (0.54, 149.10)	-	0.56 (0.12, 2.49)	0.10 (0.01, 0.95)	0.35 (0.10, 1.27)	-	-	-	-	0.56 (0.12, 2.49)	0.79 (0.18, 3.41)	0.37 (0.11, 1.28)	0.96 (0.30, 3.09)	1.03 (0.31, 3.39)	0.24 (0.06, 0.91)	-	-	-	0.24 (0.06, 0.91)
Double-K	17.55 (0.36, 820.50)	4.53 (0.25, 90.35)	0.53 (0.03, 8.48)	-	0.18 (0.02, 1.95)	0.63 (0.14, 2.86)	-	-	-	-	1.00 (0.18, 5.46)	1.43 (0.27, 7.52)	0.67 (0.15, 2.91)	1.73 (0.42, 7.11)	1.85 (0.44, 7.74)	0.43 (0.09, 2.03)	-	-	-	0.43 (0.09, 2.03)
Feiz-Mannis	2.20 (0.02, 145.80)	0.59 (0.01, 15.97)	0.07 (0.00, 1.64)	0.13 (0.00, 3.46)	-	3.47 (0.37, 32.74)	-	-	-	-	5.50 (0.51, 59.01)	7.86 (0.75, 82.13)	3.67 (0.40, 33.71)	9.53 (1.08, 84.14)	10.15 (1.13, 90.94)	2.39 (0.25, 23.01)	-	-	-	2.39 (0.25, 23.01)

Meta-analysis and network meta-analysis results

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP	
Haigis-L	15.45 (0.44, 630.20)	4.00 (0.33, 61.03)	0.47 (0.04, 5.51)	0.88 (0.07, 11.93)	6.75 (0.37, 328.20)	-	-	-	-	-	1.58 (0.35, 7.17)	2.26 (0.52, 9.83)	1.02 (0.51, 2.02)	2.74 (0.84, 8.94)	2.92 (0.87, 9.78)	0.69 (0.18, 2.61)	-	0.07 (0.02, 0.20)	-	0.69 (0.18, 2.61)	
HofferQ DK	3.68 (0.26, 50.80)	0.97 (0.02, 44.53)	0.11 (0.00, 4.34)	0.22 (0.00, 10.12)	1.68 (0.03, 184.60)	0.24 (0.01, 7.79)	-	-	-	1.57 (0.62, 4.00)	-	-	-	-	-	1.95 (0.77, 4.96)	1.26 (0.49, 3.23)	-	1.57 (0.62, 4.00)	-	
HofferQ K	6.00 (0.08, 518.00)	1.56 (0.05, 63.77)	0.18 (0.01, 6.20)	0.34 (0.01, 13.15)	2.78 (0.06, 261.40)	0.39 (0.02, 7.74)	1.60 (0.02, 125.70)	-	0.46 (0.10, 1.98)	-	-	-	-	-	-	-	-	0.63 (0.16, 2.43)	-	0.46 (0.10, 1.98)	
HofferQ TNP	2.53 (0.03, 198.90)	0.66 (0.02, 27.58)	0.08 (0.00, 2.82)	0.14 (0.00, 6.06)	1.15 (0.02, 119.30)	0.16 (0.01, 3.52)	0.67 (0.01, 57.33)	0.42 (0.03, 6.24)	-	-	-	-	-	-	-	-	-	-	1.37 (0.29, 6.61)	-	1.00 (0.19, 5.31)
Holladay2 DK	5.83 (0.42, 82.42)	1.56 (0.04, 72.66)	0.18 (0.00, 6.71)	0.34 (0.01, 15.19)	2.71 (0.04, 294.60)	0.38 (0.01, 12.49)	1.58 (0.13, 20.93)	0.99 (0.01, 69.46)	2.34 (0.03, 182.90)	-	-	-	-	-	-	1.24 (0.50, 3.09)	0.80 (0.32, 2.02)	-	1.00 (0.40, 2.50)	-	
Masket	17.47 (0.38, 814.40)	4.51 (0.26, 87.62)	0.52 (0.03, 8.83)	0.99 (0.06, 18.32)	7.79 (0.31, 467.40)	1.12 (0.08, 13.95)	4.64 (0.11, 208.30)	2.88 (0.08, 95.93)	6.88 (0.17, 270.30)	2.94 (0.07, 128.20)	-	1.43 (0.27, 7.52)	0.67 (0.15, 2.91)	1.73 (0.42, 7.11)	1.85 (0.44, 7.74)	0.43 (0.09, 2.03)	-	-	-	-	0.43 (0.09, 2.03)
Modified Masket	25.83 (0.58, 1224.00)	6.73 (0.37, 128.50)	0.78 (0.05, 12.25)	1.47 (0.09, 26.82)	11.47 (0.46, 681.20)	1.67 (0.13, 20.40)	6.85 (0.17, 301.80)	4.29 (0.12, 134.10)	10.23 (0.27, 362.90)	4.31 (0.11, 201.20)	1.49 (0.08, 25.81)	-	0.47 (0.11, 1.95)	1.21 (0.31, 4.76)	1.29 (0.32, 5.19)	0.30 (0.07, 1.37)	-	-	-	-	0.30 (0.07, 1.37)
Shammas-PL	13.19 (0.36, 515.30)	3.45 (0.26, 50.02)	0.40 (0.03, 4.76)	0.76 (0.06, 10.23)	5.86 (0.31, 286.60)	0.86 (0.14, 4.99)	3.56 (0.10, 133.40)	2.20 (0.09, 52.58)	5.28 (0.18, 150.60)	2.24 (0.07, 83.46)	0.76 (0.06, 10.92)	0.51 (0.04, 7.03)	-	2.60 (0.84, 8.07)	2.77 (0.87, 8.84)	0.65 (0.18, 2.37)	-	-	-	-	0.65 (0.18, 2.37)
SRKT A-P	32.41 (0.79, 1340.00)	8.36 (0.54, 141.30)	0.96 (0.07, 13.33)	1.84 (0.12, 30.37)	14.38 (0.66, 757.50)	2.08 (0.19, 22.65)	8.58 (0.22, 341.20)	5.34 (0.16, 159.30)	12.68 (0.37, 466.30)	5.39 (0.14, 214.50)	1.84 (0.12, 30.10)	1.24 (0.08, 19.41)	2.39 (0.21, 26.76)	-	1.07 (0.36, 3.14)	0.25 (0.07, 0.85)	-	-	-	-	0.25 (0.07, 0.85)
SRKT C-P	34.02 (0.83, 1408.00)	8.83 (0.58, 145.40)	1.03 (0.08, 14.14)	1.95 (0.13, 30.74)	15.09 (0.68, 831.20)	2.21 (0.19, 23.11)	9.07 (0.24, 373.40)	5.70 (0.18, 163.20)	13.73 (0.38, 458.20)	5.69 (0.16, 230.60)	1.97 (0.13, 30.91)	1.32 (0.09, 19.92)	2.55 (0.23, 29.17)	1.06 (0.08, 14.37)	-	0.24 (0.07, 0.82)	-	-	-	-	0.24 (0.07, 0.82)
SRKT DK	7.35 (0.53, 104.30)	1.94 (0.12, 35.33)	0.23 (0.01, 3.24)	0.42 (0.03, 7.05)	3.31 (0.14, 190.00)	0.48 (0.04, 5.34)	1.97 (0.16, 26.69)	1.23 (0.04, 37.44)	2.94 (0.08, 104.20)	1.25 (0.10, 16.39)	0.43 (0.03, 6.89)	0.29 (0.02, 4.42)	0.56 (0.04, 6.64)	0.23 (0.02, 3.10)	0.22 (0.02, 2.97)	-	0.65 (0.26, 1.62)	-	0.81 (0.32, 2.01)	1.00 (0.25, 3.93)	

Meta-analysis and network meta-analysis results

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
SRKT Feiz-Mannis	4.67 (0.34, 67.63)	1.22 (0.03, 56.19)	0.14 (0.00, 5.68)	0.27 (0.01, 11.82)	2.11 (0.04, 236.80)	0.30 (0.01, 10.31)	1.27 (0.10, 16.86)	0.79 (0.01, 54.08)	1.86 (0.02, 151.40)	0.80 (0.06, 10.32)	0.27 (0.01, 11.89)	0.18 (0.00, 7.91)	0.35 (0.01, 12.94)	0.15 (0.00, 5.68)	0.14 (0.00, 5.32)	0.63 (0.05, 8.18)	-	-	1.25 (0.50, 3.13)	-
SRKT K	2.04 (0.04, 124.20)	0.53 (0.03, 14.55)	0.06 (0.00, 1.34)	0.12 (0.01, 2.90)	0.94 (0.03, 66.34)	0.13 (0.02, 1.27)	0.54 (0.01, 34.83)	0.34 (0.03, 5.01)	0.81 (0.06, 14.05)	0.34 (0.01, 20.26)	0.12 (0.01, 2.82)	0.08 (0.00, 1.86)	0.15 (0.01, 2.31)	0.06 (0.00, 1.34)	0.06 (0.00, 1.32)	0.27 (0.02, 6.20)	0.43 (0.01, 25.76)	-	-	0.73 (0.15, 3.50)
SRKT Ladas-Stark	5.86 (0.42, 84.94)	1.57 (0.03, 69.48)	0.18 (0.00, 6.77)	0.34 (0.01, 14.92)	2.68 (0.05, 284.60)	0.39 (0.01, 12.06)	1.59 (0.13, 20.83)	0.98 (0.01, 65.53)	2.35 (0.03, 186.80)	1.00 (0.08, 12.46)	0.34 (0.01, 14.34)	0.23 (0.01, 9.70)	0.45 (0.01, 15.39)	0.19 (0.00, 6.86)	0.17 (0.00, 6.28)	0.80 (0.06, 9.94)	1.26 (0.10, 15.77)	2.97 (0.05, 124.20)	-	-
SRKT TNP	4.50 (0.11, 187.50)	1.17 (0.08, 19.22)	0.14 (0.01, 1.87)	0.26 (0.02, 3.98)	2.01 (0.09, 107.30)	0.29 (0.04, 2.33)	1.21 (0.03, 49.20)	0.76 (0.05, 9.75)	1.77 (0.11, 28.02)	0.76 (0.02, 30.60)	0.26 (0.02, 3.90)	0.17 (0.01, 2.59)	0.34 (0.03, 3.39)	0.14 (0.01, 1.76)	0.13 (0.01, 1.74)	0.61 (0.04, 8.43)	0.96 (0.03, 38.36)	2.19 (0.22, 18.56)	0.75 (0.02, 29.15)	-





Figure 68: Myopic corneal refractive surgery: within 0.5D – relative effect of all options versus common comparator

**Table 115: Myopic corneal refractive surgery: within 0.5D – rankings for each comparator**

	Probability best	Median rank (95%CI)
SRKT Clinical history	0.001	19 (8, 20)
BESSt	0.002	14 (5, 20)
Camellin-Calossi	0.199	3 (1, 14)
Double-K	0.069	6 (1, 17)
Feiz-Mannis	0.002	16 (5, 20)
Haigis-L	0.017	7 (2, 15)
HofferQ DK	0.011	14 (3, 20)
HofferQ K	0.028	12 (1, 19)
HofferQ TNP	0.008	16 (3, 20)
Holladay2 DK	0.024	12 (2, 19)
Masket	0.070	6 (1, 17)
Modified Masket	0.142	5 (1, 15)
Shammas-PL	0.013	8 (2, 16)
SRKT A-P	0.171	4 (1, 13)
SRKT C-P	0.199	3 (1, 13)
SRKT DK	0.002	11 (4, 17)
SRKT Feiz-Mannis	0.018	13 (2, 19)
SRKT K	0.001	17 (7, 20)
SRKT Ladas-Stark	0.024	12 (2, 19)
SRKT TNP	0.001	13 (5, 19)



**Figure 69: Myopic corneal refractive surgery: within 0.5D – rank probability histograms**

**Table 116: Myopic corneal refractive surgery: within 0.5D – model fit statistics**


Residual deviance	Dbar	Dhat	pD	DIC	tau
27.42 (compared to 26 datapoints)	117.472	91.607	25.865	143.337	0.955 (95%CI: 0.065, 1.925)

**Table 117: Myopic corneal refractive surgery: within 0.5D – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)



**PROPORTION WITHIN 1.0 DIOPTRE – random effects model**



**Figure 70: Myopic corneal refractive surgery: within 1.0D – evidence network**

**Table 118: Myopic corneal refractive surgery: within 1.0D – input data**

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
Xu et al. (2014)								14/37	3/37									8/37		5/37
Huang et al. (2013)						36/46							39/46							
Kim et al. (2013)						38/47												16/47		
Saiki et al. (2013)		12/28	14/19	8/12	6/12	13/25					10/12	9/12	20/28	21/28	17/25	14/28				17/28
Fam & (2008)	11/37						28/37			30/37						25/37	23/37		23/37	

**Table 119: Myopic corneal refractive surgery: within 1.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
SRKT Clinical history		-	-	-	-	-	7.35 (2.63, 20.60)	-	-	10.13 (3.43, 29.93)	-	-	-	-	-	4.92 (1.84, 13.19)	3.88 (1.47, 10.23)	-	3.88 (1.47, 10.23)	-
BESSt	3.81 (0.06, 227.60)		3.73 (1.05, 13.24)	2.67 (0.65, 10.97)	1.33 (0.34, 5.18)	1.44 (0.49, 4.27)	-	-	-	-	6.67 (1.23, 36.23)	4.00 (0.89, 18.03)	3.33 (1.10, 10.12)	4.00 (1.28, 12.46)	2.83 (0.92, 8.73)	1.33 (0.47, 3.82)	-	-	-	2.06 (0.71, 5.98)
Camellin-Calossi	15.54 (0.26, 888.10)	4.05 (0.21, 78.19)		0.71 (0.15, 3.45)	0.36 (0.08, 1.64)	0.39 (0.11, 1.40)	-	-	-	-	1.79 (0.29, 11.13)	1.07 (0.20, 5.63)	0.89 (0.24, 3.31)	1.07 (0.28, 4.06)	0.76 (0.20, 2.85)	0.36 (0.10, 1.26)	-	-	-	0.55 (0.15, 1.97)
Double-K	10.98 (0.17, -)	2.87 (0.15, -)	0.70 (0.03, -)		0.50 (0.10, -)	0.54 (0.13, -)	-	-	-	-	2.50 (0.36, -)	1.50 (0.25, -)	1.25 (0.29, -)	1.50 (0.34, -)	1.06 (0.25, -)	0.50 (0.12, -)	-	-	-	0.77 (0.19, -)

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP	
	731.40)	59.91)	15.96)		2.60)	2.27)					17.32)	8.84)	5.35)	6.55)	4.60)	2.05)				3.20)	
Feiz-Mannis	5.22 (0.08, 311.00)	1.37 (0.07, 27.48)	0.34 (0.02, 7.02)	0.48 (0.02, 10.31)		1.08 (0.27, 4.29)	-	-	-	-	5.00 (0.75, 33.21)	3.00 (0.53, 16.90)	2.50 (0.62, 10.11)	3.00 (0.73, 12.39)	2.13 (0.52, 8.70)	1.00 (0.26, 3.87)	-	-	-	1.55 (0.40, 6.03)	
Haigis-L	9.30 (0.19, 449.10)	2.43 (0.18, 33.65)	0.60 (0.04, 8.86)	0.85 (0.05, 12.83)	1.79 (0.12, 26.69)		-	-	-	-	4.62 (0.84, 25.49)	2.77 (0.60, 12.71)	1.87 (0.86, 4.06)	2.77 (0.87, 8.84)	1.96 (0.62, 6.19)	0.92 (0.31, 2.72)	-	0.12 (0.05, 0.31)	-	1.43 (0.48, 4.25)	
HofferQ DK	7.79 (0.44, 134.90)	2.06 (0.03, 120.40)	0.51 (0.01, 30.84)	0.71 (0.01, 45.22)	1.50 (0.02, 99.39)	0.84 (0.02, 42.06)		-	-	1.38 (0.45, 4.20)	-	-	-	-	-	0.67 (0.24, 1.85)	0.53 (0.19, 1.44)	-	0.53 (0.19, 1.44)	-	
HofferQ K	11.10 (0.11, 1221.00)	2.94 (0.08, 119.80)	0.73 (0.02, 30.60)	1.02 (0.02, 42.35)	2.15 (0.05, 94.42)	1.20 (0.05, 27.15)	1.44 (0.01, 159.70)		0.14 (0.04, 0.56)	-	-	-	-	-	-	-	-	0.45 (0.16, 1.27)	-	0.26 (0.08, 0.81)	
HofferQ TNP	1.41 (0.01, 169.20)	0.36 (0.01, 17.53)	0.09 (0.00, 4.53)	0.13 (0.00, 6.43)	0.27 (0.01, 13.24)	0.15 (0.01, 4.11)	0.18 (0.00, 21.37)	0.13 (0.01, 2.40)		-	-	-	-	-	-	-	-	-	3.13 (0.76, 12.89)	-	1.77 (0.39, 8.02)
Holladay2 DK	10.95 (0.63, 198.80)	2.91 (0.05, 163.90)	0.70 (0.01, 43.02)	1.00 (0.01, 66.08)	2.09 (0.03, 126.40)	1.18 (0.02, 56.26)	1.41 (0.08, 24.39)	0.98 (0.01, 101.70)	7.78 (0.06, 909.80)		-	-	-	-	-	0.49 (0.17, 1.42)	0.38 (0.13, 1.10)	-	0.38 (0.13, 1.10)	-	
Masket	32.02 (0.46, 2442.00)	8.29 (0.35, 219.80)	2.03 (0.08, 61.95)	2.90 (0.11, 84.96)	6.01 (0.23, 186.40)	3.37 (0.19, 75.67)	4.05 (0.06, 306.10)	2.82 (0.06, 150.30)	22.62 (0.40, 1487.00)	2.95 (0.04, 216.80)		0.60 (0.08, 4.45)	0.50 (0.09, 2.81)	0.60 (0.11, 3.43)	0.43 (0.07, 2.41)	0.20 (0.04, 1.08)	-	-	-	0.31 (0.06, 1.69)	
Modified Masket	17.37 (0.27, 1161.00)	4.50 (0.22, 100.40)	1.12 (0.05, 27.63)	1.59 (0.06, 40.92)	3.31 (0.15, 87.14)	1.85 (0.11, 34.73)	2.21 (0.03, 143.70)	1.56 (0.03, 76.63)	12.41 (0.23, 690.50)	1.57 (0.02, 106.70)	0.55 (0.02, 15.91)		0.83 (0.18, 3.90)	1.00 (0.21, 4.77)	0.71 (0.15, 3.35)	0.33 (0.07, 1.50)	-	-	-	0.52 (0.11, 2.33)	
Shammas-PL	13.84 (0.28, 686.00)	3.59 (0.25, 53.09)	0.89 (0.05, 14.03)	1.26 (0.07, 21.07)	2.63 (0.16, 44.96)	1.47 (0.20, 11.10)	1.76 (0.03, 85.45)	1.24 (0.04, 37.72)	9.73 (0.28, 351.80)	1.27 (0.03, 61.34)	0.44 (0.02, 8.57)	0.80 (0.04, 13.41)		1.20 (0.37, 3.92)	0.85 (0.26, 2.75)	0.40 (0.13, 1.21)	-	-	-	0.62 (0.20, 1.89)	
SRKT A-P	16.35 (0.28, 935.50)	4.26 (0.24, 78.67)	1.06 (0.05, 20.89)	1.51 (0.07, 29.39)	3.10 (0.16, 65.42)	1.74 (0.13, 24.64)	2.08 (0.04, 119.80)	1.46 (0.04, 56.51)	11.52 (0.26, 512.40)	1.49 (0.03, 86.26)	0.52 (0.02, 11.81)	0.95 (0.04, 19.81)	1.18 (0.08, 17.37)		0.71 (0.21, 2.35)	0.33 (0.11, 1.03)	-	-	-	0.52 (0.16, 1.62)	
SRKT C-P	11.16 (0.20, 0.20)	2.99 (0.16, 0.16)	0.73 (0.04, 0.04)	1.03 (0.05, 0.05)	2.18 (0.11, 0.11)	1.23 (0.09, 0.09)	1.45 (0.02, 0.02)	1.02 (0.03, 0.03)	8.14 (0.17, 0.17)	1.03 (0.02, 0.02)	0.36 (0.01, 0.01)	0.66 (0.03, 0.03)	0.82 (0.05, 0.05)	0.70 (0.04, 0.04)		0.47 (0.15, 0.15)	-	-	-	0.73 (0.23, 0.23)	

Meta-analysis and network meta-analysis results

	SRKT Clinical history	BESSt	Camellin-Calossi	Double-K	Feiz-Mannis	Haigis-L	HofferQ DK	HofferQ K	HofferQ TNP	Holladay2 DK	Masket	Modified Masket	Shammas-PL	SRKT A-P	SRKT C-P	SRKT DK	SRKT Feiz-Mannis	SRKT K	SRKT Ladas-Stark	SRKT TNP
	666.50)	52.55)	14.10)	21.10)	44.03)	16.46)	83.72)	39.19)	371.30)	57.93)	8.30)	13.48)	12.32)	12.77)		1.44)				2.26)
SRKT DK	5.13 (0.30, 90.12)	1.35 (0.08, 23.55)	0.33 (0.02, 6.31)	0.47 (0.02, 9.54)	0.99 (0.05, 19.41)	0.55 (0.04, 7.31)	0.66 (0.04, 11.39)	0.46 (0.01, 17.53)	3.68 (0.08, 168.00)	0.47 (0.03, 8.18)	0.16 (0.01, 3.82)	0.30 (0.01, 5.98)	0.37 (0.03, 5.39)	0.31 (0.02, 5.78)	0.46 (0.03, 7.87)		0.79 (0.30, 2.05)	-	0.79 (0.30, 2.05)	1.55 (0.54, 4.46)
SRKT Feiz-Mannis	4.01 (0.23, 68.91)	1.06 (0.02, 61.32)	0.26 (0.00, 15.85)	0.37 (0.01, 23.36)	0.78 (0.01, 46.62)	0.43 (0.01, 20.86)	0.52 (0.03, 8.69)	0.36 (0.00, 35.39)	2.88 (0.02, 332.60)	0.37 (0.02, 6.33)	0.13 (0.00, 8.85)	0.23 (0.00, 15.16)	0.29 (0.01, 14.21)	0.25 (0.00, 14.64)	0.36 (0.01, 19.83)	0.78 (0.05, 12.83)		-	1.00 (0.39, 2.56)	-
SRKT K	2.80 (0.04, 216.40)	0.74 (0.03, 19.53)	0.18 (0.01, 4.91)	0.26 (0.01, 7.12)	0.54 (0.02, 14.87)	0.30 (0.03, 3.14)	0.36 (0.01, 28.41)	0.25 (0.02, 3.79)	2.02 (0.11, 38.82)	0.26 (0.00, 20.06)	0.09 (0.00, 2.91)	0.16 (0.01, 4.87)	0.20 (0.01, 3.39)	0.17 (0.01, 4.29)	0.25 (0.01, 6.02)	0.54 (0.02, 12.99)	0.70 (0.01, 53.95)		-	0.57 (0.17, 1.93)
SRKT Ladas-Stark	4.06 (0.24, 70.52)	1.07 (0.02, 62.02)	0.26 (0.00, 15.31)	0.37 (0.01, 22.91)	0.77 (0.01, 48.40)	0.44 (0.01, 21.22)	0.52 (0.03, 8.77)	0.36 (0.00, 35.32)	2.91 (0.03, 336.20)	0.37 (0.02, 6.26)	0.13 (0.00, 8.54)	0.23 (0.00, 14.58)	0.29 (0.01, 14.89)	0.25 (0.00, 14.05)	0.36 (0.01, 20.29)	0.79 (0.05, 13.65)	1.00 (0.06, 16.65)	1.45 (0.02, 96.99)		-
SRKT TNP	4.85 (0.09, 239.20)	1.27 (0.08, 19.62)	0.31 (0.02, 5.20)	0.44 (0.02, 7.52)	0.92 (0.05, 16.07)	0.52 (0.05, 4.81)	0.62 (0.01, 32.52)	0.44 (0.03, 6.58)	3.46 (0.18, 61.45)	0.44 (0.01, 22.90)	0.15 (0.01, 3.15)	0.28 (0.01, 5.18)	0.35 (0.03, 4.09)	0.30 (0.02, 4.59)	0.43 (0.03, 6.30)	0.93 (0.06, 13.63)	1.22 (0.02, 60.79)	1.72 (0.16, 16.40)	1.20 (0.02, 58.13)	




Figure 71: Myopic corneal refractive surgery: within 1.0D – relative effect of all options versus common comparator

**Table 120: Myopic corneal refractive surgery: within 1.0D – rankings for each comparator**

	Probability best	Median rank (95%CI)
SRKT Clinical history	0.001	19 (6, 20)
BESSt	0.003	14 (4, 20)
Camellin-Calossi	0.080	6 (1, 18)
Double-K	0.053	8 (1, 19)
Feiz-Mannis	0.010	13 (2, 20)
Haigis-L	0.008	9 (2, 17)
HofferQ DK	0.052	10 (1, 19)
HofferQ K	0.091	8 (1, 19)
HofferQ TNP	0.004	18 (4, 20)
Holladay2 DK	0.095	8 (1, 19)
Masket	0.290	3 (1, 16)
Modified Masket	0.119	6 (1, 18)
Shammas-PL	0.038	7 (1, 17)
SRKT A-P	0.080	6 (1, 17)
SRKT C-P	0.039	8 (1, 18)
SRKT DK	0.001	13 (4, 18)
SRKT Feiz-Mannis	0.016	14 (2, 20)
SRKT K	0.002	16 (4, 20)
SRKT Ladas-Stark	0.015	14 (2, 20)
SRKT TNP	0.002	13 (4, 19)




Figure 72: Myopic corneal refractive surgery: within 1.0D – rank probability histograms


**Table 121: Myopic corneal refractive surgery: within 1.0D – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
27.01 (compared to 26 datapoints)	119.699	93.504	26.195	145.894	1.213 (95%CI: 0.294, 1.954)

**Table 122: Myopic corneal refractive surgery: within 1.0D – notes**


- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

**PAIRWISE COMPARISONS: PROPORTION WITHIN 1.5 DIOPETRES AND 2.0 DIOPETRES**





**PROPORTION WITHIN 2.0 DIOPTRE – fixed effects model**




**Figure 73: Myopic corneal refractive surgery: within 2.0D – evidence network**

**Table 123: Myopic corneal refractive surgery: within 2.0D – input data**

	SRKT Clinical history	HofferQ DK	Holladay2 DK	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
Fam & (2008)	33/37	35/37	34/37	35/37	32/37	35/37

**Table 124: Myopic corneal refractive surgery: within 2.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT Clinical history	HofferQ DK	Holladay2 DK	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Clinical history		2.12 (0.36, 12.36)	1.37 (0.29, 6.61)	2.12 (0.36, 12.36)	0.78 (0.19, 3.15)	2.12 (0.36, 12.36)
HofferQ DK	2.32 (0.39, 19.84)		0.65 (0.10, 4.12)	1.00 (0.13, 7.50)	0.37 (0.07, 2.02)	1.00 (0.13, 7.50)
Holladay2 DK	1.42 (0.27, 8.24)	0.61 (0.07, 4.32)		1.54 (0.24, 9.82)	0.56 (0.12, 2.56)	1.54 (0.24, 9.82)
SRKT DK	2.33 (0.39, 19.87)	1.00 (0.10, 9.99)	1.63 (0.23, 15.74)		0.37 (0.07, 2.02)	1.00 (0.13, 7.50)
SRKT Feiz-Mannis	0.76 (0.17, 3.29)	0.33 (0.04, 1.74)	0.53 (0.10, 2.50)	0.33 (0.04, 1.81)		2.73 (0.50, 15.09)
SRKT Ladas-Stark	2.30 (0.39, 19.99)	0.99 (0.10, 9.99)	1.62 (0.23, 14.79)	0.99 (0.10, 10.03)	3.02 (0.56, 26.29)	



**Figure 74:** Myopic corneal refractive surgery: within 2.0D – relative effect of all options versus common comparator

**Table 125:** Myopic corneal refractive surgery: within 2.0D – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT Clinical history	0.029	5 (1, 6)
HofferQ DK	0.292	2 (1, 6)
Holladay2 DK	0.093	4 (1, 6)
SRKT DK	0.294	2 (1, 6)
SRKT Feiz-Mannis	0.008	6 (2, 6)
SRKT Ladas-Stark	0.284	2 (1, 6)




Figure 75: Myopic corneal refractive surgery: within 2.0D – rank probability histograms

Table 126: Myopic corneal refractive surgery: within 2.0D – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC
6.394 (compared to 6 datapoints)	23.465	17.567	5.898	29.364

Table 127: Myopic corneal refractive surgery: within 2.0D – notes

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

H.3.3.3 Sensitivity analyses: no historical data methods only

Proportion within 0.5D – random effects model




Figure 76: Myopic CRS No historical data methods: within 0.5D – evidence network

**Table 128: Myopic CRS No historical data methods: within 0.5D – input data**

	SRKT K	BESSt	Haigis-L	HofferQ K	HofferQ TNP	Shammas-PL	SRKT A-P	SRKT C-P	SRKT TNP
Xu et al. (2014)	4/37			6/37	3/37				3/37
Huang et al. (2013)			21/46			21/46			
Kim et al. (2013)	5/47		30/47						
Saiki et al. (2013)		3/28	6/25			7/28	13/28	12/25	5/28

**Table 129: Myopic CRS No historical data methods: within 0.5D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT K	BESSt	Haigis-L	HofferQ K	HofferQ TNP	Shammas-PL	SRKT A-P	SRKT C-P	SRKT TNP
SRKT K	-	-	14.82 (4.93, 44.61)	1.60 (0.41, 6.20)	0.73 (0.15, 3.50)	-	-	-	0.73 (0.15, 3.50)
BESSt	1.91 (0.08, 36.38)	-	2.63 (0.58, 11.90)	-	-	2.78 (0.64, 12.10)	7.22 (1.76, 29.56)	7.69 (1.84, 32.20)	1.81 (0.39, 8.44)
Haigis-L	7.71 (0.83, 59.26)	3.99 (0.33, 55.38)	-	-	-	1.02 (0.51, 2.02)	2.74 (0.84, 8.94)	2.92 (0.87, 9.78)	0.69 (0.18, 2.61)
HofferQ K	2.94 (0.20, 38.58)	1.54 (0.05, 61.70)	0.38 (0.02, 8.18)	-	0.46 (0.10, 1.98)	-	-	-	0.46 (0.10, 1.98)
HofferQ TNP	1.25 (0.07, 17.11)	0.66 (0.02, 24.84)	0.16 (0.01, 3.45)	0.42 (0.02, 6.30)	-	-	-	-	1.00 (0.19, 5.31)
Shammas-PL	6.54 (0.44, 72.95)	3.38 (0.27, 48.07)	0.86 (0.14, 4.80)	2.21 (0.08, 50.70)	5.22 (0.21, 135.60)	-	2.60 (0.84, 8.07)	2.77 (0.87, 8.84)	0.65 (0.18, 2.37)
SRKT A-P	15.89 (0.76, 273.70)	8.16 (0.55, 144.60)	2.06 (0.19, 21.26)	5.34 (0.16, 156.30)	12.65 (0.36, 447.50)	2.43 (0.22, 26.60)	-	1.07 (0.36, 3.14)	0.25 (0.07, 0.85)
SRKT C-P	16.96 (0.78, 285.30)	8.84 (0.60, 153.10)	2.23 (0.20, 24.06)	5.74 (0.17, 166.20)	13.68 (0.40, 460.80)	2.58 (0.23, 29.24)	1.08 (0.08, 14.84)	-	0.24 (0.07, 0.82)

	SRKT K	BESSt	Haigis-L	HofferQ K	HofferQ TNP	Shammas-PL	SRKT A-P	SRKT C-P	SRKT TNP
SRKT TNP	2.20 (0.21, 18.06)	1.16 (0.08, 19.14)	0.29 (0.04, 2.33)	0.75 (0.05, 9.28)	1.78 (0.12, 27.68)	0.34 (0.04, 3.41)	0.14 (0.01, 1.77)	0.13 (0.01, 1.72)	




Figure 77: Myopic CRS No historical data methods: within 0.5D – relative effect of all options versus common comparator

Table 130: Myopic CRS No historical data methods: within 0.5D – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT K	0.002	8 (4, 9)
BESSt	0.008	7 (2, 9)
Haigis-L	0.061	3 (1, 7)
HofferQ K	0.057	6 (1, 9)
HofferQ TNP	0.015	8 (2, 9)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Shammas-PL	0.043	4 (1, 8)
SRKT A-P	0.379	2 (1, 7)
SRKT C-P	0.430	2 (1, 7)
SRKT TNP	0.004	6 (3, 9)






Figure 78: Myopic CRS No historical data methods: within 0.5D – rank probability histograms


Table 131: Myopic CRS No historical data methods: within 0.5D – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC	tau
14.86 (compared to 14 datapoints)	64.031	50.43	13.601	77.632	0.942 (95%CI: 0.066, 1.925)

**Table 132: Myopic CRS No historical data methods: within 0.5D – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

**Proportion within 1.0D – random effects model**



**Figure 79: Myopic CRS No historical data methods: within 1.0D – evidence network**

**Table 133: Myopic CRS No historical data methods: within 1.0D – input data**

	SRKT K	BESSt	Haigis-L	HofferQ K	HofferQ TNP	Shammas-PL	SRKT A-P	SRKT C-P	SRKT TNP
Xu et al. (2014)	8/37			14/37	3/37				5/37
Huang et al. (2013)			36/46			39/46			
Kim et al. (2013)	16/47		38/47						
Saiki et al. (2013)		12/28	13/25			20/28	21/28	17/25	17/28

**Table 134: Myopic CRS No historical data methods: within 1.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT K	BESSt	Haigis-L	HofferQ K	HofferQ TNP	Shammas-PL	SRKT A-P	SRKT C-P	SRKT TNP
SRKT K	-	-	8.18 (3.18, 21.03)	2.21 (0.79, 6.16)	0.32 (0.08, 1.32)	-	-	-	0.57 (0.17, 1.93)
BESSt	1.36 (0.06, 29.93)	-	1.44 (0.49, 4.27)	-	-	3.33 (1.10, 10.12)	4.00 (1.28, 12.46)	2.83 (0.92, 8.73)	2.06 (0.71, 5.98)
Haigis-L	3.30 (0.32, 30.30)	2.40 (0.18, 32.35)	-	-	-	1.87 (0.86, 4.06)	2.77 (0.87, 8.84)	1.96 (0.62, 6.19)	1.43 (0.48, 4.25)
HofferQ K	3.93 (0.26, 60.17)	2.89 (0.07, 114.80)	1.20 (0.06, 28.92)	-	0.14 (0.04, 0.56)	-	-	-	0.26 (0.08, 0.81)
HofferQ TNP	0.50 (0.03, 8.27)	0.37 (0.01, 16.64)	0.15 (0.01, 4.08)	0.13 (0.01, 2.49)	-	-	-	-	1.77 (0.39, 8.02)
Shammas-PL	4.89 (0.29, 73.62)	3.59 (0.25, 51.59)	1.49 (0.20, 10.83)	1.23 (0.04, 37.75)	9.68 (0.28, 348.20)	-	1.20 (0.37, 3.92)	0.85 (0.26, 2.75)	0.62 (0.20, 1.89)
SRKT A-P	5.77 (0.23, 130.60)	4.24 (0.24, 76.73)	1.76 (0.13, 23.75)	1.46 (0.04, 56.18)	11.34 (0.26, 561.10)	1.19 (0.08, 16.70)	-	0.71 (0.21, 2.35)	0.52 (0.16, 1.62)
SRKT C-P	4.00 (0.16, 91.84)	2.94 (0.16, 53.66)	1.22 (0.09, 16.85)	1.00 (0.02, 39.47)	7.88 (0.18, 378.80)	0.82 (0.05, 12.06)	0.69 (0.04, 12.78)	-	0.73 (0.23, 2.26)

	SRKT K	BESSt	Haigis-L	HofferQ K	HofferQ TNP	Shammas-PL	SRKT A-P	SRKT C-P	SRKT TNP
SRKT TNP	1.72 (0.16, 16.54)	1.27 (0.08, 19.13)	0.52 (0.06, 4.77)	0.43 (0.03, 6.28)	3.37 (0.19, 61.78)	0.35 (0.03, 4.05)	0.30 (0.02, 4.49)	0.43 (0.03, 6.83)	




Figure 80: Myopic CRS No historical data methods: within 1.0D – relative effect of all options versus common comparator

Table 135: Myopic CRS No historical data methods: within 1.0D – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT K	0.008	7 (2, 9)
BESSt	0.022	7 (2, 9)
Haigis-L	0.053	4 (1, 8)
HofferQ K	0.233	4 (1, 8)
HofferQ TNP	0.010	9 (2, 9)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Shammas-PL	0.190	3 (1, 8)
SRKT A-P	0.303	2 (1, 8)
SRKT C-P	0.169	4 (1, 9)
SRKT TNP	0.012	6 (2, 9)




Figure 81: Myopic CRS No historical data methods: within 1.0D – rank probability histograms

Table 136: Myopic CRS No historical data methods: within 1.0D – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC	tau
14.54 (compared to 14 datapoints)	66.007	52.117	13.89	79.897	1.204 (95%CI: 0.298, 1.951)

**Table 137: Myopic CRS No historical data methods: within 1.0D – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

H.3.3.4 Sensitivity analysis: historical data methods only

Mean absolute error – random effects model




Figure 82: Myopic CRS Historical data methods: mean absolute error – evidence network



**Table 138: Myopic CRS Historical data methods: mean absolute error - input data**

	Clinical history	HofferQ DK	Holladay2 DK	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
Savini et al. (2010)	1.62 (1.25)				1.33 (1.03)	1.00 (0.57)	1.79 (1.13)	0.62 (0.52)	0.56 (0.45)	0.53 (0.46)	1.60 (0.98)	1.87 (1.44)	2.04 (1.48)	2.18 (1.52)	1.08 (0.86)	0.76 (0.49)	3.64 (1.45)	1.94 (1.01)
Fam & (2008)		0.75 (0.52)	0.75 (0.62)	1.32 (0.73)		0.76 (0.60)						0.93 (0.83)		0.80 (0.63)				

**Table 139: Myopic CRS Historical data methods: mean absolute error - relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	Clinical history	HofferQ DK	Holladay2 DK	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammas	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
Clinical history	-	-	-	-	-0.29 (-0.89, 0.31)	-0.62 (-1.13, 0.11)	0.17 (-0.45, 0.79)	-1.00 (-1.50, 0.50)	-1.06 (-1.55, 0.57)	-1.09 (-1.58, 0.60)	-0.02 (-0.61, 0.57)	0.25 (-0.46, 0.96)	0.42 (-0.30, 1.14)	0.56 (-0.17, 1.29)	-0.54 (-1.10, 0.02)	-0.86 (-1.36, 0.36)	2.02 (1.31, 2.73)	0.32 (-0.28, 0.92)
HofferQ DK	-0.07 (-2.66, 2.54)	-	0.00 (-0.26, 0.26)	0.57 (0.28, 0.86)	-	0.01 (-0.25, 0.27)	-	-	-	-	-	0.18 (-0.14, 0.50)	-	0.05 (-0.21, 0.31)	-	-	-	-
Holladay2 DK	-0.08 (-2.63, 2.50)	0.00 (-2.16, 2.16)	-	0.57 (0.26, 0.88)	-	0.01 (-0.27, 0.29)	-	-	-	-	-	0.18 (-0.15, 0.51)	-	0.05 (-0.23, 0.33)	-	-	-	-
SRKT Clinical history	0.50 (-2.04, 3.08)	0.57 (-1.59, 2.72)	0.57 (-1.63, 2.74)	-	-	-0.56 (-0.86, 0.26)	-	-	-	-	-	-0.39 (-0.75, 0.03)	-	-0.52 (-0.83, 0.21)	-	-	-	-
SRKT Diehl	-0.30 (-2.52, 1.93)	-0.22 (-2.80, 2.29)	-0.22 (-2.77, 2.27)	-0.79 (-3.38, 1.74)	-	-0.33 (-0.77, 0.11)	0.46 (-0.11, 1.03)	-0.71 (-1.14, 0.28)	-0.77 (-1.19, 0.35)	-0.80 (-1.22, 0.38)	0.27 (-0.26, 0.80)	0.54 (-0.12, 1.20)	0.71 (0.04, 1.38)	0.85 (0.17, 1.53)	-0.25 (-0.75, 0.25)	-0.57 (-0.99, 0.15)	2.31 (1.65, 2.97)	0.61 (0.08, 1.14)

	Clinical history	HofferQ DK	Holladay2 DK	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shammass	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
SRKT DK	-0.35 (-2.38, 1.74)	-0.27 (-2.26, 1.69)	-0.27 (-2.22, 1.68)	-0.84 (-2.84, 1.14)	-0.05 (-2.08, 2.02)		0.79 (0.32, 1.26)	-0.38 (-0.67, 0.09)	-0.44 (-0.71, 0.17)	-0.47 (-0.74, 0.20)	0.60 (0.18, 1.02)	0.48 (-0.20, 1.16)	1.04 (0.45, 1.63)	0.58 (-0.54, 1.69)	0.08 (-0.30, 0.46)	-0.24 (-0.52, 0.04)	2.64 (2.06, 3.22)	0.94 (0.51, 1.37)
SRKT DK Awwad	0.16 (-2.08, 2.37)	0.24 (-2.40, 2.74)	0.24 (-2.29, 2.75)	-0.34 (-2.92, 2.19)	0.45 (-1.80, 2.68)	0.51 (-1.57, 2.47)		-1.17 (-1.63, 0.71)	-1.23 (-1.68, 0.78)	-1.26 (-1.71, 0.81)	-0.19 (-0.74, 0.36)	0.08 (-0.60, 0.76)	0.25 (-0.44, 0.94)	0.39 (-0.31, 1.09)	-0.71 (-1.24, 0.18)	-1.03 (-1.49, 0.57)	1.85 (1.17, 2.53)	0.15 (-0.41, 0.71)
SRKT DK Savini	-1.00 (-3.26, 1.18)	-0.93 (-3.48, 1.53)	-0.92 (-3.44, 1.56)	-1.50 (-4.07, 0.97)	-0.71 (-2.90, 1.49)	-0.66 (-2.70, 1.34)	-1.17 (-3.33, 1.05)		-0.06 (-0.31, 0.19)	-0.09 (-0.35, 0.17)	0.98 (0.57, 1.39)	1.25 (0.68, 1.82)	1.42 (0.84, 2.00)	1.56 (0.96, 2.16)	0.46 (0.09, 0.83)	0.14 (-0.12, 0.40)	3.02 (2.45, 3.59)	1.32 (0.90, 1.74)
SRKT DK Seitz/Speicher	-1.07 (-3.31, 1.13)	-0.99 (-3.57, 1.51)	-0.98 (-3.56, 1.47)	-1.57 (-4.14, 0.94)	-0.77 (-2.97, 1.44)	-0.72 (-2.79, 1.25)	-1.23 (-3.44, 0.99)	-0.06 (-2.27, 2.15)		-0.03 (-0.27, 0.21)	1.04 (0.64, 1.44)	1.31 (0.75, 1.87)	1.48 (0.91, 2.05)	1.62 (1.03, 2.21)	0.52 (0.16, 0.88)	0.20 (-0.05, 0.45)	3.08 (2.52, 3.64)	1.38 (0.97, 1.79)
SRKT DK Seitz/Speicher/Savini	-1.10 (-3.32, 1.12)	-1.02 (-3.59, 1.46)	-1.02 (-3.56, 1.49)	-1.59 (-4.16, 0.92)	-0.80 (-3.03, 1.41)	-0.75 (-2.77, 1.23)	-1.26 (-3.44, 0.96)	-0.09 (-2.29, 2.10)	-0.03 (-2.24, 2.19)		1.07 (0.67, 1.47)	1.34 (0.78, 1.90)	1.51 (0.94, 2.08)	1.65 (1.06, 2.24)	0.55 (0.19, 0.91)	0.23 (-0.02, 0.48)	3.11 (2.55, 3.67)	1.41 (1.00, 1.82)
SRKT DK Shammass	-0.03 (-2.26, 2.22)	0.05 (-2.57, 2.55)	0.05 (-2.51, 2.56)	-0.52 (-3.16, 2.01)	0.26 (-1.94, 2.45)	0.32 (-1.74, 2.33)	-0.19 (-2.44, 2.08)	0.97 (-1.25, 3.22)	1.04 (-1.18, 3.25)	1.07 (-1.14, 3.29)		0.27 (-0.38, 0.92)	0.44 (-0.22, 1.10)	0.58 (-0.09, 1.25)	-0.52 (-1.00, 0.04)	-0.84 (-1.25, 0.43)	2.04 (1.39, 2.69)	0.34 (-0.18, 0.86)
SRKT Feiz-Mannis	0.17 (-1.88, 2.25)	0.24 (-1.79, 2.24)	0.24 (-1.76, 2.21)	-0.34 (-2.37, 1.66)	0.46 (-1.57, 2.55)	0.51 (-1.02, 2.10)	0.00 (-2.01, 2.11)	1.17 (-0.81, 3.24)	1.24 (-0.77, 3.30)	1.26 (-0.74, 3.32)	0.20 (-1.81, 2.24)		0.17 (-0.59, 0.93)	-0.05 (-0.38, 0.27)	-0.79 (-1.41, 0.17)	-1.11 (-1.67, 0.55)	1.77 (1.01, 2.53)	0.07 (-0.58, 0.72)
SRKT Feiz-Mannis nomogram	0.41 (-1.85, 2.68)	0.49 (-2.16, 3.01)	0.49 (-2.12, 3.02)	-0.09 (-2.72, 2.46)	0.71 (-1.55, 2.93)	0.76 (-1.32, 2.78)	0.25 (-1.98, 2.51)	1.42 (-0.78, 3.64)	1.48 (-0.73, 3.72)	1.51 (-0.72, 3.77)	0.44 (-1.83, 2.73)	0.25 (-1.84, 2.31)		0.14 (-0.65, 0.93)	-0.96 (-1.59, 0.33)	-1.28 (-1.86, 0.70)	1.60 (0.83, 2.37)	-0.10 (-0.76, 0.56)
SRKT Ladas-Stark	0.20 (-1.77, 2.31)	0.27 (-1.70, 2.30)	0.28 (-1.63, 2.28)	-0.29 (-2.28, 1.73)	0.50 (-1.47, 2.59)	0.55 (-0.98, 2.12)	0.05 (-1.91, 2.15)	1.21 (-0.73, 3.30)	1.27 (-0.68, 3.41)	1.30 (-0.66, 3.42)	0.23 (-1.75, 2.35)	0.04 (-1.49, 1.65)	-0.20 (-2.23, 1.91)		-1.10 (-1.75, 0.45)	-1.42 (-2.01, 0.83)	1.46 (0.68, 2.24)	-0.24 (-0.92, 0.44)
SRKT Latkany	-0.55	-0.47	-0.47	-1.05	-0.25	-0.20	-0.70	0.46	0.53	0.56	-0.51	-0.71	-0.96	-0.75		-0.32	2.56	0.86

Meta-analysis and network meta-analysis results

	Clinical history	HofferQ DK	Holladay2 DK	SRKT Clinical history	SRKT Diehl	SRKT DK	SRKT DK Awwad	SRKT DK Savini	SRKT DK Seitz/Speicher	SRKT DK Seitz/Speicher/Savini	SRKT DK Shamma	SRKT Feiz-Mannis	SRKT Feiz-Mannis nomogram	SRKT Ladas-Stark	SRKT Latkany	SRKT Masket	SRKT SK Ferrara	SRKT SK Rosa
	(-2.77, 1.63)	(-3.02, 2.01)	(-3.02, 2.03)	(-3.60, 1.46)	(-2.47, 1.94)	(-2.26, 1.80)	(-2.92, 1.54)	(-1.71, 2.65)	(-1.67, 2.71)	(-1.62, 2.76)	(-2.71, 1.69)	(-2.74, 1.30)	(-3.18, 1.25)	(-2.82, 1.21)		(-0.69, 0.05)	(1.94, 3.18)	(0.37, 1.35)
SRKT Masket	-0.87 (-3.06, 1.34)	-0.79 (-3.34, 1.71)	-0.78 (-3.36, 1.71)	-1.36 (-3.93, 1.13)	-0.57 (-2.78, 1.61)	-0.52 (-2.56, 1.44)	-1.03 (-3.22, 1.20)	0.14 (-2.03, 2.29)	0.20 (-1.97, 2.40)	0.23 (-1.95, 2.43)	-0.84 (-3.03, 1.33)	-1.03 (-3.08, 0.94)	-1.28 (-3.52, 0.97)	-1.07 (-3.15, 0.87)	-0.32 (-2.50, 1.83)		2.88 (2.31, 3.45)	1.18 (0.76, 1.60)
SRKT SK Ferrara	2.01 (-0.24, 4.26)	2.08 (-0.53, 4.62)	2.09 (-0.49, 4.66)	1.52 (-1.09, 4.09)	2.31 (0.09, 4.55)	2.36 (0.29, 4.42)	1.86 (-0.36, 4.13)	3.02 (0.85, 5.24)	3.08 (0.88, 5.31)	3.11 (0.92, 5.36)	2.04 (-0.20, 4.28)	1.85 (-0.26, 3.93)	1.61 (-0.66, 3.86)	1.80 (-0.33, 3.83)	2.55 (0.35, 4.80)	2.87 (0.71, 5.11)		-1.70 (-2.35, -1.05)
SRKT SK Rosa	0.31 (-1.94, 2.54)	0.39 (-2.21, 2.92)	0.39 (-2.20, 2.89)	-0.18 (-2.73, 2.34)	0.61 (-1.56, 2.83)	0.66 (-1.41, 2.69)	0.15 (-2.02, 2.38)	1.32 (-0.86, 3.51)	1.39 (-0.81, 3.56)	1.41 (-0.79, 3.63)	0.35 (-1.84, 2.57)	0.16 (-1.92, 2.17)	-0.10 (-2.35, 2.14)	0.12 (-2.00, 2.07)	0.86 (-1.34, 3.06)	1.18 (-1.01, 3.40)	-1.69 (-3.96, 0.53)	




Figure 83: Myopic CRS Historical data methods: mean absolute error – relative effect of all options versus common comparator

**Table 140: Myopic CRS Historical data methods: mean absolute error – rankings for each comparator**

	Probability best	Median rank (95%CI)
Clinical history	0.013	11 (2, 17)
HofferQ DK	0.027	10 (1, 17)
Holladay2 DK	0.027	10 (1, 17)
SRKT Clinical history	0.008	15 (3, 18)
SRKT Diehl	0.027	8 (1, 17)
SRKT DK	0.011	7 (2, 15)
SRKT DK Awwad	0.007	12 (3, 17)
SRKT DK Savini	0.191	3 (1, 14)
SRKT DK Seitz/Speicher	0.231	3 (1, 13)
SRKT DK Seitz/Speicher/Savini	0.257	3 (1, 13)
SRKT DK Shammas	0.013	10 (2, 17)
SRKT Feiz-Mannis	0.002	12 (4, 17)
SRKT Feiz-Mannis nomogram	0.005	14 (4, 18)
SRKT Ladas-Stark	0.001	12 (5, 17)
SRKT Latkany	0.050	6 (1, 16)
SRKT Masket	0.125	4 (1, 14)
SRKT SK Ferrara	0.000	18 (12, 18)
SRKT SK Rosa	0.005	13 (3, 17)




Figure 84: Myopic CRS Historical data methods: mean absolute error – rank probability histograms

**Table 141: Myopic CRS Historical data methods: mean absolute error – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
21.08 (compared to 21 datapoints)	-20.673	-41.582	20.909	0.237	0.816 (95%CI: 0.246, 1.896)

**Table 142: Myopic CRS Historical data methods: mean absolute error – notes**

- Continuous (normal; identity link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

Proportion within 0.5D – fixed effects model




Figure 85: Myopic CRS Historical data methods: within 0.5D – evidence network



**Table 143: Myopic CRS Historical data methods: within 0.5D – input data**

	SRKT Clinical history	Double-K	Feiz-Mannis	HofferQ DK	Holladay2 DK	Masket	Modified Masket	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
Saiki et al. (2013)		4/12	1/12			4/12	5/12	5/28		
Fam & (2008)	5/37			13/37	17/37			19/37	15/37	17/37

**Table 144: Myopic CRS Historical data methods: within 0.5D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT Clinical history	Double-K	Feiz-Mannis	HofferQ DK	Holladay2 DK	Masket	Modified Masket	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Clinical history		-	-	3.47 (1.09, 11.05)	5.44 (1.73, 17.06)	-	-	6.76 (2.16, 21.16)	4.36 (1.38, 13.76)	5.44 (1.73, 17.06)
Double-K	17.01 (2.37, 129.10)		0.18 (0.02, 1.95)	-	-	1.00 (0.18, 5.46)	1.43 (0.27, 7.52)	0.43 (0.09, 2.03)	-	-
Feiz-Mannis	2.25 (0.06, 27.09)	0.14 (0.00, 1.31)		-	-	5.50 (0.51, 59.01)	7.86 (0.75, 82.13)	2.39 (0.25, 23.01)	-	-
HofferQ DK	3.64 (1.18, 13.11)	0.22 (0.03, 1.40)	1.63 (0.15, 54.84)		1.57 (0.62, 4.00)	-	-	1.95 (0.77, 4.96)	1.26 (0.49, 3.23)	1.57 (0.62, 4.00)
Holladay2 DK	5.79 (1.90, 20.76)	0.35 (0.05, 2.21)	2.59 (0.24, 86.40)	1.59 (0.62, 4.16)		-	-	1.24 (0.50, 3.09)	0.80 (0.32, 2.02)	1.00 (0.40, 2.50)
Masket	17.16 (2.30, 133.70)	1.01 (0.17, 5.95)	7.55 (0.74, 251.90)	4.69 (0.70, 31.09)	2.93 (0.43, 19.25)		1.43 (0.27, 7.52)	0.43 (0.09, 2.03)	-	-
Modified Masket	24.98 (3.69, 185.20)	1.47 (0.27, 8.50)	11.05 (1.18, 359.00)	6.82 (1.10, 44.26)	4.31 (0.70, 27.60)	1.47 (0.26, 8.61)		0.30 (0.07, 1.37)	-	-
SRKT DK	7.18 (2.39, 25.50)	0.43 (0.09, 2.14)	3.19 (0.38, 96.87)	1.97 (0.78, 5.25)	1.24 (0.50, 3.19)	0.43 (0.09, 2.21)	0.29 (0.06, 1.39)		0.65 (0.26, 1.62)	0.81 (0.32, 2.01)
SRKT Feiz-Mannis	4.61 (1.50, 16.22)	0.28 (0.04, 1.75)	2.04 (0.19, 70.47)	1.26 (0.49, 3.31)	0.80 (0.31, 2.03)	0.27 (0.04, 1.80)	0.18 (0.03, 1.16)	0.64 (0.25, 1.62)		1.25 (0.50, 3.13)

	SRKT Clinical history	Double-K	Feiz-Mannis	HofferQ DK	Holladay2 DK	Masket	Modified Masket	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Ladas-Stark	5.77 (1.90, 20.17)	0.35 (0.05, 2.18)	2.59 (0.24, 86.28)	1.59 (0.62, 4.11)	1.00 (0.40, 2.51)	0.34 (0.05, 2.27)	0.23 (0.04, 1.45)	0.80 (0.32, 2.02)	1.25 (0.50, 3.17)	




Figure 86: Myopic CRS Historical data methods: within 0.5D – relative effect of all options versus common comparator

Table 145: Myopic CRS Historical data methods: within 0.5D – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT Clinical history	0.000	10 (9, 10)
Double-K	0.230	2 (1, 8)
Feiz-Mannis	0.003	9 (3, 10)
HofferQ DK	0.001	8 (4, 9)

	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2 DK	0.011	6 (2, 9)
Masket	0.234	2 (1, 8)
Modified Masket	0.503	1 (1, 6)
SRKT DK	0.005	4 (2, 8)
SRKT Feiz-Mannis	0.003	7 (3, 9)
SRKT Ladas-Stark	0.010	6 (2, 9)




Figure 87: Myopic CRS Historical data methods: within 0.5D – rank probability histograms

Table 146: Myopic CRS Historical data methods: within 0.5D – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC
11.44 (compared to 11 datapoints)	48.9	37.768	11.132	60.032

**Table 147: Myopic CRS Historical data methods: within 0.5D – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

Proportion within 1.0 – fixed effects model




Figure 88: Myopic CRS Historical data methods: within 1.0D – evidence network

**Table 148: Myopic CRS Historical data methods: within 1.0D – input data**

	SRKT Clinical history	Double-K	Feiz-Mannis	HofferQ DK	Holladay2 DK	Masket	Modified Masket	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
Saiki et al. (2013)		8/12	6/12			10/12	9/12	14/28		
Fam & (2008)	11/37			28/37	30/37			25/37	23/37	23/37

**Table 149: Myopic CRS Historical data methods: within 1.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	SRKT Clinical history	Double-K	Feiz-Mannis	HofferQ DK	Holladay2 DK	Masket	Modified Masket	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Clinical history		-	-	7.35 (2.63, 20.60)	10.13 (3.43, 29.93)	-	-	4.92 (1.84, 13.19)	3.88 (1.47, 10.23)	3.88 (1.47, 10.23)
Double-K	10.80 (1.92, 69.43)		0.50 (0.10, 2.60)	-	-	2.50 (0.36, 17.32)	1.50 (0.25, 8.84)	0.50 (0.12, 2.05)	-	-
Feiz-Mannis	5.20 (0.93, 28.97)	0.48 (0.08, 2.57)		-	-	5.00 (0.75, 33.21)	3.00 (0.53, 16.90)	1.00 (0.26, 3.87)	-	-
HofferQ DK	7.76 (2.82, 23.22)	0.72 (0.11, 4.27)	1.51 (0.27, 8.84)		1.38 (0.45, 4.20)	-	-	0.67 (0.24, 1.85)	0.53 (0.19, 1.44)	0.53 (0.19, 1.44)
Holladay2 DK	10.94 (3.78, 34.76)	1.02 (0.15, 6.16)	2.14 (0.36, 12.56)	1.41 (0.45, 4.37)		-	-	0.49 (0.17, 1.42)	0.38 (0.13, 1.10)	0.38 (0.13, 1.10)
Masket	30.55 (4.54, 309.80)	2.80 (0.40, 27.85)	5.91 (0.92, 57.06)	3.89 (0.56, 40.10)	2.77 (0.38, 29.29)		0.60 (0.08, 4.45)	0.20 (0.04, 1.08)	-	-
Modified Masket	16.88 (2.84, 124.70)	1.56 (0.25, 11.03)	3.27 (0.58, 22.60)	2.19 (0.34, 15.67)	1.55 (0.24, 11.70)	0.55 (0.06, 4.51)		0.33 (0.07, 1.50)	-	-
SRKT DK	5.12 (1.93, 14.38)	0.48 (0.10, 1.98)	1.00 (0.25, 4.05)	0.66 (0.23, 1.83)	0.47 (0.15, 1.37)	0.17 (0.02, 0.86)	0.31 (0.05, 1.31)		0.79 (0.30, 2.05)	0.79 (0.30, 2.05)
SRKT Feiz-Mannis	4.02 (1.53, 11.17)	0.37 (0.06, 2.07)	0.78 (0.14, 4.30)	0.52 (0.18, 1.41)	0.37 (0.12, 1.05)	0.13 (0.01, 0.89)	0.24 (0.03, 1.38)	0.79 (0.30, 2.05)		1.00 (0.39, 2.56)

	SRKT Clinical history	Double-K	Feiz-Mannis	HofferQ DK	Holladay2 DK	Masket	Modified Masket	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Ladas-Stark	4.02 (1.54, 11.05)	0.38 (0.06, 2.06)	0.78 (0.14, 4.32)	0.52 (0.18, 1.42)	0.37 (0.12, 1.04)	0.13 (0.01, 0.89)	0.24 (0.03, 1.39)	0.78 (0.29, 2.08)	1.00 (0.39, 2.58)	




Figure 89: Myopic CRS Historical data methods: within 1.0D – relative effect of all options versus common comparator

Table 150: Myopic CRS Historical data methods: within 1.0D – rankings for each comparator

	Probability best	Median rank (95%CI)
SRKT Clinical history	0.000	10 (9, 10)
Double-K	0.076	4 (1, 9)
Feiz-Mannis	0.007	7 (2, 10)
HofferQ DK	0.021	5 (2, 8)



	<b>Probability best</b>	<b>Median rank (95%CI)</b>
Holladay2 DK	0.078	4 (1, 7)
Masket	0.592	1 (1, 5)
Modified Masket	0.225	2 (1, 8)
SRKT DK	0.000	7 (4, 9)
SRKT Feiz-Mannis	0.000	8 (4, 9)
SRKT Ladas-Stark	0.000	8 (4, 9)




Figure 90: Myopic CRS Historical data methods: within 1.0D – rank probability histograms

**Table 151: Myopic CRS Historical data methods: within 1.0D – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	
11.31 (compared to 11 datapoints)	49.357	38.204	11.152	60.509	

**Table 152: Myopic CRS Historical data methods: within 1.0D – notes**

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

Proportion within 2.0 – fixed effects model





Figure 91: Myopic CRS Historical data methods: within 2.0D – evidence network

Table 153: Myopic CRS Historical data methods: within 2.0D – input data

	SRKT Clinical history	HofferQ DK	Holladay2 DK	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
Fam & (2008)	33/37	35/37	34/37	35/37	32/37	35/37

**Table 154: Myopic CRS Historical data methods: within 2.0D – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**


	SRKT Clinical history	HofferQ DK	Holladay2 DK	SRKT DK	SRKT Feiz-Mannis	SRKT Ladas-Stark
SRKT Clinical history		2.12 (0.36, 12.36)	1.37 (0.29, 6.61)	2.12 (0.36, 12.36)	0.78 (0.19, 3.15)	2.12 (0.36, 12.36)
HofferQ DK	2.32 (0.39, 19.84)		0.65 (0.10, 4.12)	1.00 (0.13, 7.50)	0.37 (0.07, 2.02)	1.00 (0.13, 7.50)
Holladay2 DK	1.42 (0.27, 8.24)	0.61 (0.07, 4.32)		1.54 (0.24, 9.82)	0.56 (0.12, 2.56)	1.54 (0.24, 9.82)
SRKT DK	2.33 (0.39, 19.87)	1.00 (0.10, 9.99)	1.63 (0.23, 15.74)		0.37 (0.07, 2.02)	1.00 (0.13, 7.50)
SRKT Feiz-Mannis	0.76 (0.17, 3.29)	0.33 (0.04, 1.74)	0.53 (0.10, 2.50)	0.33 (0.04, 1.81)		2.73 (0.50, 15.09)
SRKT Ladas-Stark	2.30 (0.39, 19.99)	0.99 (0.10, 9.99)	1.62 (0.23, 14.79)	0.99 (0.10, 10.03)	3.02 (0.56, 26.29)	



**Figure 92: Myopic CRS Historical data methods: within 2.0D – relative effect of all options versus common comparator**

**Table 155: Myopic CRS Historical data methods: within 2.0D – rankings for each comparator**

	Probability best	Median rank (95%CI)
SRKT Clinical history	0.029	5 (1, 6)
HofferQ DK	0.292	2 (1, 6)
Holladay2 DK	0.093	4 (1, 6)
SRKT DK	0.294	2 (1, 6)
SRKT Feiz-Mannis	0.008	6 (2, 6)
SRKT Ladas-Stark	0.284	2 (1, 6)



**Figure 93:** Myopic CRS Historical data methods: within 2.0D – rank probability histograms

**Table 156:** Myopic CRS Historical data methods: within 2.0D – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC
6.394 (compared to 6 datapoints)	23.465	17.567	5.898	29.364

**Table 157:** Myopic CRS Historical data methods: within 2.0D – notes

- Dichotomous synchronic (binomial; logit link); fixed effects
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

### H.3.4 Intraocular lens constant optimisation – Network meta-analysis results

#### H.3.4.1 Model fit statistics for all outcomes

**Table 158: Model fit statistics used to select fixed or random effect models for all comparisons and outcomes**

Studies	Outcome	Model	Total model DIC	Total model DIC (FE – RE)	Total residual deviance	No. of data-points	Between-study SD (95% CrI)	Preferred model
4 (Charalampidou, Day, Lee, Sharma)	Mean absolute error	FE	-21.74	2.116	17.87	14	-	FE
		RE	-23.856		13.56		0.216 (0.028, 1.093)	
3 (Aristodemou, Day, Eom)	Within 0.25D	FE	537.2	426.3	446.4	16	-	RE
		RE	110.9		15.3		1.05 (0.59, 1.87)	
6 (Aristodemou, Charalampidou, Day, Eom, Fam, Lee)	Within 0.5D	FE	254.756	112.652	137.4	20	-	RE
		RE	142.104		19.72		0.900 (0.473, 1.776)	
7 (Aristodemou, Charalampidou, Day, Eom, Fam, Lee, Sharma)	Within 1.0D	FE	204.06	54.239	80.73	24	-	RE
		RE	149.821		22.77		0.611 (0.284, 1.489)	
<b>1 (Lee – pairwise comparison)</b>	Within 1.5D	FE	-	-	-	-	-	FE



H.3.4.2 Full dataset

MEAN ABSOLUTE ERROR – random effects model




Figure 94: Mean absolute error (RE) – evidence network

**Table 159: Mean absolute error (RE) – input data**

	StandardIOLC	OptimisedLenstar	Pezero	ULIB	ULIBpersonalised
Sharma et al. (2014)	0.56 (0.40)			0.49 (0.50)	
Day et al. (2012)	0.47 (0.39)		0.46 (0.39)		
Day et al. (2012)	0.84 (0.53)		0.50 (0.37)		
Day et al. (2012)	0.89 (0.80)		0.74 (0.58)		
Day et al. (2012)	0.88 (0.53)		0.83 (0.61)		
Charalampidou et al. (2010)				0.38 (0.31)	0.36 (0.30)
Lee et al. (2015)	0.67 (0.52)	0.55 (0.49)			

**Table 160: Mean absolute error (RE) – relative effectiveness of all pairwise combinations (MD and 95% credible interval)**

	StandardIOLC	OptimisedLenstar	Pezero	ULIB	ULIBpersonalised
StandardIOLC		-0.12 (-0.26, 0.02)	-0.13 (-0.33, 0.06)	-0.07 (-0.25, 0.11)	-
OptimisedLenstar	-0.12 (-0.26, 0.02)		-	-	-
Pezero	-0.08 (-0.17, 0.02)	0.05 (-0.12, 0.21)		-	-

	StandardIOLC	OptimisedLenstar	Pezero	ULIB	ULIBpersonalised
ULIB	-0.07 (-0.25, 0.10)	0.05 (-0.17, 0.27)	0.01 (-0.19, 0.20)		-0.02 (-0.08, 0.04)
ULIBpersonalised	-0.09 (-0.27, 0.09)	0.03 (-0.20, 0.26)	-0.01 (-0.22, 0.19)	-0.02 (-0.08, 0.04)	




Figure 95: Mean absolute error (RE) – relative effect of all options versus common comparator

Table 161: Mean absolute error (RE) – rankings for each comparator

	Probability best	Median rank (95%CI)
StandardIOLC	0.001	5 (3, 5)
OptimisedLenstar	0.494	2 (1, 5)
Pezero	0.167	3 (1, 5)
ULIB	0.063	3 (1, 5)
ULIBpersonalised	0.275	2 (1, 5)




Figure 96: Mean absolute error (RE) – rank probability histograms


Table 162: Mean absolute error (RE) – model fit statistics

Residual deviance	Dbar	Dhat	pD	DIC
17.87 (compared to 14 datapoints)	-32.725	-43.709	10.948	-21.740

**Table 163: Mean absolute error (FE) – notes**

- Continuous (normal; identity link); fixed effects
- 50000 burn-ins; 10000 recorded iterations

**PROPORTION WITHIN 0.25 DIOPTRES – random effects model**



**Figure 97: Within 0.25 dioptres (RE) – evidence network**

**Table 164: Within 0.25 dioptres (RE) – input data**

	StandardIOLC	OptimisedK	Pezero
Eom et al. (2013)	34/123	38/123	
Eom et al. (2013)	49/114	62/114	
Day et al. (2012)	4/32		10/32
Day et al. (2012)	33/100		39/100
Day et al. (2012)	2/19		3/19
Day et al. (2012)	2/12		4/12
Aristodemou et al. (2011)	1170/6159		2525/6159
Aristodemou et al. (2011)	585/1949		1735/1949

**Table 165: Within 0.25 dioptres (RE) – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	StandardIOLC	OptimisedK	Pezero
StandardIOLC		1.37 (0.94, 2.00)	<b>3.36</b> <b>(1.11, 10.14)</b>
OptimisedK	1.37 (0.25, 7.44)		-
Pezero	<b>3.66</b> <b>(1.21, 10.00)</b>	2.66 (0.35, 19.12)	




Figure 98: Within 0.25 dioptres (RE) – relative effect of all options versus common comparator

Table 166: Within 0.25 dioptres (RE) – rankings for each comparator

	Probability best	Median rank (95%CI)
StandardIOLC	0.005	3 (2, 3)
OptimisedK	0.147	2 (1, 3)
Pezero	0.848	1 (1, 2)




Figure 99: Within 0.25 dioptres (RE) – rank probability histograms


**Table 167: Within 0.25 dioptres (RE) – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
15.33 (compared to 16 datapoints)	96.113	81.324	14.789	110.903	1.049 (95%CI: 0.585, 1.870)

**Table 168: Within 0.25 dioptres (RE) – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations (thinned from 500000)

**PROPORTION WITHIN 0.5 DIOPTRES – random effects model**





**Figure 100: Within 0.5 dioptres (RE) – evidence network**

**Table 169: Within 0.5 dioptres (RE) – input data**

	StandardIOLC	OptimisedK	OptimisedKAL	OptimisedLenstar	Pezero
Eom et al. (2013)	68/123	78/123			
Eom et al. (2013)	84/114	90/114			
Day et al. (2012)	10/32				18/32
Day et al. (2012)	62/100				60/100
Day et al. (2012)	8/19				9/19
Day et al. (2012)	4/12				4/12
Aristodemou et al. (2011)	2587/6159				4373/6159
Aristodemou et al. (2011)	1111/1949				1793/1949
Fam & (2009)	43/90		57/90		
Lee et al. (2015)	46/100			62/100	

**Table 170: Within 0.5 dioptres (RE) – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	StandardIOLC	OptimisedK	OptimisedKAL	OptimisedLenstar	Pezero
StandardIOLC		1.38	1.89	1.92	2.51

	StandardIOLC	OptimisedK	OptimisedKAL	OptimisedLenstar	Pezero
		(0.93, 2.04)	(1.04, 3.43)	(1.09, 3.37)	(1.31, 4.81)
OptimisedK	1.37 (0.31, 6.35)		-	-	-
OptimisedKAL	1.91 (0.21, 16.86)	1.38 (0.10, 18.75)		-	-
OptimisedLenstar	1.92 (0.22, 16.46)	1.40 (0.10, 19.34)	1.01 (0.05, 21.58)		-
Pezero	2.49 (0.92, 5.88)	1.81 (0.28, 9.91)	1.30 (0.12, 13.16)	1.30 (0.12, 12.99)	




Figure 101: Within 0.5 dioptres (RE) – relative effect of all options versus common comparator

Table 171: SENSITIVITY ANALYSIS: Within 0.5 dioptres (RE) – rankings for each comparator

	Probability best	Median rank (95%CI)
StandardIOLC	0.001	4 (2, 5)

	Probability best	Median rank (95%CI)
OptimisedK	0.103	3 (1, 5)
OptimisedKAL	0.282	3 (1, 5)
OptimisedLenstar	0.282	3 (1, 5)
Pezero	0.332	2 (1, 4)




Figure 102: SENSITIVITY ANALYSIS: Within 0.5 dioptres (RE) – rank probability histograms


**Table 172: SENSITIVITY ANALYSIS: Within 0.5 dioptres (RE) – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
19.72 (compared to 20 datapoints)	123.021	103.938	19.083	142.104	0.900 (95%CI: 0.473, 1.776)

**Table 173: SENSITIVITY ANALYSIS: Within 0.5 dioptres (RE) – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations

**PROPORTION WITHIN 1.0 DIOPTRE – random effects model**



**Figure 103: Within 1.0 dioptre (RE) – evidence network**


**Table 174: Within 1.0 dioptre (RE) – input data**

	StandardIOLC	OptimisedK	OptimisedKAL	OptimisedLenstar	Pezero	ULIB	ULIBpersonalised

	StandardIOLC	OptimisedIK	OptimisedKAL	OptimisedLenstar	Pezero	ULIB	ULIBpersonalised
Sharma et al. (2014)	44/51					44/51	
Eom et al. (2013)	106/123	111/123					
Eom et al. (2013)	110/114	111/114					
Day et al. (2012)	23/32				28/32		
Day et al. (2012)	91/100				92/100		
Day et al. (2012)	12/19				14/19		
Day et al. (2012)	6/12				6/12		
Aristodemou et al. (2011)	4989/6159				5851/6159		
Aristodemou et al. (2011)	1735/1949				1813/1949		
Charalampidou et al. (2010)						205/214	205/214
Fam & (2009)	69/90		81/90				
Lee et al. (2015)	76/100			82/100			

**Table 175: Within 1.0 dioptre (RE) – relative effectiveness of all pairwise combinations (RR and 95% credible interval)**

	StandardIOLC	OptimisedK	OptimisedKAL	OptimisedLenstar	Pezero	ULIB	ULIBpersonalised
StandardIOLC		1.45 (0.72, 2.92)	2.74 (1.18, 6.37)	1.44 (0.72, 2.86)	2.01 (1.03, 3.91)	1.00 (0.32, 3.09)	-
OptimisedK	1.45 (0.38, 5.49)		-	-	-	-	-
OptimisedKAL	2.86 (0.50, 16.69)	1.96 (0.22, 18.33)		-	-	-	-
OptimisedLenstar	1.45 (0.28, 7.79)	1.01 (0.12, 8.56)	0.51 (0.04, 5.71)		-	-	-
Pezero	2.12 (0.97, 4.17)	1.46 (0.30, 6.42)	0.74 (0.11, 4.55)	1.47 (0.22, 8.37)		-	-
ULIB	1.02 (0.15, 7.02)	0.69 (0.07, 7.62)	0.36 (0.03, 4.93)	0.70 (0.06, 9.19)	0.48 (0.06, 4.03)		1.00 (0.39, 2.57)
ULIBpersonalised	1.03 (0.07, 15.11)	0.71 (0.04, 15.08)	0.37 (0.01, 8.83)	0.72 (0.03, 17.42)	0.49 (0.03, 8.03)	1.02 (0.17, 6.18)	



**Figure 104: Within 1.0 dioptre (RE) – relative effect of all options versus common comparator**

**Table 176: Within 1.0 dioptre (RE) – rankings for each comparator**

	Probability best	Median rank (95%CI)
StandardIOLC	0.000	5 (3, 7)
OptimisedK	0.089	4 (1, 7)
OptimisedKAL	0.452	2 (1, 7)
OptimisedLenstar	0.121	4 (1, 7)
Pezero	0.155	3 (1, 6)
ULIB	0.046	5 (1, 7)
ULIBpersonalised	0.137	5 (1, 7)






Figure 105: Within 1.0 dioptre (RE) – rank probability histograms

**Table 177: Within 1.0 dioptre (RE) – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
22.77 (compared to 24 datapoints)	128.075	106.33	21.746	149.821	0.611 (95%CI: 0.284, 1.489)

**Table 178: Within 1.0 dioptre (RE) – notes**

- Dichotomous synchronic (binomial; logit link); random effects
- Prior distribution for between-study heterogeneity: uniform (Min=0; Max=2)
- 50000 burn-ins; 10000 recorded iterations

**PROPORTION WITHIN 1.5D – pairwise comparison**


Study or Subgroup	IOLC optimisation		Standard IOLC		Weight	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
	Events	Total	Events	Total			
<b>1.1.4 Less than 1.5D</b>							
Lee 2015 - SN60VWF	94	100	90	100	100.0%	1.04 [0.96, 1.13]	
<b>Subtotal (95% CI)</b>		<b>100</b>		<b>100</b>	<b>100.0%</b>	<b>1.04 [0.96, 1.13]</b>	
Total events	94		90				
Heterogeneity: Not applicable							
Test for overall effect: Z = 1.04 (P = 0.30)							

### H.3.4.3 Wang 2011 (people with axial lengths >25mm): unconnected to networks

#### Prediction error

Study or Subgroup	IOLC optimisation			Standard IOLC			Weight	Mean Difference IV, Random, 95% CI
	Mean	SD	Total	Mean	SD	Total		
Wang 2011 - MA60MA and MA60AC	-0.31	0.38	23	0.42	0.39	23	34.8%	-0.73 [-0.95, -0.51]
Wang 2011 - SA60AT SN60AT and SN60T	-0.03	0.67	28	0.35	0.61	28	27.6%	-0.38 [-0.72, -0.04]
Wang 2011 - SN60WF	-0.08	0.5	55	0.22	0.46	55	37.5%	-0.30 [-0.48, -0.12]
<b>Total (95% CI)</b>			<b>106</b>			<b>106</b>	<b>100.0%</b>	<b>-0.47 [-0.76, -0.18]</b>


Heterogeneity: Tau<sup>2</sup> = 0.05; Chi<sup>2</sup> = 8.92, df = 2 (P = 0.01); I<sup>2</sup> = 78%  
 Test for overall effect: Z = 3.19 (P = 0.001)



#### Proportion of eyes with a hyperopic refractive outcome

Study or Subgroup	IOLC optimisation		Standard IOLC		Weight	Risk Ratio M-H, Random, 95% CI
	Events	Total	Events	Total		
<b>1.6.4 Proportion of eyes with a hyperopic refractive outcome</b>						
Wang 2011 - MA60MA and MA60AC	6	23	20	23	24.0%	0.30 [0.15, 0.61]
Wang 2011 - SA60AT SN60AT and SN60T	11	28	18	28	31.9%	0.61 [0.36, 1.05]
Wang 2011 - SN60WF	26	55	37	55	44.1%	0.70 [0.50, 0.98]
<b>Subtotal (95% CI)</b>		<b>106</b>		<b>106</b>	<b>100.0%</b>	<b>0.55 [0.35, 0.86]</b>
Total events	43		75			

Heterogeneity: Tau<sup>2</sup> = 0.09; Chi<sup>2</sup> = 4.71, df = 2 (P = 0.09); I<sup>2</sup> = 58%  
 Test for overall effect: Z = 2.61 (P = 0.009)




1 **H.3.5 Other considerations in biometry: Forest plots of outcomes**

2 **H.3.5.1 Second eye prediction refinement**


3 **50% adjusted of first eye prediction error vs unadjusted prediction**

4 **Mean absolute prediction errors**




5

6 **Cumulative proportion of eyes within various ranges of absolute prediction errors**



7


8 **Mean prediction errors**



9


10 H.3.5.2 Comparison of results from using 100% adjusted and 50% adjusted first eye prediction error

12 Mean absolute prediction errors



13


14 Cumulative proportion of eyes within various ranges of absolute prediction errors



15

16

Mean prediction errors



17  
18


19 **H.4 Intraocular lens selection**

- 20 • Are different lens design (aspheric vs. spheric, plate vs. loop) effective in improving  
 21 postoperative vision (refractive outcomes, optical aberrations) in cataract surgery?  
 22 • Are different lens design (square-edged vs. round-edge, plate vs. loop) and material  
 23 (hydrophilic acrylic, hydrophobic acrylic, collagen, hydroxyethyl methacrylate-based vs.  
 24 silicone-based) effective in preventing posterior capsule opacification in cataract surgery?  
 25 • Are tinted lenses effective in preventing the progression of age-related macular  
 26 degeneration compared with colourless lenses in cataract surgery?  
 27 • What is the optimal strategy to facilitate simultaneous distance and near vision following  
 28 cataract surgery?  
 29 • What is the optimal strategy to address pre-existing astigmatism in people undergoing  
 30 cataract surgery?

31 **H.4.1 Lens design**


32 **H.4.1.1 PMMA versus silicone**

33 **PCO score**



34


35 **Nd:YAG capsulotomy rate**



36

37 H.4.1.2 PMMA versus hydrophobic acrylic


38 Nd:YAG capsulotomy rate



39


40 H.4.1.3 Hydrophobic acrylic versus silicone

41 BCDVA (decimal acuity)



42


43 PCO score



44




45 **Nd:YAG capsulotomy rate**




46

47 **Lens decentration (mm)**



48


49 **Lens tilt (degrees)**



50


51 **H.4.1.4 Hydrophobic acrylic versus hydrophilic acrylic**

52 **BCDVA (decimal acuity)**




53

54 **Nd:YAG capsulotomy rate**



55  
56 **H.4.1.5 Network meta-analyses (lens material)**

57 **PCO score (hydrophobic acrylic as reference category)**




58  
59 **Pairwise mean differences from NMA**

	Silicone	Hydrophobic acrylic	PMMA	Hydrophilic acrylic
Silicone	N/A			
Hydrophobic acrylic	0.20 (-0.28, 0.68)	N/A		
PMMA	7.99 (3.87, 12.11)	7.79 (3.64, 11.94)	N/A	
Hydrophilic acrylic	75.50 (68.90, 82.09)	75.30 (68.71, 81.89)	67.51 (59.94, 75.08)	N/A

60 Quantifying heterogeneity/inconsistency:

61 tau<sup>2</sup> = 0.1953; I<sup>2</sup> = 94.8%

62 **Network graph**



63

64 **Comparison of direct and indirect evidence**

65

Random effects model:

66

	comparison	k	prop	nma	direct	indir.	Diff	z	p-value
67	Hydrophilic acrylic:Hydrophobic acrylic	1	0.66	-75.2968	-94.2000	-39.0404	-55.1596	-7.79	< 0.0001
68	Hydrophilic acrylic:PMMA	1	0.25	-67.5094	-17.0000	-84.4988	67.4988	7.59	< 0.0001
69	Hydrophilic acrylic:Silicone	1	0.31	-75.4992	-45.2000	-89.2012	44.0012	6.06	< 0.0001
70	Hydrophobic acrylic:PMMA	0	0.00	7.7875	.	7.7875	.	.	.
71	Hydrophobic acrylic:Silicone	7	1.00	-0.2024	-0.2678	54.1836	-54.4513	-7.74	< 0.0001
72	PMMA:Silicone	3	0.99	-7.9899	-6.6522	-209.3312	202.6790	7.80	< 0.0001

73

Legend:

74

comparison - Treatment comparison

75

prop - Direct evidence proportion

76

nma - Estimated treatment effect (MD) in network meta-analysis

77

direct - Estimated treatment effect (MD) derived from direct evidence

78

indir. - Estimated treatment effect (MD) derived from indirect evidence

79

Diff - Difference between direct and indirect treatment estimates

80


z - z-value of test for disagreement (direct versus indirect)

81

p-value - p-value of test for disagreement (direct versus indirect)

82

**PCO score (without hydrophilic acrylic - hydrophobic acrylic as reference category)**



83

84

**Pairwise mean differences from NMA**


	Silicone	Hydrophobic acrylic	PMMA
--	----------	---------------------	------

Silicone	N/A		
Hydrophobic acrylic	0.23 (-0.16, 0.62)	N/A	
PMMA	6.65 (2.54, 10.77)	6.43 (2.29, 10.56)	N/A

85 Quantifying heterogeneity/inconsistency:

86  $\tau^2 = 0.1242$ ;  $I^2 = 92.9\%$

87 **Network graph**



88

89 **Comparison of direct and indirect evidence**

	comparison	k	prop	nma	direct	indir.	Diff	z	p-value
91	Hydrophobic acrylic:PMMA	0	0	6.4250	.	6.4250	.	.	.
92	Hydrophobic acrylic:Silicone	7	1	-0.2293	-0.2293	.	.	.	.
93	PMMA:Silicone	3	1	-6.6544	-6.6544	.	.	.	.

94 Legend:

95 comparison - Treatment comparison

96 prop - Direct evidence proportion

97 nma - Estimated treatment effect (MD) in network meta-analysis

98 direct - Estimated treatment effect (MD) derived from direct evidence


99 indir. - Estimated treatment effect (MD) derived from indirect evidence

100 Diff - Difference between direct and indirect treatment estimates

101 z - z-value of test for disagreement (direct versus indirect)

102 p-value - p-value of test for disagreement (direct versus indirect)

103 **Nd:YAG capsulotomy rate (hydrophobic acrylic as reference category)**



104


105 **Pairwise relative risks from NMA**

	Silicone	Hydrophobic acrylic	PMMA	Hydrophilic acrylic
Silicone	N/A			
Hydrophobic acrylic	1.02 (0.47, 2.23)	N/A		
PMMA	2.98 (1.41, 6.32)	2.90 (1.27, 6.63)	N/A	
Hydrophilic acrylic	3.33 (1.17, 9.50)	3.24 (1.38, 7.61)	1.12 (0.41, 3.00)	N/A

106 Quantifying heterogeneity/inconsistency:

107  $\tau^2 = 0.5280$ ;  $I^2 = 54.9\%$

108 **Network graph**



109

110 **Comparison of direct and indirect evidence**

111 Random effects model:

comparison	k	prop	nma direct	indir.	RoR	z	p-value	
Hydrophilic acrylic:Hydrophobic acrylic	6	0.75	0.3090	0.2394	0.6723	0.3560	-1.02	0.3071
Hydrophilic acrylic:PMMA	1	0.47	0.8965	1.5472	0.5507	2.8094	1.02	0.3070
Hydrophilic acrylic:Silicone	0	0.00	0.3006	.	0.3006	.	.	.
Hydrophobic acrylic:PMMA	2	0.39	2.9013	6.0780	1.8222	3.3356	1.39	0.1645
Hydrophobic acrylic:Silicone	8	0.72	0.9727	0.6233	3.1085	0.2005	-1.82	0.0685
PMMA:Silicone	6	0.74	0.3353	0.5477	0.0842	6.5060	2.15	0.0315


119 Legend:

120 comparison - Treatment comparison

- 121 prop - Direct evidence proportion
- 122 nma - Estimated treatment effect (RR) in network meta-analysis
- 123 direct - Estimated treatment effect (RR) derived from direct evidence
- 124 indir. - Estimated treatment effect (RR) derived from indirect evidence
- 125 RoR - Ratio of Ratios (direct versus indirect)
- 126 z - z-value of test for disagreement (direct versus indirect)
- 127 p-value - p-value of test for disagreement (direct versus indirect)


128 **H.4.1.6 Square-edge versus round-edge**

129 **BCDVA (decimal acuity)**




130

131 **PCO score**



132


133 **Nd:YAG capsulotomy rate**



134


135 H.4.1.7 Loop versus 3-piece

136 UCDVA (logMAR)




137

138 BCDVA (logMAR)




139

140 BCDVA (decimal acuity)



141


142 PCO score



143

144


**Nd:YAG capsulotomy rate**



145

146


**Lens decentration (mm)**



147

148


**Lens tilt (degrees)**



149

**150 H.4.1.8 Aspheric versus spheric**

**151 UCDVA (logMAR)**




152



153


**BCDVA (logMAR)**



154

155


**BCDVA (decimal acuity)**



156

157


**Contrast sensitivity (Pelli-Robson test)**



158

159


**Spherical aberrations**



160

161


**Higher-order aberrations**



162

163


**Comatic aberrations**



164

165

**PCO score**




166

167


168 H.4.2 Tinted vs colourless lenses

169 H.4.2.1 Post-operative best corrected visual acuity (logMAR)




170

171 H.4.2.2 Post-operative best corrected visual acuity (logMAR) – OECD only




172

173 H.4.2.3 Overall post-operative colour vision




174

175 H.4.2.4 Post-operative colour vision in the blue light spectrum (photopic)



176


177 H.4.2.5 Post-operative colour vision in the blue light spectrum (photopic) – OECD only



178


179 H.4.2.6 Post-operative colour vision in the blue light spectrum (mesopic)

180



181

182 H.4.2.7 Post-operative colour vision in the blue light spectrum (mesopic) – OECD only




183

184

185 **H.4.3 Multifocal vs monofocal intraocular lenses**

186 **H.4.3.1 Multifocal versus monofocal**

187 **Uncorrected distance visual acuity worse than 6/6**




Footnotes

- (1) 2 to 4 months, study eye
- (2) 3 to 6 months, study eye
- (3) 4 to 6 months, study eye
- (4) 12 months, study eye
- (5) 5 months, study eye
- (6) 3 month, binocular
- (7) 1 month, by eye (35 people in multifocal and 40 people in monofocal group, not adjusted for within-person correlation)
- (8) 6 weeks, binocular

188

189 **Corrected distance visual acuity worse than 6/6**




Footnotes

- (1) 2 to 4 months, study eye
- (2) 3 to 6 months, study eye
- (3) 4 to 6 months, study eye
- (4) 12 months, study eye
- (5) 5 months, study eye
- (6) 3 months, unclear whether eyes/people reported
- (7) 3 months, binocular
- (8) 1 month, by eye (35 people in multifocal and 40 people in monofocal group, not adjusted for within-person correlation)

190

191

192 **Uncorrected near visual acuity worse than J3/J4 or equivalent**




Footnotes

- (1) 2 to 4 months, study eye
- (2) 4 to 6 months, study eye
- (3) 12 months, study eye
- (4) 5 months, study eye
- (5) 3 of 6 months, binocular
- (6) 3 months, binocular, could not read N5 size print
- (7) 6 weeks, binocular
- (8) 3 months, unclear whether eyes/people reported

193

194 **Mean uncorrected distance visual acuity (logMAR)**




Footnotes

- (1) 3 months, binocular
- (2) 3 months, unclear whether eyes/people reported
- (3) 3 months, binocular
- (4) 18 months, binocular
- (5) 6 months, binocular
- (6) 12 months, unclear whether eyes/people reported

195

196 **Mean corrected distance visual acuity**




Footnotes

- (1) 3 months, binocular
- (2) 3 months, unclear whether eyes/people reported
- (3) 18 months, binocular
- (4) 3 months, binocular
- (5) 12 months, unclear whether eyes/people reported
- (6) 6 months, binocular

197

198

**Mean uncorrected intermediate visual acuity**




Footnotes

- (1) 6 months, binocular
- (2) 6 months, binocular

199

200

**Mean corrected intermediate visual acuity**




Footnotes

- (1) 6 months, binocular
- (2) 6 months, binocular

201

202

**Mean uncorrected near visual acuity**




Footnotes

- (1) 3 months, binocular
- (2) 3 months, binocular
- (3) 18 months, binocular
- (4) 6 months, binocular
- (5) 12 months, unclear whether eyes/people reported
- (6) 6 months, binocular

203

204

**Mean corrected near visual acuity**




Footnotes

- (1) 3 months, binocular
- (2) 3 months, binocular
- (3) 3 months, binocular
- (4) 18 months, binocular
- (5) 12 months, unclear whether eyes/people reported
- (6) 6 months, binocular
- (7) 6 months, binocular

205

206

**Spectacle dependence (any)**




Footnotes

- (1) "What visual aid do you use to improve vision?" "None" (event swapped in figure) at 3 to 6 months
- (2) "Required no spectacles" (event swapped for figure) at 12 months
- (3) "Reported never using spectacles for distance or near" (event swapped in this figure) 5 months
- (4) "Reported never wearing glasses" (event swapped in figure) at 3 to 6 months
- (5) "Complete freedom from glasses" (event swapped in figure) at 12 months
- (6) "Completely spectacle independent" (event swapped in figure) at 18 months
- (7) "Complete spectacle independence" (event swapped in this figure) at 12 months
- (8) "Reported being spectacle independent" (event swapped in figure) at 6 months
- (9) "Reported overall spectacle independence" (event swapped for figure) at 6 months
- (10) "Considered to not require spectacles to perform tasks"

207

208

**Spectacle dependence (distance or near)**



Footnotes


- (1) "Never used spectacles for distance" (event swapped in the figure) at 5 months
- (2) "Reported wore glasses none of the time for distance vision" (event swapped in figure) at 3 to 6 months
- (3) "Reported using spectacles for distance vision always/most of the time/quite often" at 3 months
- (4) "Reported spectacle independence for distance vision" (event swapped in figure) at 6 months
- (5) "Never used spectacles for near tasks" (event swapped in the figure) at 5 months
- (6) "Reported wore glasses none of the time for near vision" (event swapped in figure) at 3 to 6 months
- (7) "Do you need additional glasses for near work?" at 3 months
- (8) "Reported using spectacles for near vision always/most of the time/quite often" at 3 months
- (9) "Dependence on near correction" at 3 months
- (10) "Reported spectacle independence for near vision" (event swapped in figure) at 6 months

209



210

**Contrast sensitivity**




Footnotes

- (1) Pelli-Robson chart, 18 months
- (2) Binocular, Pelli-Robson chart at 1 metre, follow-up 6 weeks, recalc SD
- (3) Pelli-Robson test, 0.05 to 2.25 logunits, 12 months
- (4) Vision Contrast Test System at 6 cycles per degree, 1 month

211

212

**Visual function**




Footnotes

- (1) Modified VF-7 score at 12 months
- (2) VF-14 at 3 months
- (3) Change in VF-7 score at 1 month
- (4) VF-7 score at 6 months

213

214

**Patient satisfaction**




Footnotes

- (1) 5-point scale at 12 months, 1=very dissatisfied, 5=very satisfied
- (2) 5 point scale (satisfaction minus expectations) at 3 months
- (3) 10 point scale at 6 months (1=incapacitating, 10=excellent)
- (4) 4 point scale (multiplied by -1 as higher scores worse) at 1 month
- (5) 7 point scale (multiplied by -1 as higher scores worse) at 3 to 6 months,
- (6) 5 point scale at 6 months,

215

216

**Glare**




Footnotes

- (1) 4 to 6 months
- (2) 12 months
- (3) 5 months
- (4) 3 months
- (5) 1 month
- (6) 12 months
- (7) 18 months
- (8) 6 months

217

218

**Halos**




Footnotes

- (1) 12 months
- (2) 5 months
- (3) 3 months
- (4) 6 months
- (5) 4 to 6 months
- (6) 12 months
- (7) 1 month
- (8) 6 months

219

220 H.4.3.2 Multifocal versus monovision


221 Visual acuity



222

223

224 Spectacle dependence




Footnotes

- (1) Follow-up 6 months: outcome was "spectacle-free patients" (event swapped in the figure)
- (2) Follow-up: 4 months. Outcome was "reported never wearing glasses" (event swapped in figure)

225

226

**Contrast sensitivity**




Footnotes

- (1) Follow-up: 6 months
- (2) Follow-up: 4 months

227


**228 H.4.3.3 Refractive vs diffractive multifocal lenses**

**229 Uncorrected distance visual acuity**




230

**231 Spectacle dependence**



232


**233 Glare**



234

235


**Halo**



236


**237 H.4.3.4 Bifocal versus trifocal intraocular lenses**

**238 Uncorrected visual acuity**



239

**240 Corrected visual acuity**




241  
242

243 **H.4.4 Multifocal vs monofocal intraocular lenses: network meta-analyses (monofocal**  
 244 **lenses used as reference category)**

245 **H.4.4.1 Uncorrected distance visual acuity**

246 **Class-level analysis**



247


248 **Pairwise mean differences from NMA (higher number favour column)**

	Monovision	Monofocal	Multifocal
Monovision	N/A		
Monofocal	0.01 (-0.09, 0.11)	N/A	
Multifocal	0.02 (-0.07, 0.11)	0.01 (-0.03, 0.05)	N/A

249 Quantifying heterogeneity/inconsistency:

250  $\tau^2 = 0.0017$ ;  $I^2 = 74.3\%$

251 **Network graph**



252

253 **Comparison of direct and indirect evidence**

254 Random effects model:

comparison	prop	nma direct	indir.	Diff	z	p-value
Monofocal:Monovision	0	-0.0126	.	-0.0126	..	.
Monofocal:Multifocal	1	0.0074	0.0074	.	..	.
Monovision:Multifocal	1	0.0200	0.0200	.	..	.

259 Legend:


260 comparison - Treatment comparison

261 prop - Direct evidence proportion

262 nma - Estimated treatment effect (MD) in network meta-analysis

- 263 direct - Estimated treatment effect (MD) derived from direct evidence
- 264 indir. - Estimated treatment effect (MD) derived from indirect evidence
- 265 Diff - Difference between direct and indirect treatment estimates
- 266 z - z-value of test for disagreement (direct versus indirect)
- 267 p-value - p-value of test for disagreement (direct versus indirect)

268 **Subdivided analysis**



269

270


**Pairwise mean differences from NMA (higher numbers favour column)**

	Refractive	Monofocal	Monovision	Diffractive
Refractive	N/A			
Monofocal	0.01 (-0.03, 0.04)	N/A		
Monovision	0.02 (-0.06, 0.10)	0.01 (-0.07, 0.09)	N/A	
Diffractive	0.04 (0.01, 0.07)	0.03 (-0.00, 0.07)	0.02 (-0.05, 0.09)	N/A

271 Quantifying heterogeneity/inconsistency:

272  $\tau^2 = 0.0010$ ;  $I^2 = 64.3\%$

273 **Network graph**



274

275 **Comparison of direct and indirect evidence**

276 Random effects model:


comparison	prop	nma	direct	indir.	Diff	z	p-value
Diffractive:Monofocal	0.68	-0.0311	-0.0190	-0.0567	0.0377	0.98	0.3255
Diffractive:Monovision	1.00	-0.0200	-0.0200	.	.	.	.
Diffractive:Refractive	0.90	-0.0393	-0.0460	0.0241	-0.0702	-1.50	0.1335
Monofocal:Monovision	0.00	0.0111	.	0.0111	.	.	.

281

282            Monofocal:Refractive 0.78 -0.0082 0.0107 -0.0755 0.0862 2.06 0.0394  
 283            Monovision:Refractive 0.00 -0.0193 . -0.0193 . . .  
 284 Legend:  
 285 comparison - Treatment comparison  
 286 prop - Direct evidence proportion  
 287 nma - Estimated treatment effect (MD) in network meta-analysis  
 288 direct - Estimated treatment effect (MD) derived from direct evidence  
 289 indir. - Estimated treatment effect (MD) derived from indirect evidence  
 290 Diff - Difference between direct and indirect treatment estimates  
 291 z - z-value of test for disagreement (direct versus indirect)  
 292 p-value - p-value of test for disagreement (direct versus indirect)

293 **H.4.4.2 Uncorrected near visual acuity**

294 **Class-level analysis**




295 Pairwise mean differences from NMA (higher number favour column)  
 296

	Multifocal	Monovision	Monofocal
Multifocal	N/A		
Monovision	0.04 (-0.36, 0.44)	N/A	
Monofocal	0.20 (0.04, 0.37)	0.16 (-0.27, 0.60)	N/A

297 Quantifying heterogeneity/inconsistency:

298  $\tau^2 = 0.0416$ ;  $I^2 = 98.3\%$

299 **Network graph**



300  
 301 **Comparison of direct and indirect evidence**

302 Random effects model:  
 303 comparison k prop nma direct indir. Diff z p-value  
 304 MonoFocal:MonoVision 0 0 -0.1631 . -0.1631 . . .




305 Monofocal:Multifocal 6 1 -0.2031 -0.2031 . . .  
 306 Monovision:Multifocal 1 1 -0.0400 -0.0400 . . .

307 Legend:

- 308 comparison - Treatment comparison
- 309 prop - Direct evidence proportion
- 310 nma - Estimated treatment effect (MD) in network meta-analysis
- 311 direct - Estimated treatment effect (MD) derived from direct evidence
- 312 indir. - Estimated treatment effect (MD) derived from indirect evidence
- 313 Diff - Difference between direct and indirect treatment estimates
- 314 z - z-value of test for disagreement (direct versus indirect)
- 315 p-value - p-value of test for disagreement (direct versus indirect)

316 **Subdivided analysis**




317 **Pairwise mean differences from NMA (higher numbers favour column)**

	Diffraction	Monovision	Refraction	Monofocal
Diffraction	N/A			
Monovision	0.04 (-0.33, 0.41)	N/A		
Refraction	0.18 (-0.07, 0.43)	0.14 (-0.31, 0.59)	N/A	
Monofocal	0.30 (0.09, 0.50)	0.26 (-0.17, 0.68)	0.12 (-0.07, 0.30)	N/A

319 Quantifying heterogeneity/inconsistency:

320  $\tau^2 = 0.0359$ ;  $I^2 = 98.1\%$

321 **Network graph**



323 **Comparison of direct and indirect evidence**

324 Random effects model:


325	comparison	k	prop	nma	direct	indir.	Diff	z	p-value
326	Diffractive:Monofocal	3	0.93	0.2967	0.2958	0.3074	-0.0115	-0.03	0.9776
327	Diffractive:Monovision	1	1.00	0.0400	0.0400	.	.	.	.
328	Diffractive:Refractive	1	0.46	0.1781	0.1376	0.2118	-0.0742	-0.29	0.7741
329	Monofocal:Monovision	0	0.00	-0.2567	.	-0.2567	.	.	.
330	Monofocal:Refractive	4	0.95	-0.1186	-0.1075	-0.3348	0.2273	0.52	0.6034
331	Monovision:Refractive	0	0.00	0.1381	.	0.1381	.	.	.

332 Legend:

- 333 comparison - Treatment comparison
- 334 prop - Direct evidence proportion
- 335 nma - Estimated treatment effect (MD) in network meta-analysis
- 336 direct - Estimated treatment effect (MD) derived from direct evidence
- 337 indir. - Estimated treatment effect (MD) derived from indirect evidence
- 338 Diff - Difference between direct and indirect treatment estimates
- 339 z - z-value of test for disagreement (direct versus indirect)
- 340 p-value - p-value of test for disagreement (direct versus indirect)

341 **H.4.4.3 Spectacle dependence**

342 **Class-level analysis**



343


344 **Pairwise relative risks from NMA (higher number favour column)**

	Multifocal	Monofocal	Monovision
Multifocal	N/A		
Monofocal	1.52 (1.31, 1.76)	N/A	
Monovision	2.47 (1.62, 3.78)	1.63 (1.04, 2.53)	N/A

345 Quantifying heterogeneity/inconsistency:

346  $\tau^2 = 0.0436$ ;  $I^2 = 81.0\%$

347 **Network graph**



348

349

**Comparison of direct and indirect evidence**

350

Random effects model:

351

comparison	k	prop	nma	direct	indir.	RoR	z	p-value
------------	---	------	-----	--------	--------	-----	---	---------

352

Monofocal:Monovision	0	0	1.6253	.	1.6253	..	.	.
----------------------	---	---	--------	---	--------	----	---	---

353

Monofocal:Multifocal	11	1	0.6576	0.6576	.	..	.	.
----------------------	----	---	--------	--------	---	----	---	---

354

Monovision:Multifocal	2	1	0.4046	0.4046	.	..	.	.
-----------------------	---	---	--------	--------	---	----	---	---

355

Legend:

356

comparison - Treatment comparison

357

prop - Direct evidence proportion

358

nma - Estimated treatment effect (RR) in network meta-analysis

359

direct - Estimated treatment effect (RR) derived from direct evidence

360

indir. - Estimated treatment effect (RR) derived from indirect evidence

361

RoR - Ratio of Ratios (direct versus indirect)

362


z - z-value of test for disagreement (direct versus indirect)

363

p-value - p-value of test for disagreement (direct versus indirect)

364

**Subdivided analysis**



365

366

**Pairwise mean differences from NMA (higher numbers favour column)**

	Diffractive	Refractive	Monofocal	Monovision
Diffractive	N/A			
Refractive	1.81 (1.33, 2.47)	N/A		
Monofocal	2.18 (1.65, 2.89)	1.21 (0.94, 1.54)	N/A	
Monovision	3.16 (1.83, 5.46)	1.75 (1.00, 3.06)	1.45 (0.82, 2.57)	N/A

367


Quantifying heterogeneity/inconsistency:

368

$\tau^2 = 0.0970$ ;  $I^2 = 83.9\%$

369

**Network graph**



370

371

**Comparison of direct and indirect evidence**

372

Random effects model:

373

comparison	k	prop	nma	direct	indir.	RoR	z	p-value
------------	---	------	-----	--------	--------	-----	---	---------

374

Diffractive:Monofocal	5	0.73	2.1829	1.8063	3.6192	0.4991	-2.16	0.0306
-----------------------	---	------	--------	--------	--------	--------	-------	--------

375

Diffractive:Monovision	1	0.61	3.1627	2.5830	4.3502	0.5938	-0.91	0.3623
------------------------	---	------	--------	--------	--------	--------	-------	--------

376

Diffractive:Refractive	5	0.42	1.8101	3.2402	1.1804	2.7450	3.16	0.0016
------------------------	---	------	--------	--------	--------	--------	------	--------

377

Monofocal:Monovision	0	0.00	1.4488	.	1.4488	.	.	.
----------------------	---	------	--------	---	--------	---	---	---

378

Monofocal:Refractive	6	0.81	0.8292	0.7148	1.5731	0.4544	-2.46	0.0139
----------------------	---	------	--------	--------	--------	--------	-------	--------

379

Monovision:Refractive	1	0.47	0.5723	0.4345	0.7318	0.5937	-0.91	0.3623
-----------------------	---	------	--------	--------	--------	--------	-------	--------

380

Legend:

381

comparison - Treatment comparison

382

prop - Direct evidence proportion

383

nma - Estimated treatment effect (RR) in network meta-analysis

384

direct - Estimated treatment effect (RR) derived from direct evidence

385

indir. - Estimated treatment effect (RR) derived from indirect evidence

386

RoR - Ratio of Ratios (direct versus indirect)

387


z - z-value of test for disagreement (direct versus indirect)

388

p-value - p-value of test for disagreement (direct versus indirect)

389 **H.4.4.4 Contrast sensitivity**

390 **Class-level analysis**



391

392

**Pairwise relative risks from NMA (higher number favour row)**

	<b>Multifocal</b>	<b>Monovision</b>	<b>Monofocal</b>
<b>Multifocal</b>	N/A		
<b>Monovision</b>	0.04 (0.00, 0.07)	N/A	
<b>Monofocal</b>	0.09 (-0.08, 0.26)	0.05 (-0.12, 0.22)	N/A

393


Quantifying heterogeneity/inconsistency:

394

$\tau^2 = 0.0010$ ;  $I^2 = 23.8\%$

395

**Network graph**



396

397

**Comparison of direct and indirect evidence**

398

Fixed effect model:

399

comparison	prop	nma	direct	indir.	Diff	z	p-value
Monofocal:Monovision	0	-0.0520	.	-0.0520	.	.	.
Monofocal:Multifocal	1	-0.0894	-0.0894	.	.	.	.
Monovision:Multifocal	1	-0.0373	-0.0373	.	.	.	.

400

401

402

403

Legend:

404

comparison - Treatment comparison

405

prop - Direct evidence proportion

406

nma - Estimated treatment effect (MD) in network meta-analysis

407

direct - Estimated treatment effect (MD) derived from direct evidence

408

indir. - Estimated treatment effect (MD) derived from indirect evidence

409

Diff - Difference between direct and indirect treatment estimates


410

z - z-value of test for disagreement (direct versus indirect)

411

p-value - p-value of test for disagreement (direct versus indirect)

412 **Subdivided analysis**



413


414 **Pairwise mean differences from NMA (higher numbers favour row)**

	Diffraction	Monovision	Refractive	Monofocal
Diffraction	N/A			
Monovision	0.06 (0.02, 0.11)	N/A		
Refractive	0.07 (-0.01, 0.15)	0.01 (-0.06, 0.08)	N/A	
Monofocal	0.15 (0.04, 0.27)	0.09 (-0.02, 0.20)	0.08 (-0.00, 0.17)	N/A

415 Quantifying heterogeneity/inconsistency:

416  $\tau^2 = 0.0016$ ;  $I^2 = 2.9\%$

417 **Network graph**



418

419 **Comparison of direct and indirect evidence**

420 Fixed effect model:

comparison	prop	nma	direct	indir.	Diff	z	p-value
Diffraction:Monofocal	0	0.1524	.	0.1524	.	.	.
Diffraction:Monovision	1	0.0600	0.0600	.	.	.	.
Diffraction:Refractive	0	0.0700	.	0.0700	.	.	.
Monofocal:Monovision	0	-0.0924	.	-0.0924	.	.	.
Monofocal:Refractive	1	-0.0824	-0.0824	.	.	.	.
Monovision:Refractive	1	0.0100	0.0100	.	.	.	.

428 Legend:


429 comparison - Treatment comparison

430 prop - Direct evidence proportion

- 431 nma - Estimated treatment effect (MD) in network meta-analysis
- 432 direct - Estimated treatment effect (MD) derived from direct evidence
- 433 indir. - Estimated treatment effect (MD) derived from indirect evidence
- 434 Diff - Difference between direct and indirect treatment estimates
- 435 z - z-value of test for disagreement (direct versus indirect)
- 436 p-value - p-value of test for disagreement (direct versus indirect)

437 **H.4.4.5 Glare**

438 **Class-level analysis**



439


440 **Pairwise relative risks from NMA (higher number favour column)**

	Monofocal	Monovision	Multifocal
Monofocal	N/A		
Monovision	0.86 (0.66, 1.12)	N/A	
Multifocal	1.21 (1.03, 1.43)	1.41 (1.14, 1.73)	N/A

441 Quantifying heterogeneity/inconsistency:

442  $\tau^2 = 0$ ;  $I^2 = 0\%$

443 **Network graph**



444

445 **Comparison of direct and indirect evidence**


446 Fixed effect model:

comparison	k	prop	nma	direct	indir.	RoR	z	p-value
Monofocal:Monovision	0	0	0.8596		0.8596			
Monofocal:Multifocal	8	1	1.2103	1.2103				
Monovision:Multifocal	1	1	1.4079	1.4079				

451 Legend:

- 452 comparison - Treatment comparison
- 453 prop - Direct evidence proportion
- 454 nma - Estimated treatment effect (RR) in network meta-analysis
- 455 direct - Estimated treatment effect (RR) derived from direct evidence
- 456 indir. - Estimated treatment effect (RR) derived from indirect evidence
- 457 RoR - Ratio of Ratios (direct versus indirect)
- 458 z - z-value of test for disagreement (direct versus indirect)
- 459 p-value - p-value of test for disagreement (direct versus indirect)

460 **Subdivided analysis**



461


462 **Pairwise mean differences from NMA (higher numbers favour row)**

	Monovision	Monofocal	Diffractive	Refractive
Monovision	N/A			
Monofocal	1.22 (0.93, 1.60)	N/A		
Diffractive	1.41 (1.14, 1.73)	1.15 (0.97, 1.37)	N/A	
Refractive	1.82 (1.35, 2.43)	1.49 (1.18, 1.88)	1.29 (1.05, 1.59)	N/A

463 Quantifying heterogeneity/inconsistency:

464  $\tau^2 = 0$ ;  $I^2 = 0\%$

465 **Network graph**



466

467 **Comparison of direct and indirect evidence**

468 Fixed effect model:

comparison	k	prop	nma direct	indir.	RoR	z	p-value	
Diffractive:Monofocal	3	0.84	0.8670	0.8690	0.8565	1.0146	0.06	0.9520

470




471 Diffractive:Monovision 1 1.00 0.7103 0.7103 . . . .  
 472 Diffractive:Refractive 4 0.74 1.2892 1.2878 1.2931 0.9959 -0.02 0.9863  
 473 Monofocal:Monovision 0 0.00 0.8193 . 0.8193 . . . .  
 474 Monofocal:Refractive 5 0.43 1.4870 1.4984 1.4785 1.0134 0.06 0.9556  
 475 Monovision:Refractive 0 0.00 1.8151 . 1.8151 . . . .

476 Legend:  
 477 comparison - Treatment comparison  
 478 prop - Direct evidence proportion  
 479 nma - Estimated treatment effect (RR) in network meta-analysis  
 480 direct - Estimated treatment effect (RR) derived from direct evidence  
 481 indir. - Estimated treatment effect (RR) derived from indirect evidence  
 482 RoR - Ratio of Ratios (direct versus indirect)  
 483 z - z-value of test for disagreement (direct versus indirect)  
 484 p-value - p-value of test for disagreement (direct versus indirect)

485 **H.4.4.6 Halo**

486 **Subdivided analysis**




487  
 488 **Pairwise relative risks from NMA (higher number favour column)**

	Monofocal	Diffractive	Refractive
Monofocal	N/A		
Diffractive	1.83 (1.50, 2.24)	N/A	
Refractive	2.71 (2.05, 3.59)	1.48 (1.21, 1.81)	N/A

489 Quantifying heterogeneity/inconsistency:

490  $\tau^2 = 0$ ;  $I^2 = 0\%$

491 **Network graph**



492

493 **Comparison of direct and indirect evidence**

494 Fixed effect model:


495	comparison	k	prop	nma	direct	indir.	RoR	z	p-value
496	Diffractive:Monofocal	4	0.97	0.5459	0.5539	0.3372	1.6427	0.82	0.4150
497	Diffractive:Refractive	4	0.97	1.4808	1.4535	2.5310	0.5743	-0.97	0.3338
498	Monofocal:Refractive	4	0.07	2.7125	4.6366	2.6083	1.7777	1.01	0.3108

499 Legend:

- 500 comparison - Treatment comparison
- 501 prop - Direct evidence proportion
- 502 nma - Estimated treatment effect (RR) in network meta-analysis
- 503 direct - Estimated treatment effect (RR) derived from direct evidence
- 504 indir. - Estimated treatment effect (RR) derived from indirect evidence
- 505 RoR - Ratio of Ratios (direct versus indirect)
- 506 z - z-value of test for disagreement (direct versus indirect)
- 507 p-value - p-value of test for disagreement (direct versus indirect)
- 508


509 **H.4.5 Optimal strategy to address pre-existing astigmatism**

510 **Mean Visual Acuity – uncorrected distance (logMAR)**




511

512 **Proportion with visual acuity worse than 20/25 – uncorrected distance**



513


514 **Mean Visual Acuity – corrected distance (logMAR)**



515

516


**Residual astigmatism (Refractive cylinder dioptres)**



517

518

**Spectacle dependence**



519

520

Note: Non OECD country studies removed for meta-analysis

521 **H.5 Wrong lens implant errors**

- 522
- 523
- What are the procedural causes of wrong lens implant errors?
  - What strategies should be adopted to reduce the risk of wrong lens implant errors?

524 There were no meta-analyses conducted for these questions.


525

526 **H.6 Surgical timing and technique**

- 527 • What is the effectiveness of laser-assisted phacoemulsification cataract surgery compared  
 528 with standard ultrasound phacoemulsification cataract surgery?  
 529 • What is the effectiveness of bilateral simultaneous (rapid sequential) cataract surgery  
 530 compared with unilateral eye surgery?  
 531 • What is the appropriate timing of second eye surgery, taking into account issues such as  
 532 refractive power after first eye surgery?


533 **H.6.1 Laser-assisted cataract surgery**

534 **H.6.1.1 Intra-operative complications**



535  
536


537 H.6.1.2 Post-operative complications



538


Test for subgroup differences: Chi<sup>2</sup> = 0.36, df = 2 (P = 0.84), I<sup>2</sup> = 0%

539 H.6.1.3 Visual acuity (logMAR)



540 Test for subgroup differences: Chi<sup>2</sup> = 1.58, df = 5 (P = 0.90), I<sup>2</sup> = 0%

541 H.6.1.4 Duration of procedure (minutes)



Footnotes  
(1) "Mean surgical time"  
(2) "Total surgery time"


542  
543



544 **H.6.2 Bilateral surgery**


545 **H.6.2.1 Bilateral simultaneous versus unilateral cataract surgery**

546 **Any intraoperative complication**




547

548 **Any postoperative complication**




549

550 **Any intra- or postoperative complication**




551

552 **Serious postoperative complications**



553


554 **Visual function**



555


556 H.6.2.2 Second-eye surgery versus no second-eye surgery

557 Visual acuity (logMAR)




558

559 Contrast sensitivity



560

561 Visual function



562

563


564 **H.7 Anaesthesia**

- 565 • What is the optimal type and administration of anaesthesia for cataract surgery?
- 566 • What is the effectiveness of sedation as an adjunct to local anaesthesia during cataract
- 567 surgery?
- 568 • What is the effectiveness of hyaluronidase as an adjunct to local anaesthesia during
- 569 cataract surgery?
- 570 • In what circumstances should general anaesthesia be considered in phacoemulsification
- 571 cataract surgery?

572 **H.7.1 Type and administration of anaesthesia**


573 **H.7.1.1 Pain on application**

574 **Warmed (37 degrees) vs room temperature anaesthetic**




575

576 **Topical vs peribulbar anaesthesia**



577


578 **Topical vs sub-Tenon's**



579


580 **H.7.1.2 Pain during surgery**

581 **Topical versus peribulbar**





582


583 **Topical versus retrobulbar**




584  
585 **Topical versus topical with intracameral**



587  
588 **Topical versus sub-Tenon's**




589  
590 **Peribulbar versus retrobulbar**



591


592 H.7.1.3 Surgical complications

593 Topical versus topical with intracameral (adverse surgical event)



594

595 Peribulbar vs retrobulbar (conjunctival chemosis)




596

597 H.7.2 Network meta-analyses

598 H.7.2.1 Anaesthetic drug (lidocaine used as reference category)

599 Pain on application



600


601 Pairwise mean differences from NMA

	Benoxinate	Bupivacaine	Lidocaine	Levobupivacaine
Benoxinate	N/A			
Bupivacaine	5.00 (3.61, 6.39)	N/A		
Lidocaine	19.40 (16.08, 29.72)	14.40 (11.98, 16.82)	N/A	
Levobupivacaine	22.90 (17.03, 21.77)	17.90 (11.06, 24.74)	3.50 (-2.89, 9.89)	N/A

602 Quantifying heterogeneity/inconsistency:

603 tau<sup>2</sup> = 0; I<sup>2</sup> = 0%

604 Network graph



605

606

**Comparison of direct and indirect evidence**

607

Fixed effect model:

608

609

610

611

612

613

614

	comparison	prop	nma	direct	indir.	Diff	z	p-value
	Benoxinate:Bupivacaine	1	5.0000	5.0000	.	..	.	.
	Benoxinate:Levobupivacaine	0	22.9000	.	22.9000	..	.	.
	Benoxinate:Lidocaine	1	19.4000	19.4000	.	..	.	.
	Bupivacaine:Levobupivacaine	0	17.9000	.	17.9000	..	.	.
	Bupivacaine:Lidocaine	1	14.4000	14.4000	.	..	.	.
	Levobupivacaine:Lidocaine	1	-3.5000	-3.5000	.	..	.	.

615

Legend:

616

comparison - Treatment comparison

617

prop - Direct evidence proportion

618

nma - Estimated treatment effect (MD) in network meta-analysis

619

direct - Estimated treatment effect (MD) derived from direct evidence

620

indir. - Estimated treatment effect (MD) derived from indirect evidence

621

Diff - Difference between direct and indirect treatment estimates

622


z - z-value of test for disagreement (direct versus indirect)

623

p-value - p-value of test for disagreement (direct versus indirect)

624

**Pain during surgery**



625

626

**Pairwise mean differences from NMA**


	Benoxinate	Bupivacaine	Lidocaine	Levobupivacaine
Benoxinate	N/A			

<b>Bupivacaine</b>	-30.00 (-39.53, -20.47)	N/A		
<b>Lidocaine</b>	-55.00 (-63.66, -46.34)	-25.00 (-35.40, -14.60)	N/A	
<b>Levobupivacaine</b>	-59.00 (-68.71, -49.29)	-29.00 (-40.29, -17.71)	-4.00 (-8.39, 0.39)	N/A

627 Quantifying heterogeneity/inconsistency:

628  $\tau^2 = 0$ ;  $I^2 = 0\%$

629 **Network graph**



630

631 **Comparison of direct and indirect evidence**

632 Fixed effect model:

	comparison	prop	nma	direct	indir.	Diff	z	p-value
634	Benoxinate:Bupivacaine	1	-30.0000	-30.0000	.	..	.	.
635	Benoxinate:Levobupivacaine	0	-59.0000	.	-59.0000	..	.	.
636	Benoxinate:Lidocaine	1	-55.0000	-55.0000	.	..	.	.
637	Bupivacaine:Levobupivacaine	0	-29.0000	.	-29.0000	..	.	.
638	Bupivacaine:Lidocaine	1	-25.0000	-25.0000	.	..	.	.
639	Levobupivacaine:Lidocaine	1	4.0000	4.0000	.	..	1	.

640 Legend:

641 comparison - Treatment comparison

642 prop - Direct evidence proportion

643 nma - Estimated treatment effect (MD) in network meta-analysis

644 direct - Estimated treatment effect (MD) derived from direct evidence

645 indir. - Estimated treatment effect (MD) derived from indirect evidence


646 Diff - Difference between direct and indirect treatment estimates

647 z - z-value of test for disagreement (direct versus indirect)

648 p-value - p-value of test for disagreement (direct versus indirect)

649 H.7.2.2 Method of anaesthesia (topical used as reference category)

650 Pain on application



651


652 Pairwise mean differences from NMA

	Topical	sub-Tenon's	Peribulbar	Retrobulbar
Topical	N/A			
sub-Tenon's	6.15 (-4.81, 17.11)	N/A		
Peribulbar	8.86 (-4.57, 17.11)	2.71 (-14.63, 20.04)	N/A	
Retrobulbar	49.10 (29.94, 68.26)	42.95 (20.88, 65.02)	40.24 (16.85, 63.64)	N/A

653 Quantifying heterogeneity/inconsistency:

654  $\tau^2 = 89.5629$ ;  $I^2 = 96.4\%$

655 Network graph



656

657 Comparison of direct and indirect evidence

658 Random effects model:


comparison	prop	nma	direct	indir.	Diff	z	p-value
Peribulbar:Retrobulbar	0	40.2431	.	40.2431	.	.	.
Peribulbar:sub-Tenon's	0	-2.7073	.	-2.7073	.	.	.
Peribulbar:Topical	1	-8.8569	-8.8569	.	.	.	.
Retrobulbar:sub-Tenon's	0	-42.9504	.	-42.9504	.	.	.
Retrobulbar:Topical	1	-49.1000	-49.1000	.	.	.	.
sub-Tenon's:Topical	1	-6.1496	-6.1496	.	.	.	.

656 Legend:



- 667 comparison - Treatment comparison
- 668 prop - Direct evidence proportion
- 669 nma - Estimated treatment effect (MD) in network meta-analysis
- 670 direct - Estimated treatment effect (MD) derived from direct evidence
- 671 indir. - Estimated treatment effect (MD) derived from indirect evidence
- 672 Diff - Difference between direct and indirect treatment estimates
- 673 z - z-value of test for disagreement (direct versus indirect)
- 674 p-value - p-value of test for disagreement (direct versus indirect)

675 **Pain during surgery**



676

677


**Pairwise mean differences from NMA**

	Topical	Topical + intracameral	Peribulbar	Retrobulbar	sub-Tenon's
Topical	N/A				
Topical + intracameral	-2.73 (-7.84, 2.39)	N/A			
Peribulbar	-6.49 (-10.96, -2.02)	-3.76 (-10.55, 3.03)	N/A		
Retrobulbar	-7.50 (-12.28, -2.72)	-4.77 (-11.77, 2.23)	-1.01 (-6.62, 4.61)	N/A	
sub-Tenon's	-12.97 (-21.62, -4.31)	-10.24 (-20.29, -0.19)	-6.48 (-16.21, 3.26)	-5.47 (-15.35, 4.41)	N/A

678 Quantifying heterogeneity/inconsistency:

679  $\tau^2 = 26.0174$ ;  $I^2 = 82.2\%$

680 **Network graph**



681

682 **Comparison of direct and indirect evidence**

683 Random effects model:

684	comparison	prop	nma	direct	indir.	Diff	z	p-value
685	Peribulbar:Retrobulbar	0.42	-1.0076	-0.3423	-1.4877	1.1454	0.20	0.8435
686	Peribulbar:sub-Tenon's	0.00	-6.4774	.	-6.4774	.	.	.
687	Peribulbar:Topical	0.81	6.4896	6.2715	7.4172	-1.1457	-0.20	0.8435
688	Peribulbar:Topical + intracameral	0.00	3.7619	.	3.7619	.	.	.
689	Retrobulbar:sub-Tenon's	0.00	-5.4699	.	-5.4699	.	.	.
690	Retrobulbar:Topical	0.77	7.4972	7.7593	6.6139	1.1454	0.20	0.8435
691	Retrobulbar:Topical + intracameral	0.00	4.7695	.	4.7695	.	.	.
692	sub-Tenon's:Topical	1.00	12.9671	12.9671	.	.	.	.
693	sub-Tenon's:Topical + intracameral	0.00	10.2393	.	10.2393	.	.	.
694	Topical:Topical + intracameral	1.00	-2.7277	-2.7277	.	.	.	.

695 Legend:

- 696 comparison - Treatment comparison
- 697 prop - Direct evidence proportion
- 698 nma - Estimated treatment effect (MD) in network meta-analysis
- 699 direct - Estimated treatment effect (MD) derived from direct evidence
- 700 indir. - Estimated treatment effect (MD) derived from indirect evidence
- 701 Diff - Difference between direct and indirect treatment estimates
- 702 z - z-value of test for disagreement (direct versus indirect)
- 703 p-value - p-value of test for disagreement (direct versus indirect)


704 **H.8 Preventing and managing complications**

- 705 • What is the effectiveness of interventions (for example, prophylactic laser surgery) to
- 706 prevent retinal detachment in people with myopia undergoing cataract surgery?
- 707 • What is the effectiveness of capsular tension rings applied during phacoemulsification
- 708 cataract surgery?
- 709 • What is the effectiveness of interventions to increase pupil size to improve visual
- 710 outcomes and reduce complications during phacoemulsification cataract surgery?
- 711 • What is the effectiveness of postoperative eye shields to prevent complications after
- 712 cataract extraction?
- 713 • What is the effectiveness of prophylactic antiseptics (for example, topical iodine) and
- 714 antibiotics to prevent endophthalmitis after cataract surgery?
- 715 • What is the effectiveness of prophylactic topical corticosteroids and/or NSAIDs to prevent
- 716 inflammation and cystoid macular oedema after phacoemulsification cataract surgery?
- 717 • What is the effectiveness of interventions to reduce the impact of perioperative posterior
- 718 capsule rupture?
- 719 • What is the effectiveness of interventions used to manage cystoid macular oedema
- 720 following cataract surgery?

721 **H.8.1 Capsular tension rings**


722 **H.8.1.1 Full population**

723 **CDVA (3 months postoperatively)**



724


725 **UDVA (3 months postoperatively)**



726

727 **H.8.1.2 People with pseudoexfoliation**


728 **Zonular dehiscence**



729

730

**IOL in the bag successfully**




731  
732

733 **H.8.2 Intervention to prevent cystoid macular oedema**

734 **H.8.2.1 Pairwise meta-analyses**

735 **NSAIDs plus steroids vs steroids**

736 **Poor vision due to CMO**




Footnotes

- (1) Follow-up: 6 weeks, "clinically significant macular oedema associated with vision loss" (cutpoint not defined)
- (2) Follow-up: 6 weeks, funduscopy and Amsler grid test "no evidence of clinically significant CME"
- (3) Follow-up: 4 weeks, OCT-confirmed CMO with visual acuity <6/9.

737

738 **CMO**




Footnotes

- (1) Follow-up: 1 month. OCT used but CMO not defined.
- (2) Follow-up: day 42. "Clinically significant MO" via funduscopy and Amsler grid test.
- (3) Follow-up: 2 weeks. "Clinically significant CME"
- (4) Follow-up: 2 months, "obvious CMO confirmed by OCT"
- (5) Follow-up: 1 month, "clinically significant CME" unclear if OCT-verified
- (6) Follow-up: 4 weeks. clinical and OCT-based
- (7) Follow-up: 3 months, "Slight fluorescein leakage into the cystic space without enclosing the entire centralfovea or complete fluorescein accumulation..."
- (8) Follow-up: 6 weeks, OCT verified but not defined

739

740 **Inflammation (events)**




Footnotes

- (1) Follow-up: 6 weeks, "inflammatory cells greater than 1+ during first week of postoperative visits.
- (2) Follow-up: day 28, corneal oedema or Tyndall reaction or conjunctival hyperemia, by day 35 had disappeared.

741

742

**BCVA [logMAR]**




743

744

**NSAIDs vs steroids**

745


**CMO**



746


747

**Inflammation (flare) [photons/ms]**



748

749 **BCVA [logMAR]**




Footnotes

- (1) Follow-up: 8 weeks, final value
- (2) Follow-up: 6 weeks

750


751 **NSAIDs plus steroids vs steroids (population with diabetic retinopathy)**

752 **CMO**




753

754 **BCVA [logMAR]**



755


756 **Proportion losing 5 or more letters of BCVA**



757

758 H.8.2.2 Network meta-analyses (steroids used as reference category)

759 BCVA [logMAR]



760

Number of studies: k=9

Number of treatments: n=3

Number of pairwise comparisons: m=11

**Differences between treatments – mean and 95% confidence interval**

	NSAIDs	NSAIDs + steroids	Steroids
NSAIDs		0.0038 [-0.0298, 0.0373]	-0.0044 [-0.0319, 0.0232]
NSAIDs + Steroids	-0.0038 [-0.0373, 0.0298]		-0.0081 [-0.0273, 0.0110]
Steroids	0.0044 [-0.0232, 0.0319]	0.0081 [-0.0110, 0.0273]	

Quantifying heterogeneity/inconsistency:

$\tau^2 = 0.0003$ ;  $I^2 = 63.2\%$


Test of heterogeneity/inconsistency:

Q d.f. p-value

21.72 8 0.005

**Network graph**





**Comparison of direct and indirect evidence**

Random effects model:


comparison	prop	nma	direct	indir.	Diff	z	p-value
NSAIDS:NSAIDS + steroids	0	-0.0038	-0.1050	-0.0033	-0.1017	-0.38	0.7029
NSAIDS:steroids	1	0.0044	0.0046	-0.1175	0.1220	0.32	0.7456
NSAIDS + steroids :steroids	1	0.0081	0.0081	.	.	.	.

Legend:

- comparison - Treatment comparison
- prop - Direct evidence proportion
- nma - Estimated treatment effect (MD) in network meta-analysis
- direct - Estimated treatment effect (MD) derived from direct evidence
- indir. - Estimated treatment effect (MD) derived from indirect evidence
- Diff - Difference between direct and indirect treatment estimates
- z - z-value of test for disagreement (direct versus indirect)
- p-value - p-value of test for disagreement (direct versus indirect)

761

**CMO**



762

- 763 Number of studies: k=12
- 764 Number of treatments: n=3
- 765 Number of pairwise comparisons: m=14

766  
767

**Differences between treatments – mean and 95% confidence interval**


	NSAIDs	NSAIDs + steroids	Steroids
NSAIDs		1.0869 [0.5102, 2.3156]	0.2639 [0.1694, 0.4109]
NSAIDs + steroids	0.9200 [0.4319, 1.9600]		0.2428 [0.1310, 0.4500]
Steroids	3.7897 [2.4336, 5.9016]	4.1191 [2.2225, 7.6343]	

768

769 Quantifying heterogeneity/inconsistency:  
770  $\tau^2 = 0$ ;  $I^2 = 0\%$

771  
772 Test of heterogeneity/inconsistency:  
773 Q d.f. p-value  
774 4.68 11 0.9455

775 **Network graph**



776

777 **Comparison of direct and indirect evidence**

778 Random effects model:

	comparison	prop	nma	direct	indir.	RoR	z	p-value
780	NSAIDs:NSAIDs + steroids	0.04	0.9200	1.0417	0.9155	1.1378	0.06	0.9490
781	NSAIDs:steroids	1.00	3.7897	3.7776	18.8152	0.2008	-0.32	0.7509
782	NSAIDs + steroids :steroids	1.00	4.1191	4.1019	11.6442	0.3523	-0.21	0.8343

783 Legend:

784 comparison - Treatment comparison

785 prop - Direct evidence proportion


786 nma - Estimated treatment effect (RR) in network meta-analysis

787 direct - Estimated treatment effect (RR) derived from direct evidence

788 indir. - Estimated treatment effect (RR) derived from indirect evidence

- 789 RoR - Ratio of Ratios (direct versus indirect)
- 790 z - z-value of test for disagreement (direct versus indirect)
- 791 p-value - p-value of test for disagreement (direct versus indirect)

792 **Inflammation (flare) [photons/ms]**



- 793
- 794 Number of studies: k=5
- 795 Number of treatments: n=3
- 796 Number of pairwise comparisons: m=7

797 **Differences between treatments – Mean and 95% confidence interval**


798

	NSAIDs	NSAIDs + steroids	Steroids
NSAIDs		2.1419 [-1.1857, 5.4694]	-1.6413 [-3.4897, 0.2070]
NSAIDs + steroids	-2.1419 [-5.4694, 1.1857]		-3.7832 [-7.2631, -0.3033]
Steroids	1.6413 [-0.2070, 3.4897]	3.7832 [0.3033, 7.2631]	

- 799
- 800 Quantifying heterogeneity/inconsistency:
- 801 tau<sup>2</sup> = 2.8678; I<sup>2</sup> = 68.5%
- 802
- 803 Test of heterogeneity/inconsistency:
- 804 Q d.f. p-value
- 805 12.69 4 0.0129

806

**Network graph**



807

**808 Comparison of direct and indirect evidence**

809

Random effects model:

810

811

812

813

814

815

816

817

818

819

820

821

822

823

comparison	prop	nma	direct	indir.	Diff	z	p-value
NSAIDS:NSAIDS + steroids	0.85	-2.1419	-2.4000	-0.6558	-1.7442	-0.36	0.7152
NSAIDS:steroids	1.00	1.6413	1.6413	.	.	.	.
NSAIDS + steroids :steroids	0.64	3.7832	3.3000	4.6516	-1.3516	-0.36	0.7152

Legend:


- comparison - Treatment comparison
- prop - Direct evidence proportion
- nma - Estimated treatment effect (MD) in network meta-analysis
- direct - Estimated treatment effect (MD) derived from direct evidence
- indir. - Estimated treatment effect (MD) derived from indirect evidence
- Diff - Difference between direct and indirect treatment estimates
- z - z-value of test for disagreement (direct versus indirect)
- p-value - p-value of test for disagreement (direct versus indirect)

824 **H.9 Postoperative assessment**

- 825 • What are the early and late complications of cataract surgery?
- 826 • What should the postoperative assessment include?
- 827 • Who and in what setting should carry out the postoperative assessment?
- 828 • What issues should be considered when organising postoperative care?
- 829 • What is the appropriate time to assess outcomes in the postoperative period?
- 830 • If the postoperative assessment and care are undertaken outside of the hospital, how
- 831 should outcomes between surgical units and these providers be effectively
- 832 communicated?


833 **H.9.1 Details of postoperative assessment**

834 **H.9.1.1 Complications**




835

836 **H.9.1.2 CDVA**



837

838 **H.9.1.3 Unscheduled visits**



839